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SUMMARY 
 
Healthcare associated infections are a major concern within the health services as they 
inflict a significant financial burdens and time constraints on the healthcare system. 
Effective skin antisepsis prior to incision of the skin, for example, during surgery, is 
essential in preventing subsequent infection. Current evidence-based guidelines recommend 
the use of 2 % (w/v) chlorhexidine digluconate (CHG), preferably in 70 % (v/v) isopropyl 
alcohol (IPA) prior to incision of the skin. However, many antimicrobial agents poorly 
permeate into the skin and microorganisms residing in the deeper layers and around hair 
follicles, may survive the procedure and cause infection. Lipid-based nanocarriers are 
promising drug delivery system with the potential to improve chemical stability, control 
drug release and alter drug pharmacokinetics.  
 
In present study, the ability of lipid-based nanocarriers to enhance the skin retention of 
antimicrobial agents was accessed. The solid lipid nanoparticles (SLNs) and nanoemulsions 
(NEs) of triclosan (TSN) and chlorhexidine digluconate (CHG) were prepared and 
compared based on their physicochemical parameter and better skin retention properties. 
SLNs of TSN was prepared using glyceryl behenate (GB) and glyceryl palmitostearate (GP) 
solid lipids, while NEs of TSN and CHG were prepared using eucalyptus oil (EO) and olive 
oil (OO) with combination of surfactants Tween
® 
80 and Span
® 
80. Characterisation and 
optimisation of SLN and NE formulations to find better skin retention ability is described 
with various other studies within this thesis.  
 
Skin permeation of TSN and CHG was subsequently investigated by in vitro Franz 
diffusion model using artificial membrane and full thickness porcine ear skin and the 
penetration profile were determined by differential stripping technique to quantify the 
amount of drug retained within skin. In both SLN and NE formulations, no detectable level 
of TSN and CHG was found in receiver medium through full thickness porcine ear skin in 
24 h, which is advantageous for topical drug delivery system.   
 
SLNs prepared with GP, as solid lipid was able to produce smaller size formulation along 
with better skin penetration compared with GB-SLNs formulation. SLNs and NEs of TSN 
was analysed and compared for enhanced skin retention properties. The results 
demonstrated a significantly enhanced skin penetration of TSN for NE formulations 
compared to SLNs, which might be due to difference in composition and physical state of 
lipids and physicochemical parameter of formulations. In case of CHG-loaded NEs, the 
results demonstrated EO show better skin penetration compared to OO formulations due to 
its skin penetration enhancing property, which might be beneficial for skin antisepsis prior 
to invasive procedure to reduce the microorganisms on and within the skin. However, 
further studies are required to study antibacterial effects of nanoformulations against 
various skin microorganisms, to analyse skin permeation and retention ability of prepared 
nanoformulations in in vivo diffusion studies and further studies to analyse toxicity and skin 
tolerance of EO alone or in combination with antimicrobial agents. 
 
Key words: skin permeation, solid lipid nanoparticles, nanoemulsions, chlorhexidine 
digluconate, triclosan, eucalyptus oil, olive oil, Franz diffusion cell 
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1. CHAPTER – INTRODUCTION 
 
1.1 Healthcare associated infections 
 
Healthcare associated infections (HAIs) are a major concern within the health services. 
These are defined as infections acquired either inside hospitals or as a direct result of a 
healthcare intervention. They inflict significant financial burdens and time constraints on 
the healthcare system due to increased morbidity and mortality rates, prolonged hospital 
occupancy and intensified treatment regimes, including repeated surgeries (Vilela et al., 
2007). The National Institute for Health and Care Excellence (NICE) estimates that HAIs 
account for approximately 300,000 infections per year in England, and contribute to 5,000 
deaths per year, with an estimated extra cost to the National Health Service (NHS) of £1 
billion annually. A significant number of HAIs (15 %) are thought to be preventable 
through compliance with infection control practices and adequate hygiene, including 
appropriate skin antisepsis prior to invasive procedures (Morse, 2009). There are many 
types of HAIs, which includes skin and soft tissue infections, primary bloodstream 
infections (BSIs), gastrointestinal infections and urinary tract infections (UTIs). 
1.1.1 Surgical site infections  
 
Surgical site infections (SSIs), are defined as infection that occurs at or near body parts after 
surgery. SSIs occurs due to microbial contamination and these microorganisms are may 
originated from either internal or external sources, which includes the patient’s skin, 
mucous membranes or any contaminated item in the sterile surgical field, including surgical 
team members, instruments, air, or materials (De Lissovoy et al., 2009).
 
Infection only 
occurs if the number and virulence of bacteria or fungi overwhelm natural host defence 
mechanisms. SSIs represent the most common infection which account for 15 % of total 
infections among surgical patients (Reichman and Greenberg, 2009).  
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1.1.1.1 Risk of developing surgical site infections 
 
In 1999, the Hospital Infection Control Practices Advisory Committee of the Centres for 
Disease Control and Prevention published guidelines for the prevention of SSIs. To identify 
risk and to prevent the SSIs, there is a need of consideration of factors related to both 
patient and surgery (Mangram et al., 1999). Several patient related factors which increase 
the risk of SSIs may include but not limited to diabetes, cigarette smoking, malnutrition, 
prolonged preoperative hospital stays, microorganisms colonisation (Blam et al., 2003). In 
addition age, obesity and body site infection may also increase the risk of SSIs. Various pre 
and post-surgery related factors includes blood transfusion, length of hospital stay, duration 
of surgery and antibiotic prophylaxis (Triantafyllopoulos et al., 2015).  
1.1.1.2 Cost of surgical site infections 
 
SSIs raise health care cost due to prolonged hospitalisation, additional diagnostic tests, 
therapeutic antibiotic treatment, and, rarely, additional surgery. In 2009, it was estimated 
that SSIs extend the length of hospital stays by 9.7 days on average and increase costs by 
$20,842 per admission, along with readmission into the hospital due to SSIs for an 
additional $700 million of total health care cost (Reichman and Greenberg, 2009; Wilson et 
al., 2015). Deep incisional SSIs cost more than the superficial infections. A study 
performed involving 16 patients to analyse SSIs cost, reported average increase of 115 % in 
the total treatment cost of SSIs compared to non-infected patients (Broex et al., 2009).  
1.1.1.3 Microorganisms 
 
Microorganisms responsible for SSIs are mainly originate from patients own flora. Most 
common isolated bacteria are Staphylococcus aureus, Escherichia coli and Enterococcus 
species (Schaberg, et al., 1991). The increase in SSIs is caused by the antibiotic resistant 
pathogen such as methicillin-resistant Staphylococcus aureus (MRSA) or Candida Albicans, 
which increases the number of severely ill patients and hence the need to use broad 
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spectrum antimicrobial agents (Schaberg, 1994). Sudden outbreak of infections might also 
cause by the uncommon microorganisms such as Clostridium perfringens, Rhodococcus 
bronchialis, Nocardia farcinica and Legionella pneumophila due to the contaminated 
dressings, tap water, elastic bandages or contaminated disinfectant solution (Mangram et al., 
1999). 
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1.2 Wounds  
 
A wound is defined as damage or disruption in the protective function of skin caused by 
loss of barrier property of epithelium followed by cuts, surgery, chemicals, friction force 
and pressure or as a result of disease. 
1.2.1 Classification of wounds 
 
Wounds can be classified in various methods, their location, type of injury or symptoms and 
the time require for healing. Based on the time require for healing wounds can be classified 
either acute or chronic. 
1.2.1.1 Acute wounds 
 
Acute wounds are common health problems involving process of tissue repair immediately 
after injury. It is well-organised process with predictable healing which damages only 
epidermis and superficial dermis layer (Korting et al., 2011a).  
The acute wounds occur due to sudden loss of tissue or after surgery, which usually takes 
up to 30 days for healing process. Acute wounds are categorised based on cause (surgical 
incisions, abrasions, lacerations, thermal burns) and type (size and depth of tissue damage). 
Surgical incision wounds: Surgical wounds are cuts through skin during surgery, which 
might be small or long depending upon the type of surgery. Incision wounds in blood 
vessels, heart or lungs can be painful and life threatening (Richardson, 2004). 
Abrasion wounds: Abrasion wounds caused due to minor cuts or friction of injured skin 
with other surface results in damaged or removal of surface layer of skin. These wounds are 
generally small, pain free and less to no bleeding (Korting et al., 2011b). 
Laceration wounds: Laceration wounds occurs due to sudden trauma or accident forms an 
deeper cuts than the abrasion wounds with severe pain and more bleeding (Monaco and 
Lawrence, 2003). 
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Thermal burn wounds: A thermal burn is a damage of surface skin along with deeper 
layers of skin tissues, caused by contact with heat, electricity, chemicals, light, radiation or 
friction. Severe loss of skin can lead to infection and the loss of skin functions such as 
thermoregulation and immunity. Wounds caused by sun exposure or heat surface can be 
managed by first aid treatment while burns with heat flame or electric charge needs to be 
hospitalised (Li et al., 2007). 
1.2.1.2 Chronic wounds  
 
Multiple local disturbances and systemic disease, impaired wound healing, prolonged 
inflammation and a toxic environment are the main reasons for transition of acute wound to 
chronic state (Eming et al., 2002). Some of the most common types of chronic wounds are 
as follows (Degreef, 1998; Robson et al., 2001a; Szycher and Lee, 1992): 
Infectious wounds: Infectious wounds are caused by bacterial, fungal or viral. They usually 
have drainage of pus, debris, bad odour and inflammation symptoms such as pain, fever or 
redness. 
Ischemic wounds: Ischemic wound occurs due to lack of blood supply to tissue. The area 
will usually be pale and cold. Wound healing can be delayed due to less oxygen and 
nutrients supply. 
Surgical wounds: Incision or cuts made during surgery results in surgical wounds, which 
might turn into chronic wounds if proper medical treatment or care is not provided.  
Ulcers are the most common type of chronic wound, and can be further divided into 
categories as follows: 
1. Venous ulcers: It is a most common vascular ulcer especially in lower legs including 
deep vein thrombosis, varicose veins and venous hypertension. Patients often have a history 
of lower limb oedema (swollen legs) or damaged leaking veins. 
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2. Diabetic ulcers: These are chronic, painless and clean ulcerations that develop due to 
vascular, neurological and metabolic disorders in diabetes. It results in nerve damage, poor 
blood supply and impaired immune function, which cause skin damage and ulceration. 
Even in the absence of infection, poor blood supply can lead to the establishment of dry 
diabetic gangrene. 
3. Pressure ulcers: Pressure ulcers are also known as pressure sores and decubitus ulcers, 
which causes injury to skin or underlying tissue. These ulcers mainly develop over bony 
area that are close to skin due to the pressure or friction, which prevents the blood flow to 
soft tissue. These ulcers show symptoms such as redness followed by itching, blistering, 
swelling and discoloration of the area. 
1.2.2 Wound infection 
 
Wound infection occurs due to colonisation of microorganisms at or near wounds, delaying 
process of wound healing. Wounds or insertion or insertion of intravascular lines and 
catheters causes disruption of epidermis, which can lead to pathogenic infection.. Infected 
wounds usually occur due to microorganisms present within skin and other areas of body or 
from external sources (Klimek, 1985). If the skin is intact microorganisms present within 
skin are normally harmless, but in wound the protective barrier of skin is disrupted and 
these microorganisms accumulate at injured area resulting in delay in wound healing.  
The most common bacteria that lead to wound infection are Staphylococcus aureus and 
other groups of Streptococci (Williford, 1999). The microorganisms such as Pesudomonas 
aeruginosa, Escherichia coli, and Staphylococcus epidermis are also known to contribute to 
skin infections (Percival et al., 2012). In terms of the treatment of contaminated burns, 
pathogenic bacteria that are resistant to multiple drugs are an increasing problem (Dai et al., 
2009). Inadequate care of wound infections may lead to reduced healing response, loss of 
soft tissue, limb amputation and death (Edward and Harding, 2004). A recent report 
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suggests that microbial infection is the cause of death for at least 10,000 in every million 
wound patients (Percival et al., 2012). 
1.2.3 Wound healing 
 
Wound healing is a continuous process taking place in all the damaged tissue which is 
categorised into four different phase to understand the mechanism of tissue healing 
(Richardson, 2004). Healing proceeds via four overlapping phases: haemostasis, 
inflammation, proliferation and remodelling; each phase is characterised by the infiltration 
of specific cell types into the wound site (Diegelmann and Evans, 2004).  
1.2.3.1 Haemostasis phase 
 
Immediately following injury, haemostasis takes place in the wound to prevent further 
tissue loss from damaged blood vessels (Broughton et al., 2006; Pool, 1977). This provides 
the matrix for incoming cells that are needed for the later phases of healing (Lawrence, 
1998; Robson et al., 2001). Haemostasis is achieved upon platelet adhesion and aggregation 
through the synthesis of insoluble fibrin; adhesive molecules such as fibronectin and 
vitronectin are deposited onto the fibrin mesh. The formation of fibrin-based clots within 
damaged blood vessels facilitates cessation of haemorrhage, whereas discharge from blood 
vessels into the surrounding tissue provides a provisional matrix over which cells 
responsible for repair can migrate. In the final stages of haemostasis, fibrin degradation 
products, together with platelet-derived growth factors activates the inflammatory cells. 
1.2.3.2 Inflammatory phase 
 
The haemostasis phase is followed by cellular inflammatory phase to create an immune 
barrier against microorganisms. In this phase, a variety of leukocytes are released from 
blood vessels in response to cellular signals. Inflammation is traditionally separated into an 
early and late stage, each of which is characterised by the predominance of particular 
leucocytes (Hart, 2002). The early stage features wound debridement, facilitated by the 
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phagocytosis and eventual destruction of bacteria and cell debris by neutrophils, whereas 
the late stage consists of macrophage predominance and the eventual infiltration of 
lymphocytes into the wound site.  
1.2.3.3 Proliferation 
 
Stimulated growth and migration of neighbouring dermal and epidermal cells to the site of 
injury is the hallmark of the proliferative phase. This phase is characterised by migration of 
fibroblast and deposition of newly synthesised extracellular matrix, which replaces the 
provisional network of fibrin and fibronectin and last for about 2 weeks. Central to 
proliferative phase of wound healing is the formation of granulation tissue. Dermal 
fibroblast proliferation, migration and differentiation (into contractile myofibroblast) occur 
under the influence of growth factors (Traversa and Sussman, 2001). Fibroblasts are crucial 
for the production of extracellular matrix, which is comprised of collagen, 
glycosaminoglycans, proteoglycans, fibronectin and elastin (Wild et al., 2010). During the 
proliferative phase, wound contraction is an important process that occurs through the 
action of myofibroblast differentiated from mesenchymal fibroblast cell lines (Gilbane et al., 
2013). 
1.2.3.4 Remodeling phase 
 
As the final phase of wound healing, the remodelling phase is responsible for the 
development of new epithelium and the formation of final scar tissue. Traditionally, it has 
been treated as a separate phase, primarily because it continues for up to two years 
following injury, long after the proliferation phase has ended (Ramasastry, 2005; Witte and 
Barbul, 1997). During remodelling phase, nutrient requirement of wound decreases, which 
is characterised by reduced proliferation and inflammation, active re-organisation of the 
extracellular matrix and regression of newly formed capillaries (O’Toole, 2001).  During 
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remodelling, collagen becomes more organised, fibronectin disappears and hyaluronic acid 
and glycosaminoglycan are replaced by proteoglycans (Guo and Dipietro, 2010). 
1.2.4 Wound dressings 
 
Until the 1960s, traditional wound dressings used for wound healing were based on 
technologies to absorb wound exudates and keep the wound dry, but later it was found that 
maintenance of hydration and moisture helps in faster wound healing. As a result of these 
findings, several modern dressings have been formulated to retain the moisture via 
occlusion (Boateng et al., 2008; Fan et al., 2011a; Schultz et al., 2003). 
Wound dressings are local therapeutic agents widely used as the first line of treatment for 
minor superficial wounds as well as for complicated exuding or infected wounds. Besides 
arresting bleeding, wound dressings function as an artificial barrier to protect the wound 
against further trauma or environmental bacterial contamination, while promoting healing 
by preventing the presence of excessive wound exudates (Quinn et al., 1985). 
The ideal properties of wound dressings are directly related to the physiological condition 
of the wound. The functions of wound dressings are described as follows (Lawrence and 
Diegelmann, 1994): 
 Preservation of humid environment 
 Absorption of exudates and microorganisms 
 Formation of mechanical barrier against secondary infections and thermal isolation 
 Promotion of debridement 
1.2.5 Types of wound dressings 
 
Wound dressings can be generally divided into traditional and modern dressings. Gauzes, 
natural or synthetic bandages, and cotton wool are referred as traditional dressings, while 
hydrocolloids, alginates, hydrogels, biological dressings, semipermeable adhesive film 
dressings and foam dressings are modern dressings (Falabella, 2006; Queen et al., 2004). 
Further classification is based on the function of dressings for the wound (debridement, 
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antibacterial, occlusive, absorbent, adherence) (Purner and Babu, 2000). Dressings that 
make physical contact with the wound surface are referred to as primary dressings, while 
secondary dressings cover the primary dressings (Van Rijswijk, 2006).  
Gauze dressings are made from fibres of cotton, rayon polyester or a combination of both. 
They have been widely used in wound care throughout history due to their ability to offer 
good absorption and the fact that they are affordable and easily accessible (Jones, 2006). 
However, as later research has revealed the importance of maintaining a moist wound bed, 
traditional cotton gauze has been found to be inappropriate for wounds that produce little 
wound exudate. In addition, the drying nature of gauze can potentially lead to discomfort 
and trauma during removal. It has been suggested that traditional dressings should be 
employed only for wounds that are clean and dry, or be used as secondary dressings to 
absorb exudates and protect the wound (Harding et al., 2000; Morgan, 2002).  
Films are thin, adhesive and semi-occlusive membranes that can be used as both primary 
and secondary dressings. They manage moisture via vapour transmission and are good 
barriers against foreign liquid and bacteria. As film dressings are non-absorbent and hence 
may lead to trapping of fluid and subsequent maceration of wound tissue, they are 
recommended for wounds with minimal wound exudate or as secondary dressings. Patients 
using films can also benefit from the fact that the dressings can be left in place without 
being changed for up to 7 days (Fonder et al., 2008; Schultz et al., 2004). 
Hydrocolloid dressings are most commonly used dressings and are usually composed of 
gelatin, pectin and carboxymethylcellulose. These dressings are available in the form of thin 
sheets or films and adhesive hydrocolloid gel form (Bethell, 2003). In the intact state, the 
outer dressing layer is impermeable to bacteria, oxygen and water vapour, but as the gelling 
process takes place and the dressing becomes progressively more permeable. This keeps 
wound at an optimal stable temperature and moisture level. Therefore, hydrocolloids are 
recommended for wounds with low to moderate amounts of exudate (Barnea et al., 2004). 
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Branded hydrocolloid products include Granuflex
 
and Aquacel

 (ConvaTec, UK), 
Comfeel
 
(Coloplast, UK) and Tegasorb

 (3M Healthcare, UK). 
Foam dressings are prepared with porous polyurethane foam have the ability to absorb 
moderate amounts of fluid, making them useful for the management of wounds with light 
and moderate levels of exudate (Morgan, 2002). Foam dressings have been found to be 
useful for treatment of granulating wounds but are not suitable for dry epithelising wounds 
or dry scars, as foam dressings rely on exudates (Marcia and Castro, 2002; Morgan, 1999). 
Foam dressing products include Lyofoam

 (ConvaTec) and Allevyn

  (Smith and Nephew). 
Alginate dressings are composed of sodium and calcium salts of alginic acid, an anionic 
polysaccharide and are available in the form of a plate or a band. When applied to wounds, 
calcium ions present in the alginate fibre are exchanged with sodium ions present in the 
blood to form a protective gel film (Thomas, 2000). Examples of alginate dressings 
available in the market are Sorbsan

 (Maersk, UK), Kaltostat
 
(ConvaTec, UK). 
Hydrogels were first developed in the 1950s, and applied to wound therapy about 30 years 
later (Kennedy-Evans and Lutz, 2010). They are insoluble, swellable hydrophilic materials 
made from synthetic polymers such as poly(methacrylates) and polyvinylpyrrolidone, and 
have ability to transfer vapour and water and provide moisture to the wound (Fan et al., 
2011b). Hydrogel dressings work by rehydrating dead tissues and enhancing autolytic 
debridement for the treatment of dry, necrotic wounds. The dressings are non-reactive with 
biological tissue, are permeable to metabolites and are non-irritating (Wichterle and Lim, 
1960). Recently, a flexible methacrylate dressing (Altrazeal
®
, Uluru Inc., US) was 
introduced. Altrazeal is available as sterile dressing powder which is used for treatment of 
exuding wounds such as burns, abrasions, surgical wounds and chronic wounds (Fitzgerald 
et al., 2009). Altrazeal powder is composed of small particles containing a poly-2-
hydroxyethyl-/poly-2-hydroxypropyl (pHEMA/pupa)-methacrylate backbone and a terminal 
hydroxyl group, which is transformed into a porous gel matrix once in contact with wound 
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exudate. Hence, it can be directly applied to a wound, transforming in the presence of 
wound exudate, or can be hydrated using saline or other sterile solutions, becoming a 
flexible dressing. 
Biological dressings are made from biomaterials that play an active part in the wound 
healing process; hence, they are also known as bioactive dressings. Bioactive dressings are 
prepared using  polymers such as collagen, hyaluronic acid, chitosan, alginates and elastin 
(Ishihara et al., 2002; Ramshaw et al., 1995). The biomaterials incorporated into biological 
dressings have the advantage of forming part of the natural tissue matrix in the normal 
wound healing process (Ueno et al., 1999).  
Antimicrobial dressings are used to minimise the growth of microorganisms in wounds. 
They provide local treatment and have a therapeutic effect on the dermis and superficial 
dermis, since the active ingredients are concentrated at the skin surface and less reaches the 
subcutaneous fat. The ideal antimicrobial drug for topical treatment should have broad 
activity, and be microbicide, non-toxic, and non-allergenic (Kaye, 2000). Topical treatment 
with antimicrobial agents can limit and reduce the risk of wound infections. These dressings 
can be used on both acute and chronic wounds that are critically infected, which can lead to 
compromised wound healing (Flores and Kingsley, 2007). Different antiseptics such as 
silver, iodine, polyhexamethyl biguanide (PHMB), and chlorhexidine have been used in 
antimicrobial dressings (McDonnell and Russell, 1999). 
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1.3 Skin 
1.3.1 Structure of skin 
 
Skin is a complex organ that primarily functions as a protective barrier and a sensory organ 
and is also involved in maintenance of haemostasis. The skin has a layered structure, which 
is broadly categorised into the outermost layer of tissue (non-viable epidermis), the stratum 
corneum (SC); the viable epidermis; the overlying dermis; and the innermost subcutaneous 
hypodermis (Figure 1.1). The skin is the largest organ of the body, accounting for 
approximately 10 % of the total body mass (Mills and Cross, 2006). The structure (such as 
the number of sebaceous glands, hair density and thickness) and physiology (such as 
metabolic activity, pH and humidity) of skin may display both inter-individual and even 
intra-individual variability, depending on the body site and age (Waller and Maibach, 2009, 
2005). The normal pH of skin has been estimated at 4.7. However, many external factors 
such as the use of water and soap affect the skin surface pH, and therefore it ranges between 
4 to 7 (Lambers et al., 2006).  
 
 
 
                        Figure 1.1 Schematic diagram of mammalian skin (Visscher, 2009). 
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1.3.1.1 Stratum corneum  
 
The outermost layer of skin, the SC, is generated by the epidermis and is about 10 to 20 µm 
in thickness and is known as non-viable epidermis composed of flattened, hexagonal and 
cornified cells. SC is surrounded by extracellular lamellar lipid matrix of mostly ceramides, 
free fatty acids and cholesterol, which is known the brick and mortar model (Waller and 
Maibach, 2005). In this model, the bricks represent the corneocytes embedded in the mortar, 
the lipid phase. The corneocytes are tightly packed and flattened (approximately 0.5 µm 
thick) due to contraction of keratin filaments and loss of intracellular organelles such as the 
nucleus, and are connected by corneodesmosomes, enhancing the SC barrier properties 
(Haftek et al., 1998; Korting et al., 2011). Furthermore, the cell membrane of keratinocytes 
in the SC is covered by a protective cornified envelope, which provides additional strength. 
The intercellular spaces in the SC are filled with lipid bilayers (lamellae), composed of non-
polar lipids, including ceramides (47 %), free fatty acids (9 %) and esters, as well as 
cholesterol (27 %) and its sulphates. The structure of the lipid bilayer displays heterogeneity, 
having both lipophilic and hydrophilic domains (Rosso and Levin, 2011).  
1.3.1.2 Epidermis 
 
The epidermis is composed of stratified squamous epithelium, which contains keratinocytes, 
melanocytes, Langerhans cells and Merkel cells. The epidermis is divided into four 
different layers depending on the status of keratinocyte differentiation (Mills and Cross, 
2006). The thickness of epidermis is varies from 0.05 mm on the eyelids to 0.8 ± 1.5 mm on 
the soles of feet and palm. It is composed of different sub-layers: the uppermost granular 
cell layer, the central spinous cell layer and the basal layer at the bottom. The basal cells 
undergo several stages of differentiation during progressive movement up through the 
layers towards the SC, replacing the dead SC cells that are shed from the skin surface. The 
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entire process from a basal cell layer to SC shedding takes around 28 days (Blanpain and 
Fuchs, 2009).  
1.3.1.3 Dermis 
 
The dermis is an underlying layer of connective tissue consisting of thick fibrous and elastic 
layer containing blood vessels, lymphatic channels and sensory nerves. Below the dermis 
lie papillary layers of loose collagenous and elastic fibres, which extend from the base of 
the papillary layer to subcutaneous tissue. The dermis is made up of fibroblasts, which 
produce collagen, elastin and structural proteoglycans, together with immune-competent 
mast cells and macrophages (Cevc and Vierl, 2010). The fibrous tissue of dermis also 
contains sweat glands, nerve endings, sebaceous glands and hair follicles. 
 
1.3.1.4 Skin appendages 
 
Skin appendages include the hair follicles and the sebaceous, apocrine and eccrine glands, 
which are located within the skin. The follicles are derived from the epidermis and the 
dermis, and are very dense on the scalp and face. The pilosebaceous unit is composed of 
hair follicles, the hair shaft and the associated sebaceous glands. The hair shaft is composed 
of the medulla, the cortex with melanosomes, and the cuticula, represented by flat cornified 
cells arranged similarly to roof tiles (Gawkrodger and Arden-Jones, 2002; Jakubovic and 
Ackerman, 1992).  
Human skin contains two types of hair: terminal hairs are pigmented, long and thick (>2 
cm) with roots deep in the dermis (>3 mm depth), while the thinner and shorter vellus hairs 
reach a depth of 1 mm. Each hair follicle is lined by germinative cells, which produce 
keratin and melanocytes and synthesise pigment (Lauer, 2005). The hair shaft consists of an 
outer cuticle, a cortex of keratinocytes and an inner medulla. The outer root sheath that 
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surrounds the hair follicle is a stratified epithelium that is continuous with the epidermis 
(Knaggs, 2007; Otberg et al., 2007; Schaefer and Lademann, 2001). 
Sebaceous glands are closely associated with hair follicles, especially those of the scalp, 
face, chest and back. They produce an oily sebum via holocrine secretion, in which the cells 
break down and release their lipid cytoplasm (Meidan et al., 2005; Tobin, 2001). Apocrine 
and eccrine glands are sweat glands; the eccrine glands produce sweat and for temperature 
regulation, and apocrine glands produce lipid-rich secretions (Mills and Cross, 2006).  
1.3.2 Penetration pathways into the skin 
 
Skin penetration is a passive process that is affected by drug solubility and partitioning in 
the vehicle, skin structures, and diffusion of the drug into the skin. Generally, the 
penetration of topically applied substances through the skin occurs via three separate 
pathways, as illustrated in Figure 1.2 (Bunge et al., 1999). The first is the transcellular 
pathway, which encompasses the direct transportation of substances through the lipophilic 
and hydrophilic domains. The second is the intercellular pathway, by which substances 
passively diffuse between cells along the tortuous lipid matrix around the corneocytes.  
 
 
 
Figure 1.2 Schematic representation of drug penetration routes through the skin (Lane, 2013). 
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Lipophilic compounds are thought to travel along the lipid domains of the lipid bilayer 
(hydrocarbon chains), while hydrophilic compounds travel along the polar head group 
regions. The transappendageal route, which includes hair follicles and sweat glands, is 
called the ‘shunt route,’ as there are less lipid membranes to be crossed compared to the 
transcellular and intercellular pathways (Otberg et al., 2004). The important role of hair 
follicles in skin penetration and reservoir function has already been validated and reported 
in literature (Knorr et al., 2009). In present research work, importance of follicular pathway 
to enhance the skin penetration of triclosan has been studied using differential stripping 
technique which is described in detail in chapter 3 (Refer section 3.4.3.7). 
1.3.3 Skin penetration enhancers 
 
Penetration enhancers are defined as substances or strategies that promote penetration of 
drugs into the skin, or drug permeation through the skin. Penetration enhancers are the most 
common agents used for increasing dermal absorption of antimicrobial agent to the deeper 
layers of the skin (Sapra et al., 2008). Several physical and chemical penetration enhancers 
have been reported in the literature; these have successfully resulted in elevated levels of 
drugs delivered across and into the skin (Ghosh et al., 1997). 
1.3.3.1 Chemical approach 
 
The chemical approach to penetration enhancement includes the use of chemicals such as 
surfactants (e.g. Tween or propylene glycol), solvents (e.g. alcohols), fatty acids (e.g. lauric 
acid, palmitic acid and oleic acid), esters, glycols, and sulphoxides. Chemical penetration 
enhancers can reversibly alter the barrier properties of the skin through several mechanisms 
such as reversible disruption of lipid structure in SC, enhancing partition of vehicle or 
transport of solvent into the skin (Barry, 1987; Guy and Hadgraft, 1987):  
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Alcohols, fatty alcohols and glycols: 
Alcohols such as ethanol, methanol and fatty acids like oleic acids are commonly used in 
many dermal formulations. Ethanol can also be used as a co-solvent during in vitro 
permeation experiments to maintain sink condition and it has been shown to  enhance the 
flux of levonorgestrel, estradiol, hydrocortisone and 5-fluorouracil through rat skin (Friend 
et al., 1988) and of estradiol through human skin in vivo (Pershing et al., 1990). The 
permeation enhancing ability of oleic acid and palmitoleic acid has been studied using 
propylene glycol (PG) as co-solvent, which has shown approximately a 10-fold increase in 
permeation across skin (Yokomizo and Sagitani, 1996). Since 1932, PG has been used 
either as a co-solvent for poorly soluble materials or to enhance drug permeation through 
skin from topical preparations (Barrett et al., 1965; Hoelgaard and Mollgaard, 1985).  
 
Azone: 
Azone (1-dodecylazacycloheptan-2-one or laurocapram), the first molecule or agent 
specifically designed as a skin penetration enhancer (Stoughton and McClure, 1983), was 
investigated extensively in the 1980s and 1990s (Harrison et al., 1996). Azone is a highly 
lipophilic material that is soluble and compatible with the most organic solvents, including 
alcohol and PG. Azone interacts with lipid domains of SC by partitioning into the lipid 
bilayer (Williams and Barry, 2004).  Azone has low irritation and toxicity with nearly no 
pharmacological activity. It can be used as a penetration enhancers for hydrophilic and 
lipophilic substances (Wiechers et al., 1987). Azone and its derivatives acts effectively as 
penetration enhancers when used in low concentrations between 1 – 5 %. 
 
Glycol ethers – Transcutol® P 
Transcutol
 
P (TP),
 
a monoethyl ether of diethylene glycol, has also been reported to increase 
the solubility of drugs in the skin. Harrison et al., (1996) demonstrated the effects of TP
 
on 
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the diffusivity and solubility of 4-cyanophenol in human skin in an in vitro skin diffusion 
study. Although many reports in the literature have demonstrated the ability of this 
molecule to enhance penetration (El Nabarawi et al., 2013; Pandey et al., 2014; Prasanthi 
and Lakshmi, 2012),  further mechanistic studies are required to elucidate its exact 
interaction with skin components. 
Sulphoxides: 
Dimethyl sulphoxide (DMSO) has been extensively reported in the literature as a co-solvent 
and penetration enhancer (Coldman et al., 1971; Maibach and Feldmann, 1967; Roth and 
Fuller, 2011). It is typically considered to be a ‘universal solvent’ in many areas of 
pharmaceutical science. Recent work using molecular simulations has suggested that 
DMSO must be present in high concentrations in the skin in order to be efficacious as a 
chemical penetration enhancer (Junyaprasert et al., 2013). Because of the relatively high 
amounts of DMSO needed for penetration enhancement, as well as the associated issues of 
irritation and production of a malodourous metabolite in the breath, this compound has very 
limited use in commercial topical products.  
 
Surfactants: 
There are many surfactants that are capable of interacting with the SC to enhance the 
absorption of drugs and other active compounds from products applied to the skin. When 
surfactants are deposited onto the SC, they cause disruption of the SC structure. Anionic 
surfactants, such as sodium lauryl sulphate (SLS), induce fluidisation of SC lipids and 
increase skin absorption (Van-der Valk et al., 1985). Kushla and Zatz (1991) investigated a 
range of cationic surfactants for their ability to act as chemical penetration enhancers for 
water and lidocaine in vitro. Results showed a greater enhancement ratio for both water and 
lidocaine with higher concentrations of surfactants.  
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 Cationic surfactants such as benzalkonium chloride (Basketter et al., 2004) and 
cetylpyridinium chloride (Lin and Hemming, 1996) are reported as irritant to the skin and 
hence they are not suitable for dermal delivery. Non-ionic surfactants are generally 
considered to be less irritating than ionic surfactants and the most often reported compounds 
used as permeation enhancers include the polyoxyethylene alkyl ether (Brij) and 
polyoxyethylenesorbitan fatty acid ester (Tween) series. Ashton et al., (1986) investigated 
the influence of Brij 36T on the time of erythema induced by nicotine when applied as gel. 
Another study reported by Ryan and Mezei (1975) observed that the application of 10 % 
Tween 85 in petrolatum to the forearm of human subjects increases epidermal permeability 
due to water loss.  
 
Essential oils, terpenes and terpenoids: 
The application of monoterpenes and sesquiterpenes in dermal drug delivery has been 
extensively investigated over the years (Cornwell and Barry, 1994; Williams and Barry, 
1991; Yamane et al., 1995). Terpenes act by modification of the SC, improving drug 
partitioning into the skin. They are found in essential oils, and the compounds comprise of 
only carbon, hydrogen and oxygen atoms. Menthol is traditionally used in inhalation 
pharmaceuticals and has mild antipruritic effects when added to emollient preparations. The 
essential oils of eucalyptus and chenopodium have been shown to be effective penetration 
enhancers for 5-fluorouracil in human skin in vivo (Williams and Barry, 1989). L-menthol 
has been shown to enhance the in vitro permeation of morphine hydrochloride through 
hairless rat skin (Morimoto et al., 2002),  imipramine hydrochloride across rat skin (Jain et 
al., 2002) and hydrocortisone through hairless mouse skin (El-Kattan et al., 2000). 
However, the success of chemical enhancers is limited to low molecular mass permeants 
and their inclusion in the formulation may enhance the absorption of components other than 
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the permeants, which can lead to skin damage and irritation problems (Prausnitz et al., 
2004). 
1.3.3.2 Physical approach 
 
Physical enhancement utilises external energy to physically reduce the SC biological barrier, 
promoting penetration of exogenous compounds. This approach can be further categorised 
based on the energy force used, such as electrical (ionophoresis, electroporation); 
mechanical (abrasion and microneedles); and miscellaneous methods (ultrasound and laser 
wave) (Brown et al., 2006). These approaches are mainly used for large and hydrophilic 
molecules such as peptides and proteins. Furthermore, some of these techniques are 
associated with a sensation of discomfort and mechanical damage to the skin barrier (Lau et 
al., 2008). It has been proposed that using a combination of physical and chemical 
enhancers may achieve synergistic effects. For example, enhanced transdermal permeation 
of insulin has been achieved by combining iontophoresis with chemical enhancers, 
compared to the individual techniques employed separately (Pillai et al., 2004). 
1.3.4 Techniques for quantification of drug retained into skin 
 
The skin absorption of drugs from various topical formulations is studied using a variety of 
experimental approaches that permit the measurement of either in vivo or ex vivo 
penetration or the permeation profiles of substances that pass through the SC barrier. 
The well-known tape stripping technique, first introduced in 1951 by Pinkus, is widely used 
as a minimally invasive technique for evaluating the localisation and distribution of 
substances within the SC (Pinkus, 1951). The development of the differential stripping 
technique enabled quantitative evaluation of the hair follicular penetration process by 
combining the classical tape stripping process with cyanoacrylate skin surface stripping 
technique (Teichmann et al., 2005). Briefly, after application of a substance onto the skin, 
the tape stripping process is performed, which removes the portion of substance present 
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within the SC and the rest of the substance, located inside the hair follicle orifices, is 
removed by the cyanoacrylate skin surface stripping technique. Thus, substances accessing 
the intercellular, transcellular and transfollicular pathways can be quantitatively evaluated 
by region. A further technique was developed in 2006, in which the hair follicle orifices are 
artificially blocked by nail varnish or wax within a predetermined skin region (Teichmann 
et al., 2006). This approach allows the evaluation of skin penetration in vivo by detecting 
and comparing the blood concentrations of substance in both blocked and unblocked hair 
follicle orifices.  
For ex vivo studies, the skin mounted in Franz diffusion cells is exposed to the drug for 
defined time periods. The skin is then removed and drug penetration is quantified, either in 
full-thickness skin or in horizontally sliced skin of defined thickness. The amount of drug 
present in the receiver fluid is normally analysed using high-pressure liquid 
chromatography (HPLC) (Gysler et al., 1999). Other quantification methods include 
infrared (IR) imaging, confocal laser scanning microscopy (CLSM) and Raman 
spectroscopy (Alvarez-Román et al., 2004; Mao et al., 2012; Tanja et al., 2010). 
Most of these approaches, however, do not reach a spatial resolution at the subcellular level. 
In some skin absorption studies, dyes are used in place of drug as a suitable model for 
visualizing the uptake and transport of substances by fluorescence microscopy (Küchler et 
al., 2009). Confocal laser scanning microscopy and two-photon microscopy, for example, 
have the inherent advantage of high sensitivity, reaching single-molecule detection (Peter et 
al., 2000). However, fluorescence microscopy can rarely be used to probe the uptake of 
drugs into skin because it requires the drug to display fluorescence.  
Mass spectroscopy based techniques, such as matrix assisted desorption/ionisation mass 
spectrometry imaging (MALDI-MSI) (Brendan et al., 2007; Philippa et al., 2011) and time-
of-flight secondary ion mass spectrometry (TOF-SIMS) (Judd et al., 2013) have also been 
used. These techniques mainly focus on the characterisation of skin (Tanja et al., 2010) or 
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the penetration of fluorescent molecules (Alvarez-Román et al., 2004), surfactants (Mao et 
al., 2012) or non-active ingredients (e.g. solvents) (Kazarian and Chan, 2013) into the skin. 
Mass spectroscopy has the advantage of high chemical specificity without requiring the use 
of labels such as isotopes or fluorescence (Michell et al., 2003). 
 
1.3.5 Topical antimicrobial agents 
 
Appropriate and effective skin antisepsis is essential in preventing infections that can arise 
from a breach of the skin, such as during surgery or prior to insertion of intravascular 
devices. A variety of topical antimicrobial agents for skin antisepsis are currently available 
in different concentrations and formulations. The antiseptics used most commonly for skin 
preparation before surgery are alcohols, chlorhexidine digluconate (CHG) and povidone-
iodine (PVP-I), of which CHG and PVP-I have shown more persistent antimicrobial activity 
compared to alcohols. 
1.3.5.1 Alcohols 
 
Various alcohols such as ethanol, isopropyl alcohol and n-propanol have been used 
effectively as antimicrobials against bacteria, viruses and fungi (Morton, 1983). Current 
uses of alcohol within the hospital environment include alcohol-based hand rubs for general 
antisepsis, alcoholic CHG solution for cutaneous decontamination prior to catheter insertion 
and for skin preparation before invasive procedures due to rapid volatile nature.  The 
mechanism of action of alcohols is non-specific but they denature proteins and cause 
membrane damage and cell lysis. Alcohols, if used alone for skin antisepsis, does not 
exhibit prolonged action on the skin. Therefore, it is recommended to use alcohols in 
combination with another antimicrobials such as CHG or iodine to enhance the longevity of 
the antimicrobial effect. Combining CHG with isopropyl alcohol, for example, has 
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demonstrated superior activity compared to IPA alone in preventing infections associated 
with peripheral venous catheters (Small et al., 2008). 
1.3.5.2 Povidone – iodine  
 
Povidone-iodine (PVP-I) is the most common iodophor used in the healthcare environment 
(Figure 1.3), which is a complex of iodine and polyvinylpyrrolidone. It releases 
concentration of free iodine, whose exact mode of action is not known but is thought to 
involve multiple cellular effects by binding to proteins, nucleotides and fatty acids. Iodine 
likely reacts with the phenolic groups of tyrosine and the N-H groups of amino acids (such 
as arginine, histidine and lysine) to block hydrogen bonding and also oxidises the S-H 
bonds of cysteine and methionine. It reacts with the bases of nucleotides (such as adenine, 
cytosine and guanine) to prevent hydrogen bonding, and reacts with C=C bonds in fatty 
acids to alter the membrane structure (McDonnell and Russell, 1999). It has a broad 
spectrum of activity against bacteria, mycobacteria, fungi, protozoa and viruses.  
 
 
Figure 1.3 Povidone-iodine, the iodine complex with neutral polyvinylpyrrolidone polymer carrier. 
 
Alcoholic solutions of CHG have been reported to exhibit superior antimicrobial activity 
compared to PVP-I; these studies have compared, for example, PVP-I and alcoholic 0.5 % 
(w/v) CHG in reducing catheter-related blood stream infections (CR-BSI), central venous 
catheter (CVC) tip colonisation and CVC skin site colonisation (Humar et al., 2000), 
tincture of iodine and CHG in reducing blood culture contamination (Traunter et al., 2002) 
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and alcoholic and aqueous CHG and PVP-I against Staphylococcus epidermis in a 
planktonic and a biofilm modes of growth in vitro (Small et al., 2008). 
1.3.5.3 Chlorhexidine digluconate 
 
CHG is the most commonly used broad spectrum topical antimicrobial agent for skin 
preparations available in different salt forms such as diacetate, digluconate and 
dihydrochloride (Block, 1991; Rosenberg et al., 1976). CHG shows antimicrobial activity 
against both Gram-positive and Gram-negative bacteria. At very low concentrations, CHG 
exerts bacteriostatic effects and at high concentrations, CHG shows bactericidal effects, but 
however the effects vary from species to species. CHG acts by binding to bacterial cell 
walls and a rapid electrostatic attraction between the negatively charged bacterial cell wall 
and positively charged CHG, leads to leakage of bacterial cytoplasm showing rapid 
bactericidal effects (Paulson, 2014). Studies have also reported a biphasic effect of higher 
concentrations of CHG on protoplast lysis (Hiom et al., 1996). 
 
 
 
Figure 1.4 Chemical structure of chlorhexidine digluconate [1,6-Bis(N5-[p-chlorophenyl]-N1-
biguanido)hexane digluconate] (Rosenberg et al., 1976). 
 
CHG is thought to be an inhibitor of both membrane-bound and soluble ATPase, as well as 
net K1 uptake in Enterococcus faecalis (Harold et al., 1969). However, only high biguanide 
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concentrations inhibit membrane-bound ATPase (Chopra, 1987). The effect of CHG and 
other biocides on Acanthameoba was reviewed by Furr (2013) which showed that 
membrane damage to protozoa is a significant factor in their inactivation. CHG activity 
against yeast is similar to its activity against bacterial cells, with the targeting of yeast cell 
membranes. However, the yeast cell wall reduces its activity, as there is limited diffusion 
through the cell wall to the target cell membranes (McDonnell and Russell, 1999).  
 
 
1.3.5.4 Triclosan 
 
Triclosan (TSN), also known as 2,4,4-trichloro-2-hydroxydiphenyl ether, is a strong, broad-
spectrum, antimicrobial agent. It is bacteriostatic at low concentrations, where it blocks 
lipid synthesis, whereas at high concentrations, membrane destabilisation and triclosan-
induced K
+
 leakage causes a rapid bactericidal effect. 
 
 
 
Figure 1.5 Structure of triclosan (Bhargava and Leonard, 1995). 
 
TSN is highly lipophilic (log P 4.8) and insoluble in water, but is easily solubilised in most 
organic solvents. It has a ionisation constant (pKa) of 7.9 and a molecular weight of 289.5 
Da. TSN is known to inhibit fatty acid synthesis through interaction with the enoyl–acyl 
carrier protein enzyme reductase (Savage, 1971). Furthermore, incorporation of TSN into 
formulations can significantly enhance their efficacy against Gram-negative bacteria and 
O
Cl
ClCl
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yeasts (Leive, 1974). It has aslo been reported that TSN exhibits anti-inflammatory activity 
(Barkvoll and Rolla., 1994; Waaler et al., 1993). While specific mode of action for TSN is 
unknown, it has been suggested that it primarily affects the cytoplasmic membrane.  
1.3.5.5 Essential oils 
 
Essential oils are volatile aromatic oils obtained from various parts of plant contains 
complex mixtures of terpenes and their oxygenated compounds (Guenther, 1948). Many 
essential oils, such as camphor, cinnamon, clove, eucalyptus, geranium, lavender, lemon, 
lime, mint, rosemary and basil, are used in foods, beverages, cosmetics and healthcare 
products such as soaps, mouthwashes and toothpastes. They have not only been used as 
aromatic substances but also as natural preservatives (due to their antioxidant or radical 
scavenging properties) as well as antimicrobial agents (Cowan, 1999).  
Many essential oils, and their terpene constituents, have demonstrated broad-spectrum 
activity (Cowan, 1999). Tea tree oil (TTO) (from the leaves of Melaleuca alternifolia), for 
example, has been shown to efficiently eradicate MRSA from skin (Caelli et al., 2000; 
Dryden et al., 2004), as well as treat pulmonary tuberculosis (Sherry et al., 2004) and 
diabetic foot ulcers (Sherry et al., 2003). Eucalyptus oil (from the leaves of Eucalyptus 
globulus) has been successfully used to treat pulmonary tuberculosis (Sherry and Warnke, 
2004). Anti-inflammatory activity has been found for basil (Singh and Majumdar, 1999). 
Lemon and rosemary oils possess antioxidant properties (Aruoma et al., 1996; Calabrese et 
al., 1999). Peppermint and orange oils have shown anticancer activity (Kumar et al., 2004). 
Essential oils are generally regarded as safe when used at low doses. However, some cases 
of toxicity and skin irritation have been reported. For example, skin irritation and toxicity of 
TTO has been described. However, the use of TTO diluted for topical use (Hammer et al., 
2006) and the protection of TTO from oxidation or other damage through proper storage 
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(Hausen et al., 1999) reduces the risk of adverse effects. Studies on irritation and toxicity 
caused by other essential oils and terpenes are not well documented.   
The antimicrobial activity reported for many of the essential oils is not yet fully understood. 
However, they are thought to act on the plasma membranes of microorganisms, increasing 
cell membrane permeability and leakage of intracellular constituents (Cowan, 1999). Other 
studies have demonstrated membrane damage by lipophilic cyclic monoterpenes such as α-
pinene and limonene, as well as their partitioning within the lipid membranes, which 
increases membrane fluidity, affecting the respiration and function of cell membrane 
enzyme activity and increasing permeability to protons and ions (Sikkema et al., 1995).  
1.3.5.6 Silver compounds 
 
Silver, and its compounds, have long been used as antimicrobial agents (Brown and 
Anderson, 1968; Russell and Hugo, 1994). Presently, silver sulfadiazine is the most 
commonly used silver compound, although silver metal, silver acetate, silver nitrate have 
also shown antimicrobial properties (Brayfield, 2014). Silver compounds has various 
medical applications in dental work, catheters, and the healing of burn wounds (Klasen, 
2000; Silver and Phung, 1996) and non-medical applications such as in electrical appliances 
(Jung et al., 2007). More recently, silver has been also incorporated in wound dressings to 
reduce bacterial infection (Gemmell et al., 2006). The antimicrobial action of silver ions is 
closely related to their interaction with thiol groups (Belly and Kydd., 1982; Bragg and 
Rainnie., 1974; Furr et al., 1994), although other target sites remain a possibility (Richards 
et al., 1984). Amino acids, such as cysteine, and other compounds containing thiol groups, 
such as sodium thioglycolate, neutralise the action of silver against bacteria (Aziz et al., 
2012; Leaper, 2006; Sepideh et al., 2013). 
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1.4 Novel carriers for dermal drug delivery 
To improve drug delivery into skin, there is always a need to modify existing, or formulate 
new, drug delivery system for drugs with poor solubility or permeability. Polymeric drug 
delivery system are the most common formulations for long term delivery of therapeutic 
agents as they also have the potential for chemical modification. Nevertheless, the number 
of products on the market that are based on polymeric microparticles and nanoparticles 
remains limited because of the toxicity of polymers and the solvent residues left over from 
their production, the high cost of biodegradable polymers, the potentially toxic or allergenic 
end products of biodegradable polymers, and the lack of suitable large scale production 
methods (Shegokar et al., 2011; Yadav et al., 2013). 
In order to overcome these problems, a great deal of interest has been focused on lipid-
based carriers such as lipid emulsions, liposomes and lipid nanoparticles (Chen et al., 2010). 
Lipid based delivery systems are an accepted approach and constitute an emerging field for 
drug delivery. They have attracted the interest of a number of research groups because of 
their inherent properties, the biocompatibility and biodegradability of physiologically 
tolerated lipids, their physiochemical diversity, lower toxicity, high incorporation efficiency 
of lipophilic drugs, their ability to protect drugs from degradation, improved bioavailability, 
and controlled release characteristics. However, there are challenges regarding stability and 
manufacturing at the commercial scale and their suitability for drug delivery at different 
sites of administration (Liu et al., 2010b).  
1.4.1 Solid Lipid Nanoparticles  
 
Lipid nanoparticles have gained more interest in pharmaceutical applications due to their 
small sizes as it influences in vitro and in vivo skin penetration. Solid lipid nanoparticles 
(SLNs) refer to colloidal carriers in size ranges from 10 to 1000 nm prepared by 
physiologically biocompatible solid lipids, which are stabilised by surfactants. SLNs are 
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mostly used for lipophilic drugs as an alternative carrier system to emulsions and liposomes 
(Chimmiri et al., 2012; Ramadan, 2010). SLNs are composed of well tolerated 
biocompatible lipids which reduces the risk of toxicity for dermal application.  
 
 
 
                            Figure 1.6 Structure of solid lipid nanoparticles (Ekambaram et al., 2012). 
 
A typical solid lipid used in such delivery systems melts at temperatures exceeding body 
temperature (37°C). Examples of some of the lipids that have been investigated include 
fatty acids, steroids, waxes, triglycerides and acylglycerols alone or in combinations. Many 
classes of emulsifiers, either by themselves or in combination, have been utilised to stabilise 
the lipid dispersion. Examples of emulsifiers include lecithin, bile salts such as sodium 
taurocholate, nonionic emulsifiers such as ethylene oxide, propylene oxide copolymers, 
sorbitan esters, fatty acid ethoxylates, and combinations of these (Rupenganta et al., 2011).  
1.4.1.2 Advantages and disadvantages of solid lipid nanoparticles 
 
SLNs has many advantages such as solid lipid matrix offers protection of chemically labile 
drugs from external environment. Preparation of SLNs avoids use of organic solvents hence 
minimise the skin irritation and also use of biodegradable lipids avoids toxicity. SLNs can 
be used to controlled and targeted drug delivery systems. SLNs offer improved storage 
stability compared to liposomes as they can  be easily freeze-dried  (Fahr and Liu, 2007; 
Rupenganta et al., 2011). However, they also have some challenges such as the potential for 
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expulsion of drug from lipid matirx during storage and modification of lipid structure to 
transform into a crystal lattice (Ekambaram et al., 2012). 
1.4.1.3 Production methods 
 
SLNs are formulated using various methods described in literature. These methods include 
high shear homogenisation (HSH) (Liedtke et al., 2000),  microemulsion techniques (Priano 
et al., 2007), emulsion solvent evaporation (Mehnert et al., 2001b), high pressure 
homogenisation (HPH) and emulsion solvent diffusion (Trotta et al., 2003),  solvent 
injection or a solvent displacement (Schubert, 2003), phase inversion (Heurtault et al., 
2002), multiple emulsion techniques (Garcý-Fuentes et al., 2002), probe ultrasonication 
(Puglia et al., 2006) and a membrane contractor technique (Charcosset et al., 2005). All 
these methods work on same principle of generation of a nanoemulsion by replacing oil 
with a molten lipid phase using high and low energy methods. Then cooling of molten lipid 
formulations causes generation of SLNs. HSH is most commonly used technique due to its 
ease of scale up, relatively low production cost and time. HSH production methods in 
general consist of premixing the heated lipid phase to 5-10°C above its melting point.  An 
hot aqueous surfactant solution heated at  the same temperature is added and the mixture is 
homogenised under HSH followed by cooling to room temperature or rapid cooling using 
dry ice to form SLNs (Ekambaram et al., 2012; Kakadia and Conway, 2014). 
1.4.2 Nanoemulsions 
 
Nanoemulsions (NEs) were introduced during 1950’s, and are heterogeneous mixtures of 
two immiscible liquids, one of which is dispersed uniformly as fine droplets throughout the 
external continuous phase. Based on the size of droplets they are also termed emulsions, 
microemulsions and sub-microemulsions. NEs have many advantages as they are a 
kinetically stable system due to their small droplet size, larger surface area which reduces 
the occurrence of creaming, flocculation and sedimentation. NEs can be incorporated into 
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various formulations such as creams, gels, liquids and foams. NEs offers easy large scale up 
production techniques. Non-toxic and non-irritant nature of NEs makes it greater choice for 
skin and mucous application. It enhances drug solubility and absorption due to lipophilic 
nature (Bali et al., 2010; Bouchemal et al., 2004). NEs can be oil-in-water (O/W), water-in-
oil (W/O) and multiple NEs based on composition of the dispersed and continuous phases 
(Sharma et al., 2010). 
1.4.2.1 Production methods 
 
Various methods have been suggested to prepare NE formulations. Production of NEs 
require high amount of energy which can either provide by mechanical equipment or 
chemical potential present within the NE system. Methods used to prepare NEs includes 
microfluidisation, HPH, HSH and probe ultrasonication that generates intense cavitation 
forces to produce very fine droplets (Azevedo et al., 2015). 
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1.5 Aims of the thesis 
 
The aims of this thesis were 
 To determine the potential for lipid nanocarriers, i.e. SLNs and NEs, to be used as 
novel drug delivery systems for dermal delivery using antimicrobial agents such as 
TSN and CHG.  
 To study the suitability of SLNs and NEs as drug carrier systems within the scope of 
topical dermal delivery, especially for the treatment and prevention of skin 
infections. 
 To formulate TSN-loaded SLNs using glyceryl behenate and glyceryl 
palmitostearate as solid lipids to study the effects of composition and concentration 
of lipids on physicochemical parameter and skin retention properties of SLNs. 
 To access the ability of SLNs to target hair follicles by performing in vitro skin 
diffusion studies using a cyanoacrylate adhesive tape stripping method. 
 To study NEs as drug carrier for various antimicrobial agents for topical delivery of 
CHG using eucalyptus oil and olive oil. 
 To compare skin permeation and retention abilities  of SLNs and NEs containing 
eucalyptus oil and olive oil.  
 To compare CHG skin permeation data obtained using Strat-M membrane and 
porcine ear skin. 
 To analyse the ability of methacrylate dressing powder as drug delivery vehicle for 
CHG controlled and prolonged release.  
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2. CHAPTER: MATERIALS AND GENERAL METHODS 
 
2.1 Materials 
 
All the excipients used in the formulation of SLNs and NEs are of analytical grade. Lipids 
and oils used are biocompatible and well tolerated, are of generally regarded as safe 
(GRAS) status, are accepted for human use. 
2.1.1 Compritol
® 
888 ATO 
 
Compritol
® 
888 ATO is a marketed product from Gattefossé GmbH (Weil am Rhein, 
Germany) is also known as glyceryl behenate (GB). The chemical structure of GB is based 
on the glycerol esters of behenic acid (C22) (Figure 2.1) and is composed of a mixture of 
glycerol tribehenate (28-32 %), glycerol dibehenate (52-54 %) and glycerol monobehenate 
(12-18 %). While the main fatty acid is behenic acid (>85 %), other fatty acids (C16-C20) are 
also present (Raymond et al., 2009).  
 
                                                        
                                           Figure 2.1 Chemical structure of glyceryl behenate. 
 
 
The melting point of GB is between 69ºC and 74ºC. Due to the presence of partial 
acylglycerols, this lipid has an amphiphilic character. Its hydrophilic lipophilic balance 
(HLB) value is about 2 and its density is 0.94 g/cm
3
. GB, when heated, is soluble in 
chloroform, methylene chloride, xylene and insoluble in ethanol, ethyl ether, mineral oils 
and water. It is used in various pharmaceutical applications as a lubricant and binding agent 
for tablets and capsules, and as a viscosity enhancer in emulsion formulations for dermal 
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delivery (Brossard, 1991). GB is used in oral enteric-coated pellets, powders, suspensions 
and as a hot-melt coating agent sprayed onto a powder (Jannin et al., 2003). It has been 
used for the formulation of SLNs as a colloidal drug carrier (Negi et al., 2014; Reddy et al., 
2006).  
2.2.2 Precirol
®
 ATO5 
 
Precirol
®
 ATO5, also known as known as glyceryl palmitostearate (GP), and 1,2,3-propane 
triol is available as a marketed product from Gattefossé GmbH (Weil am Rhein, Germany). 
It is a mixture of the mono-, di- and triglycerides of the C16 and C18 fatty acids (Figure 2.2) 
(Raymond et al., 2009). The melting point of GP is between 52ºC and 55ºC. GP has a 
peroxide value lower than 0.3 mEq O2/kg, indicating high chemical stability. It is freely 
soluble in chloroform, dichloromethane and practically insoluble in ethanol (95 %), mineral 
oil, and water.  
 
 
                                            Figure 2.2 Chemical structure of glyceryl palmitostearate. 
 
GP is used to form microspheres, which may be used in capsules or be compressed to form 
tablets (Edimo, 1993; Shaikh, 1991), pellets (Hamdani, 2003) and biodegradable gels (Gao, 
1995). It is used in lipophilic matrices for sustained release tablet and capsule formulations 
(Saraiya and Bolton, 1990). It has been used to formulate SLNs of paclitaxel (Shenoy et al., 
2009), proteins and peptides (Yang et al., 2010).  
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2.2.3 Eucalyptus oil 
 
Eucalyptus oil (EO) is obtained from the leaf of the eucalyptus tree, which belongs to the 
family Myrtaceae (Ogunwande et al., 2003). EO is pale yellow in colour and has a 
distinctive odour. It contains cineole (eucalyptol) as a major active ingredient. EO contains 
cineole, pinene and other types of terpenes along with small quantities of phellandrene, 
which has been used for medicinal purposes (Reynolds, 1982). Up to forty-one compounds 
have been detected in EO, depending on the source and purity (Brophy et al., 1985). EO is 
insoluble in water, soluble in 1:5 alcohol (70 %), and miscible with fats, paraffin, ether, and 
chloroform. The boiling point of EO is from 176ºC to 177ºC. Because of its antibacterial 
activity, EO has been widely used in food, perfume, cosmetic, pharmaceutical and chemical 
applications (Ghalem and Mohamed, 2008; Hendry et al., 2009; Takahashi et al., 2004). 
Eucalyptus leaf extracts have been used as food additives. 
Various studies have shown that EO has antimicrobial activity against a range of 
microorganisms (Cimanga et al., 2002). EO is used for respiratory tract infections such as 
coughs, asthma, throat infections and sinusitis (Salari et al., 2006). EO has various skin care 
applications for wound infections, cuts, burns and insect bites (Mulyaningsih et al., 2011; 
Sadlon and Lamson, 2010). In addition, EO has also shown antibacterial (Cimanga et al., 
2002), antifungal (Su et al., 2006), analgesic, anti-inflammatory effects (Silva et al., 2003), 
as well as antioxidative activities (Siramon and Ohtani, 2007). 
2.2.4 Olive oil 
 
Olive oil (OO) is clear, a pale yellow liquid obtained from the ripe drupes of Olea europaea 
(Romero-García et al., 2014). OO is a mixture of fatty acid glycerides. Analysis of OO 
shows a high proportion of unsaturated fatty acids, such as palmitic acid, oleic acid, stearic 
acid, myristic acid and behenic acid. OO is miscible with ether, ethanol (95 %) chloroform, 
light petroleum, and carbon disulfide.  
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OO is widely used as an edible oil, in food preparations and products such as cooking oils 
and salad dressings. It is also used in topical pharmaceutical formulations and cosmetics as 
a solvent and hair conditioner. OO is used in various formulations such as soaps, liniments, 
plasters, oral capsules and as a vehicle for oily injections (Jakate et al., 2003). It is used to 
soften ear wax (Realdon et al., 2001) and in combination with soybean oil to prepare a lipid 
emulsion for use in premature infants (Koletzko et al., 2003).  
2.2.5 Tween
®
 80 
 
Tween
®
 80 (T80) is chemically known as polysorbate 80, polyoxyethylene sorbate or 
polyoxyethylene sorbitan fatty acid esters. T80 contains a series of partial fatty acid esters 
of sorbitol and its anhydrides copolymerised with approximately 20, 5, or 4 moles of 
ethylene oxide for each mole of sorbitol and its anhydrides (Figure 2.3). T80 is hydrophilic 
in nature has a HLB value of 15 and CMC value of 0.015 mM at 25C in water (Mahmood 
and Al-Koofee, 2013). 
 
 
                                  Figure 2.3 Chemical structure of polyoxyethylene sorbitan ester. 
 
T80 is commonly used as an emulsifier in foods, particularly in ice cream, to make it 
smoother and easier to handle (Goff, 1997). It is also used as an excipient for stabilising 
aqueous formulations for parenteral administration. It is widely used as an emulsifying 
agent in the preparation of stable oil-in-water pharmaceutical emulsions (Nerurkar, 1996). 
T80 is used as a solubilising agent for essential oils, oil-soluble vitamins, and as a wetting 
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agent for oral and parenteral suspension formulation (Zhang, 2003). 
2.2.6 Span
®
 80 
 
Span
®
 80, (S80) chemically known as sorbitan monooleate or sorbitan oleate, belongs to the 
sorbitan esters group. S80 is a mixture of partial esters of sorbitol and its mono and di-
anhydrides with fatty acids (Figure 2.4). S80 is hydrophobic in nature and is generally 
soluble or dispersible in oils; it is also soluble in most organic solvents. Although insoluble 
in water, it is generally dispersible. S80 has HLB value of 4.3. 
 
 
 
                                       Figure 2.4 Chemical structure of sorbitan monooleate. 
S80 is used as a nonionic surfactant in various pharmaceutical formulations, cosmetics and 
food products. It is also used as an emulsifying agent for topical formulations such as 
creams, emulsions, and ointments. S80 is either used alone or in combination with 
polysorbate to produce stable emulsions. S80 is also used in self-emulsifying drug delivery 
systems for poorly soluble compounds (Fatouros et al., 2007). Although S80 is non-toxic 
and non-irritant in nature, hypersensitivity has been reported after topical application (Rowe 
et al., 2012). 
2.2.7 Transcutol
®
 P 
 
Transcutol
®
 P (TP), also known as diethylene glycol monoethyl ether, ethoxy diglycol, 
ethyl dioxytol, or ethyl carbitol (Figure 2.5), is a marketed product from Gattefossé GmbH 
(Weil am Rhein, Germany). 
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                                   Figure 2.5 Chemical structure of diethylene glycol monoethyl ether. 
 
TP is a clear, colourless liquid having boiling point 198C. It is freely soluble in water, 
miscible in acetone, benzene, choloroform, and insoluble in mineral oils. TP has been 
widely used as solubiliser in various pharmaceutical products such as oral, topical, 
transdermal and injectables in the United States, Asia, and Europe (Osborne, 2011). It is 
used as a skin penetration enhancer for skin products such as lotions, gels, creams and 
cosmetic formulations (Puglia and Bonina, 2008). Topical solutions and a spray containing 
TP are used as anti-parasitic agents for veterinary applications (Strickley, 2004). 
2.2.8 Sodium lauryl sulphate  
 
Sodium lauryl sulphate (SLS) is chemically known as dodecyl alcohol hydrogen sulphate, 
sodium dodecyl sulphate or sulphuric acid monododecyl ester (Figure 2.6).  It is an anionic 
surfactant with a bitter taste and a faint odour of fatty substances. 
 
 
 
                                            Figure 2.6 Chemical structure of sodium lauryl sulphate. 
 
SLS takes the form of white or cream to pale yellow coloured crystals, flakes, or a smooth 
feeling powder with melting point of 204C - 207C. It is freely soluble in water, giving an 
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opalescent solution, and is practically insoluble in chloroform and ether. The HLB value of 
SLS is ≈ 40 and its CMC value is 8.1 mM at 25C in water (Mukerjee and Mysels, 1971).  
It is widely used in non-parenteral formulations and cosmetics at different concentrations. It 
is effective as a wetting agent in both acidic and alkaline conditions and is also used as an 
emulsifying agent, tablet and capsule lubricant. It has been used as a solubilising agent for 
improving the solubility of poorly water soluble drugs, like montelukast (Priyanka and 
Abdul, 2012), and TSN (Grove et al., 2003). 
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2.2 General Methods 
2.2.1 High performance liquid chromatography method development and validation 
 
An objective of this study was to develop and validate rapid and sensitive methods for 
quantitative analysis of TSN and CHG. The reverse phase high performance liquid 
chromatography (RP-HPLC) methods developed were validated in terms of precision, 
accuracy, sensitivity, linearity, range and recovery (ICH, 2005). Applications of this method 
include determination of drug content and encapsulation efficiency and evaluation of the in 
vitro release of TSN and CHG from the developed nanoformulations. 
2.2.1.1 Method development for triclosan 
 
Materials: Triclosan was a gift from Vivimed Labs (India). HPLC grade acetonitrile was 
obtained from Fisher Scientific (UK) and ultrapure water generated in-house was used in 
the study. 
 
Method: The HPLC system was obtained from Shimadzu Corporation (UK) and comprised 
an LC-10AT pump, an auto injector (LC-20AT) and a UV-Visible detector (SPD-20AV). 
The chromatographic analysis of TSN standard solution samples was carried out on a 
pentafluorophenyl (PFP) column (Phenomenex, UK). The column was 250 mm long with 
an internal diameter of 4.6 mm and a particle size of 5 μm. The mobile phase used was 
acetonitrile and water (60:40, % v/v) and analysis was performed at 30C.  
To enhance the separation of TSN, the amount of the ionised form of the drug was kept to a 
minimum by maintaining the mobile phase pH at 6 (based on the pKa of TSN (see section 
1.3.5.4). The samples were run at a constant flow rate of 1 ml/min. Detection of the samples 
was carried out at a maximum absorption wavelength of 280 nm. A stock solution of 100 
µg/ml was prepared. This was then diluted with the mobile phase to prepare 1, 5, 10, 20, 30, 
40 and 50 μg/ml samples and responses were measured using HPLC. 
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2.2.1.2 Method development for chlorhexidine digluconate 
 
Materials: Chlorhexidine digluconate (20 % w/v) solution, sodium heptane sulphonate and 
diethylamine were purchased from Sigma Aldrich (UK). HPLC grade methanol was 
obtained from Fisher Scientific (UK) and ultrapure water generated in-house was used in 
the study. 
 
Method: The same HPLC system as described in Section 2.2.1.1 was used. The 
chromatographic analysis of the CHG containing samples was carried out using a Synergi 
C18 column (250 mm x 4.6 mm ID, 4μm) from Phenomenex, UK. The isocratic mobile 
phase consisted of methanol: water mixture (75:25, % v/v) with 0.005 M sodium heptane 
sulphonate and 0.1 % (v/v) diethylamine, adjusted to pH 4 with glacial acetic acid. The 
samples were run at a constant flow rate of 1 ml/min. Detection of the samples was carried 
out at a wavelength of 254 nm. A stock solution of 100 μg/ml was prepared for CHG. This 
was further diluted with the mobile phase to prepare 1, 5, 10, 20, 30 and 40 μg/ml samples 
and responses were measured using HPLC. 
2.2.1.3 High performance liquid chromatography method validation 
2.2.1.3.1 Specificity 
 
The analytical specificity of a method is its ability to accurately identify and measure an 
analyte in the presence of other closely related compounds. Specificity shows how well an 
assay can detect only a specific substance and not the other closely related substances in the 
sample during an analysis. The analytical specificities of the RP-HPLC methods for TSN 
and CHG were determined by comparing the chromatograms obtained from the injection of 
standard drug solution and the injection of a test sample containing all inactive excipients 
along with the drug. Figure 2.7 and Figure 2.8 shows typical HPLC chromatograms of TSN 
standard solution and TSN test sample, while Figure 2.9 and Figure 2.10 shows typical 
HPLC chromatograms of CHG standard solution and CHG test sample respectively. 
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Figure 2.7 Chromatogram of triclosan standard solution (20 μg/ml). 
 
 
 
 
Figure 2.8 Chromatogram of triclosan test sample. 
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Figure 2.9 Chromatogram of chlorhexidine digluconate standard solution (20 μg/ml). 
 
 
Figure 2.10 Chromatogram of chlorhexidine digluconate test sample. 
The HPLC chromatograms for mixtures of inactive ingredients revealed no extra peaks near 
the retention times of 7.34 min for TSN and 5.03 min for CHG, showing the HPLC 
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methods specificity for their respective drugs. 
2.2.1.3.2 Accuracy  
 
The accuracy of an analytical method represents the closeness of the test results obtained 
using the method to the true value Accuracy was evaluated by determining the recovery of a 
sample of the analyte spiked into the matrix of the sample to be analysed. Drug solutions 
were prepared that contained known amounts of drug, at 50 %, 100 % and 150 % of the 
assay concentrations. These were compared with reference standards of known purity for 
both drugs and percent recoveries (mean ± SD) were calculated. The TSN and CHG 
solutions were spiked with known amounts of excipients used in formulations and samples 
were analysed by comparing the estimated concentrations with the known concentrations of 
TSN and CHG to calculate the percentage recovered. 
Table 2.1 Recovery of triclosan from spiked samples for determination of assay accuracy (Mean ± SD, n=3). 
 
Levels 
Amount added 
(µg/ml) 
Amount recovered 
(µg/ml)
 % Recovery 
50 % 25 24.82 99.23 ± 0.06 
100 % 50 50.87 101.65 ± 0.12 
150 % 75 74.61 99.46 ± 0.08 
           
 
Table 2.2 Recovery of chlorhexidine digluconate from spiked samples for determination of assay accuracy 
(Mean ± SD, n=3). 
 
Levels 
Amount added 
(µg/ml) 
Amount recovered 
(µg/ml) 
% Recovery 
 
50 % 20 20.32 101.51 ± 0.03 
100 % 40 39.84 99.58 ± 0.09 
150 % 60 60.53 100.85 ± 0. 15 
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2.2.1.3.3 Linearity 
 
The linearity of HPLC method is the ability to detect the upper and lower concentration 
range of analyte through the system. To determine the linearity and range of an assay, a 
calibration curve must be prepared over the range of concentrations appropriate to the assay 
and the regression coefficient determined. 
The linearity was analysed for TSN in the concentration range of 1 – 50 μg/ml, whereas for 
CHG the concentration range was 1 – 40 μg/ml (all samples were prepared in triplicate). 
The regression equation for TSN (Figure 2.11) was found to be y = 5153.3x – 1085.3 (R2 > 
0.9999), while the regression equation for CHG (Figure 2.12) was found to be y = 23045x + 
10195 (R
 2 
> 0.9995). The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated from the standard curve according to Equations 2.1 and Equation 2.2 below: 
 
                                            LOD =
3XSD
slope
                                               Equation 2.1 
 
                                              LOQ =
10xSD
slope
                                             Equation 2.2 
 
All the parameters such as LOD, LOQ, capacity factor, tailing factor, theoretical plates, 
peak resolution and column efficiency were calculated for both TSN and CHG to test the 
system suitability for analysis (Table 2.5). 
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Figure 2.11 Standard calibration curve for triclosan (Mean ± SD, n=3). 
 
 
 
Figure 2.12 Standard calibration curve for chlorhexidine digluconate (Mean ± SD, n=3). 
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2.2.1.3.4 Precision 
 
The precision data of analytical methods shows close agreement between repeated test 
results of the same samples. The precision of the method measures reproducibility of results 
of analytical including sample preparation and sampling under specified operating 
conditions. Precision of HPLC methods used for both TSN and CHG was determined using 
six replicas of the TSN and CHG standard solutions, on the same day (intra-day precision) 
and once a day over a period of one week (inter-day precision). The results are expressed as 
the mean area under the curve (AUC) and percent relative standard deviation (% RSD) 
measurements (Tables 2.3 and Table 2.4). 
 
Table 2.3 Intra-day and inter-day precision of HPLC methods for triclosan (Mean ± SD, n=3). 
 
Concentration 
(μg/ml) 
Intra-day precision Inter-day precision 
Mean AUC ± SD % RSD Mean AUC ± SD % RSD 
1 6232.1 ± 142.1 0.45 6217.8 ± 274.6 0.71 
5 27116.7 ± 109.3 0.21 27032.1 ± 163.2 0.42 
10 51534.2 ± 252.5 0.05 51741.9 ± 192.5 0.62 
20 102860.7 ± 178.5 0.09 102891.4 ± 316.1 0.6 
30 155005.5 ± 214.3 0.03 154008.4 ± 287.3 0.56 
40 207583.3 ± 149.7 0.08 206714.1 ± 174.2 0.38 
50 261832.5 ± 317.2 0.10 261198.2 ± 185.3 0.74 
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Table 2.4 Intra-day and inter-day precision of HPLC method for chlorhexidine digluconate (Mean ± SD, n=3). 
 
Concentration 
(μg/ml) 
Intra-day precision Inter-day precision 
Mean AUC ± SD % RSD Mean AUC ± SD % RSD 
1 9438.2 ± 362.1 0.17 9321.6 ± 283.1 0.18 
5 31284.6 ± 273.6 0.36 32835.2 ± 253.4 0.26 
10 56930.8 ± 241.2 0.14 55628.1 ± 195.2 0.62 
20 116839.3 ± 316.3 0.24 114636.6 ± 184.7 0.58 
30 174582.7 ± 212.6 0.37 175391.4 ± 196.2 0.35 
40 235826.5 ± 325.5 0.18 237293.4 ± 314.7 0.27 
  
 
Table 2.5 Chromatographic characteristics of HPLC system suitability. 
 
HPLC Parameter TSN CHG 
LOD 0.60 μg/ml 0.63 μg/ml 
LOQ 1.83 μg/ml 1.93 μg/ml 
Theoretical plate number (N) 5230.13 cm 2564.47 cm 
Tailing factor (T) 1.25 1.57 
Capacity Factor (K) 2.92 3.96 
Height equivalent theoretical 
plate 
0.04 0.09 
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2.2.2 Skin diffusion mechanism 
 
For most chemicals, the main transport mechanism through the skin is passive diffusion, as 
is the case with most other biological membrane barriers of physiological or pharmaceutical 
relevance. Passive diffusion is a mechanism by which a substance moves from one region 
of a system to another, following random molecular motions (Figure 2.13). In other words, 
there is a random walk of an ensemble of molecules from a region of high concentration to 
regions of low concentration. The diffusion process can be expressed through Fick’s first 
law and the second law of diffusion. 
 
 
 
 
 
 
 
 
Figure 2.13 Molecular transport mechanism across a membrane. 
 
A. Fick’s first law of diffusion 
For a given medium, the particle flux (J), or the number of particles travelling through a 
unit of perpendicular area per unit time, is proportional to the concentration gradient. This is 
expressed through Fick’s first law of diffusion (Equation 2.3), 
                                       J =  −D 
dC
dX
                                               Equation 2.3 
Where, J = rate of transfer per unit surface area (the flux), dC/dX = concentration gradient 
per unit length, and D = diffusion coefficient or diffusivity. 
The proportionality constant in Equation 2.3 is the diffusion coefficient (D) of the 
corresponding medium, or a rough measure of the ease with which a molecule can move 
J 
High concentration Low concentration 
dx 
x 
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about within a medium, in this case, the SC. Since diffusion through the SC is passive, large 
molecules diffuse more slowly than small ones. In general, drugs with a molecular weight 
smaller than 500 Da have acceptable permeation rates (Aulton and Taylor, 2013). However, 
diffusivity is not only dependent on molecular weight and volume but on the degree of 
interaction between the drug and the SC. The concentration gradient across the SC will 
depend primarily upon the chemical characteristics of the drug, including solubility, 
lipophilicity, ionisation and stability.  
 
B.  Fick’s second law of diffusion 
When a formulation is placed on the skin surface, it partitions into the lipids and diffuses 
via intercellular channels. Following a short period of exposure, a nonlinear concentration 
gradient develops across the SC, the slope of which is described by Fick’s second law of 
diffusion (Equation 2.4). Fick’s second law relates the rate of change in concentration with 
time at a given point in a system to the rate of change in concentration gradient at that point. 
                               dc
dt  
=  
𝑑𝐽
ℎ
                                                Equation 2.4 
The rate of permeation across the skin (dQ/ dt) is given by:  
                                  
dQ
dt 
= Ps (Cd − Cr)                                      Equation 2.5 
Where Cd = concentration of skin penetrant in the donor compartment (e.g., on the surface 
of the SC) 
Cr = concentration in receiver compartment (e.g., body) 
Ps = the overall permeability constant of skin tissue to the penetrant 
                                               Ps =  
KsDss
hs
                                             Equation 2.6 
Where Ks represent the partition coefficient of the penetrant molecule from a formulation to 
SC, Dss is apparent diffusivity of the steady-state diffusion of the penetrant molecule and hs 
is the thickness of skin.  
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From Equation 2.5, it can be seen that the constant rate of drug permeation can be obtained 
only when Cd>>Cr, i.e., the drug concentration at the surface of the SC, i.e. Cd, is 
consistently higher than the drug concentration in the body (Cr). Hence, the equation 2.5 
thus becomes:  
                                                 
dQ
dt  
= 𝑃𝑠 𝐶𝑠                                           Equation 2.7 
 
The membrane-limited flux (J) under this steady-state condition is described by the 
equation:  
                                                 J =  
D Ko w⁄ C
h
                                           Equation 2.8 
Where  
J = Amount of drug passing through the membrane system per unit area per unit time.  
D = Diffusion coefficient within the membrane  
Ko/w = Membrane / vehicle partition coefficient  
C = Concentration gradient across the membrane  
h = Membrane thickness 
 
2.2.2.1 In vitro skin permeation model 
 
In vitro diffusion models include simple two-compartment “static” diffusion cells or multi-
jacketed “flow-through” cells which are normally inert and made of glass material. The 
membrane, in this case excised skin or the artificial membrane, is mounted as a the barrier 
between a donor and a receiver compartment of the diffusion cell and the amount drug 
diffusing from the donor to the receiver compartment is analysed as a function of time. The 
static diffusion cell is usually a Franz upright diffusion model (Figure 2.14) or side-by-side 
model. 
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Figure 2.14 Schematic diagram of Franz diffusion cell. 
 
The receiver compartment is filled with physiological saline or buffer solution which can 
provide ions and pH require to diffuse the drug from the donor compartment. The 
temperature of diffusion cell is always maintained at a constant temperature, usually at 
37°C, to maintain a surface skin temperature at 32°C as an in vivo mimic. The receiver 
compartment is stirred continuously and analyte is sampled at regular intervals. This helps 
to avoid saturation of the receiver solution and maintain sink conditions. 
2.2.2.2 Membrane selection 
 
Human skin is clearly the most relevant model for evaluating the dermal drug delivery of 
various formulations. Skin obtained from various sources, including plastic surgery, 
amputation and cadavers, has been used for ex vivo evaluation of drug penetration (Godin 
and Touitou, 2007). Skin samples are mostly taken from the abdomen, back, leg or breast 
(Schaefer et al., 2008) and varies in thickness depending on the bodysite . 
Moreover, skin permeability varies greatly between specimens taken from the same and 
different anatomical sites of the same donor and between the specimens of different subjects 
or different age groups (Haigh and Smith, 1994). These variations may be due to 
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differences in lipid composition, skin thickness or hydration, which are determined by the 
body site, sex, race, and the age of the donor, and disease state. Another limitation of using 
human skin is the metabolism and biotransformation of chemicals applied to the skin that 
occurs after excision of the tissue from the donor. Therefore, many in vitro permeation 
studies have used animal skin rather than human skin as a rate-limiting membrane. Various 
animal skins such as hairless mouse, rabbit, guinea pig, rat, pig and shed snake skin have 
been tested as a model for human skin (Gomes et al., 2014; Ngawhirunpat et al., 2008). 
 
Domestic porcine skin is reported as the most appropriate animal model due to the 
numerous anatomical, histological and physiological similarities with human skin. These 
include epidermal thickness, the dermal-epidermal thickness ratio, the resemblance of hair 
follicles and blood vessel density in the skin, as well as the content of SC 
glycosphingolipids, ceramides, dermal collagen and elastin (Dick and Scott, 1992; Godin 
and Touitou, 2007). Porcine skin is readily obtained as a waste material from animals 
slaughtered for food. The comparison of drug permeability using human and porcine skin 
has demonstrated good correlation, particularly for lipophilic substances, while skin from 
rodents has generally exhibited higher permeation rates. In addition, porcine skin exhibits 
less donor variability than human skin (Barbero and Frasch, 2009).  
 
In comparison to porcine skin models, the use of rodent skin requires ethical permission to 
be granted. The use of rodents have advantages such as their small size, low cost and easy 
handling, however, conventional rodents have the disadvantage of an extremely high 
density of hair follicles, which necessitates hair removal prior to the formulation 
administration (Godin and Touitou, 2007). Rodent skin is believed to be more permeable to 
molecules compared to human skin due to differences in SC thickness, the number of 
corneocyte layers, hair density, water content, lipid profile and morphology (Schaefer et al., 
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2008).  
Shed snake skin has been proposed as an alternative skin model and as it is non-living tissue 
hence it can be stored at room temperature for relatively long periods of time (Haigh and 
Smith, 1994). Similarities with the human SC have been confirmed in terms of structure, 
composition of lipid content and water permeability. However, the lack of hair follicles 
could influence drug permeability (Godin and Touitou, 2007). Therefore, this model is not 
appropriate for investigating dermal absorption of drugs that penetrate the skin via the 
follicular route. Rigg and Barry (1990) compared a shed snake membrane with both hairless 
mouse and human skin by evaluating the effect of different penetration enhancers on the 
permeability of 5-fluorouracil indicating non-suitability of shed snake skin as a model for 
human skin. 
 
Most current methods for investigating formulations destined for topical treatment rely on 
the use of animal models. The use of isolated epidermis or SC sheets of human or animal 
origin has a number of disadvantages, including high intra-individual and inter-individual 
variation, particularly in relation to the diseased skin for which most topical drug 
formulations are developed. The majority of artificial models are used to mimic healthy 
skin with intact barrier properties. Relatively few models offer the potential to mimic the 
compromised skin. Poly(dimethylsiloxane) (PDMS) or silicone membranes have been used 
for decades in screening the effects of different vehicles and assessing their impact on the 
overall mechanisms of drug transport across human skin (Dias et al., 2007; Nakano and 
Patel, 1970; Oliveira et al., 2011). Although these membranes can be used to predict the 
skin permeability of lipophilic compounds, it has been concluded that they are not useful for 
hydrophilic compounds (Miki et al., 2015). To improve their hydrophilic permeability, 
polyethylene glycol 6000 copolymer-impregnated membrane has been developed. So far, 
the adpated model has only been tested using drugs in aqueous solutions; its potential in 
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formulation development still needs to be elucidated. The parallel artificial membrane 
permeability assay (PAMPA) was introduced as a rapid in vitro model for assessing 
transcellular intestinal permeability (Kansy et al., 1998). The original PAMPA system 
consists of an artificial membrane containing a hydrophobic filter, coated with 
phosphatidylcholine dissolved in n-dodecane, as a membrane barrier that separates the 
donor and acceptor compartments. The model has a high throughput screening format and 
could be modified by adjusting the membrane composition. Lipid and solvent mixtures in 
the membrane are not well characterised and lack the true lipid bilayers found in biological 
membranes (Faller, 2008). Sinko and colleagues developed skin-PAMPA composites 
containing synthetic ceramides, which are analogues for ceramides and are proposed as 
replacements for naturally occurring ceramides found in SC (Sinko et al., 2012). Ceramides 
are cheaper alternatives to natural ceramides, with the potential to prolong the storage time 
(Tsinman and Sinko, 2013). Although the ceramides are structurally different from 
ceramides, their comparable molecular mass and hydrogen acceptor and donor capacity 
enable them to act as the lipid constituents in the PAMPA sandwich membrane, together 
with cholesterol, stearic acid and silicone oil (Sinko et al., 2009).  
 
Another synthetic model called Strat-M
®
 is predictive of diffusion in human skin without 
lot-to-lot variability or safety and storage limitations (Joshi et al., 2012). Strat-M
®
 is 
constructed of two layers of polyethersulfone (PES), which acts as a tight surface layer, 
creating more resistance to the entry of the drug molecule. On top of this layer, one layer of 
polyolefin forms a more porous and diffusive membrane. These polymeric layers form a 
porous structure with similar morphology to human skin (Karadzovska and Riviere, 2013). 
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2.2.3 Construction of pseudoternary phase diagrams 
 
For nanoemulsions, the water titration method of Baboota et al., (2007) was used to develop 
pseudoternary phase diagrams for investigating the concentration ranges of components for 
monophasic region formation at room temperature. Surfactant and cosurfactant (Smix) were 
mixed at different weight ratios of increasing concentrations of surfactant with respect to 
cosurfactant for a detailed phase study. For each phase diagram, a predetermined amount of oil, 
surfactant and cosurfactant were mixed thoroughly at room temperature using tdifferent ratios 
of oil to Smix (1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1) using a magnetic stirrer. Different 
weight ratios covered the full range so as to delineate the boundaries of phases precisely in the 
phase diagrams. These mixtures were continuously titrated with water. After each addition, the 
system was visually examined for physical appearance. Phase boundaries were determined by 
the end point of titration, at which the solution became turbid. The quantity of water required to 
make the solution turbid was recorded and phase diagram plotted (JPM 5 Software, USA), with 
one axis represents oil phase, second representing the water phase and third axis representing 
the Smix at a fixed ratio.  
 
Figure 2.15 Schematic representation of pseudoternary phase diagram. 
 
A typical pseudoternary phase diagram representing a three-component system of oil, water 
and surfactant can be read following the solid lines, as shown in Figure 2.15. In this work, 
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phase diagrams are referred to as “pseudoternary” phase diagrams, as the surfactant phase 
was a mixture of surfactant and cosurfactant. The titration procedure began with a zero 
loading of water and ended at a point of 100 % water loading. An infinite number of tie 
lines can be drawn in any pseudoternary phase diagram (Li et al., 2005). In the present work, 
the titration was initiated using different ratios of surfactant phase to oil phase and followed 
by drop wise addition of water. The Smix was fixed at a 2:1 ratio. 
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3. CHAPTER: FORMULATION AND EVALUATION OF SOLID LIPID 
NANOPARTICLES FOR DERMAL DELIVERY 
 
3.1 Introduction 
 
Considering non-invasive routes of administration, the dermal route seems to be one of the 
most attractive approaches for drug delivery. However, one of the challenges in dermal drug 
delivery is the requirement to overcome the barrier properties of the skin and to deliver 
effective amounts of drug for the desired therapeutic action. In addition, prediction of 
adequate skin delivery of drugs from formulations has always been difficult. It is well 
understood that the SC acts as a rate-controlling barrier for percutaneous drug delivery and 
the challenges become more pronounced in the case of poorly soluble drugs. 
 
The basic factors of the skin affecting the absorption of drug include a) skin integrity and 
regional variation, b) dimensions of orifices, aqueous pores and lipidic fluid paths, and c) 
density of appendages. Several approaches have been used to overcome the skin barrier and 
allow drugs to reach their site of action. Different formulation approaches such as 
microparticles, SLNs and nano-lipid carriers have been evaluated (Filon et al., 2015; Jana et 
al., 2009). Although these carriers are not able to penetrate the SC at high concentrations, 
they may able to deliver drugs to the skin surface and into the hair follicles. In one study it 
was shown that when the particle size was larger than 5 µm, almost no penetration of drug 
was observed through the SC, however particles with diameters of about 750 nm 
demonstrated better permeation into hair follicle of the human skin (Lademan et al., 2007). 
On the other hand, it has been claimed that ethosomes, niosomes and transferosomes change 
their morphology and squeeze past the SC cells and achieve systemic delivery (Rai et al., 
2010). Studies have also shown that hair follicles and sweat ducts provide routes for SLNs 
to penetrate through the skin (Hamishehkar et al., 2015). The hair follicles are an important 
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target for drug delivery, due to being surrounded by a close network of blood capillaries and 
dendritic cells (Hung et al., 2015; Larese et al., 2015; Mittal et al., 2015). The relevance of 
the hair follicles for the percutaneous penetration process has been identified in several 
investigations using split or full thickness porcine ear skin or other animal models such as 
mice (Fan et al., 1999), mouse (Mahe et al., 2009) and human skin (Vogt et al., 2006). Thus, 
follicular transport is considered to be a potential pathway for dermal and cosmetic 
formulations. There are many reports on different results about drug permeation through 
excised and intact full thickness skin which might be explained by differences in size, type 
and density of the follicles, lipid composition and SC thickness (Lauterbach and Müller-
Goymann, 2014). Irrespective of individual skin differences, the excision of the skin may 
also have an influence on the penetration rate. After cutting a piece of skin and removing 
the subcutaneous fatty tissue, the skin contracts to a certain degree (Starcher et al., 2005). 
This may be due to several physiological factors such as water loss and the sudden absence 
of blood flow. Additionally, the elastic fibres, which endow the skin with resilience 
presumably contract after being cut. On one hand, this means that the hair follicle density 
per cm
2
 increases, possibly influencing the follicular penetration rate. However, it is 
possible that after cutting the skin, the hair follicles are constricted by the contracting elastic 
fibres and therefore, are significantly less receptive to the penetration process (Patzelt et al., 
2008).  
 
SLNs with diameters about 200 nm were found to improve the penetration of diclofenac 
sodium through rat skin (Liu et al., 2010a). The importance of particle size on drug delivery 
to skin was emphasised, but in addition, absorption was also influenced by type of 
excipients used in the formulation. Irrespective of the penetration route, the uptake of 
particles requires adequate wetting and thus the use of surfactants in the formulation plays a 
very important role. In the present work T80 and TP were used as surfactant and 
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cosurfactant in different ratios to study their effect on particle size and drug encapsulation. 
Two solid lipids, GB and GP, were used in different concentrations to compare their effect 
on drug permeability while TSN was used as the model drug. There are limited reports on 
TSN formulations for delivery to the skin, however, topical lipid formulations hold great 
promise for delivery of this very poorly soluble drug. 
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3.2 Aims of the study  
The aims of this study were, 
 To develop TSN-loaded SLNs for topical drug delivery using the solid lipids GB 
and GP. To analyse effect of type and concentration of lipid and surfactants on 
physicochemical properties of SLNs by formulating various compositions of 
preliminary formulations. 
 To analyse prepared SLN formulations based on physicochemical properties and 
stability studies to select optimised SLNs to perform in vitro skin diffusion using 
Franz diffusion model. 
 To evaluate and compare the ability of GB-SLNs and GP-SLNs to permeate through, 
and retain the TSN within skin using an in vitro diffusion study using frozen excised 
full thickness porcine ear skin. 
 To evaluate the ability of SLNs to enhance the delivery of TSN to deeper layers 
within the skin and hair follicles using differential stripping techniques. 
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3.3 Materials and methods 
3.3.1 Materials 
 
Triclosan was obtained from Vivimed Ltd. (Mumbai, India). Glyceryl behenate, glyceryl 
palmitostearate and Transcutol
®
P were a kind gift from Gattefossé (Weil am Rhein, 
Germany). Phosphate buffered saline tablets (pH 7.4), sodium lauryl sulphate and 
Parafilm
®
M were purchased from Sigma Aldrich (UK). Tween
®
80 was obtained from 
Fisher Scientific Ltd (UK). All other solvents and chemicals were of analytical grade. 
3.3.2 Methods 
3.3.2.1 Solubility studies of triclosan in buffer 
 
The solubility of TSN was determined in phosphate buffer solution (PBS, pH 7.4). 
Approximately 10 ml of buffer solution was added to a vial, an excess quantity of TSN was 
placed in each vial, which was greater than the quantity expected to dissolve in the receiver 
medium. Solubility was also determined in PBS solution containing various concentrations 
of 1 % w/v SLS (50 mM, 100 mM, 150 mM, 200 mM and 250 mM) to find a suitable 
concentration of SLS require to enhance TSN solubility and maintain sink conditions in the 
receiver medium during diffusion studies. All vials were tightly closed and placed in a 
shaking water bath (GLS aqua 12 plus, Grant, UK) at 25 ± 1ºC, 350 rpm for 24 h after 
which time, the samples were filtered through a 0.45 µm syringe filter (Fisher Scientific, 
UK) and analysed by HPLC (Section 2.2.1.1). 
3.3.2.2 Formulation of solid lipid nanoparticles 
 
TSN-loaded SLNs were prepared by hot HSH followed by probe ultrasonication (Nerella et 
al., 2014; Patel et al., 2012). Briefly, the lipid phase was prepared by heating lipids (GB and 
GP) to 5ºC above their melting points and TSN (equivalent to 10 mg/g of formulation) was 
added to the lipids while the aqueous phase was prepared by mixing Smix (T80 and TP) and 
water heated to same temperature. The hot lipid phase was slowly added to the hot aqueous 
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phase under HSH (Silverson, UK). This hot primary emulsion was then subjected to probe 
ultrasonication (Sonics and Materials Inc., USA) for 10 min at 70 % frequency amplitude. 
The resultant dispersion was cooled to room temperature to solidify the lipids and form 
SLN dispersions. The impact of homogenisation conditions on the SLNs was investigated 
(i.e. homogenisation speed was varied from 6000 rpm to 10,000 rpm and duration of 
homogenisation time from 5 min to 15 min).  Also, the effect of various formulation 
parameters, such as ratio of surfactant to cosurfactant and lipid to drug on mean particle size 
and entrapment efficiency were also studied.  
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Table 3.1 Composition of preliminary TSN-loaded SLN formulations. 
 
Formulation 
Code 
Lipid 
T80: TP 
(% w/w) Type 
Concentration 
(% w/w) 
GB3-1 
Glyceryl behenate 
3 1:1 
GB3-2  2:1 
GB3-3  3:1 
GB3-4  4:1 
GB5-1 5 1:1 
GB5-2  2:1 
GB5-3  3:1 
GB5-4  4:1 
GB7.5-1 7.5 1:1 
GB7.5-2  2:1 
GB7.5-3  3:1 
GB7.5-4  4:1 
GB10-1 10 1:1 
GB10-2  2:1 
GB10-3  3:1 
GB10-4  4:1 
GP3-1 
Glyceryl 
palmitostearate 
3 1:1 
GP3-2  2:1 
GP3-3  3:1 
GP3-4  4:1 
GP5-1 5 1:1 
GP5-2  2:1 
GP5-3  3:1 
GP5-4  4:1 
GP7.5-1 7.5 1:1 
GP7.5-2  2:1 
GP7.5-3  3:1 
GP7.5-4  4:1 
GP10-1 10 1:1 
GP10-2  2:1 
GP10-3  3:1 
GP10-4  4:1 
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3.3.2.3 Lyophilisation of solid lipid nanoparticles 
 
The primary purpose of drying the SLN dispersion was to obtain a powder for further solid 
state characterisation. The TSN loaded SLNs were frozen overnight at – 20C before freeze 
drying under vacuum at atmospheric pressure for 24 h. (Christ LD 2-4 plus, UK).  
3.3.3 Physicochemical characterisation 
3.3.3.1 Particle size analysis 
 
The particle size and polydispersity index (PDI) of TSN-loaded SLNs were measured using 
nanoparticle tracking analysis (NTA, Nanosight LM10, UK). This technique utilises both 
light scattering and Brownian motion in order to obtain particle size distributions of samples 
in liquid suspensions. The laser beam is passed through a prism-edged flat glass surface 
within the sample chamber into the nanoparticle suspension. Suspended particles in the path 
of this beam scatter light in such a manner that they can be easily visualised via a 
microscope (Filipe et al., 2010). Particle size distribution within formulations is expressed 
as the PDI, which can be calculated from 10 %, 50 % and 90 % of total volume of sample. 
All the samples were measured in triplicate to obtain the mean particle size and PDI, which 
was calculated using Equation 3.1, 
 
                                             PDI =  
D 90%−D 10%
D 50%
                                                Equation 3.1 
 
3.3.3.2 Determination of drug entrapment efficiency  
 
The percentage drug entrapment efficiency (% DEE), which corresponds to the percentage 
of TSN encapsulated within the SLNs, was determined by measuring the concentration of 
free TSN in the dispersion medium. The free TSN was determined by adding 500 µl of TSN 
loaded SLNs to 9.5 ml chloroform and methanol (1:1) mixture and centrifuged at 5000 rpm 
(Eppendorf AG 5702, Germany) for 20 min. The supernatant was filtered through a syringe 
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filter (0.45 µm) and analysed for unencapsulated TSN at 280 nm using HPLC after suitable 
dilution (Khurana et al., 2010). The analysis was performed in triplicate. The % DEE was 
calculated according to Equation 3.2 as follows, 
 
 
                          % DEE =  
 W initial drug – W free drug
W initial drug 
 x 100                                 Equation 3.2 
 
 
3.3.3.3 Zeta potential measurement  
 
In order to quantify the surface charge on nanoparticles, the zeta potential (ZP) was 
measured using a Zetasizer Nano Z (Malvern Instruments Ltd, UK). Each sample was 
suitably diluted with the aqueous phase of the formulation and placed in a disposable zeta 
cell. Zeta limits ranged from -200 mV to +200 mV. The average of three measurements of 
each sample was used to derive the average ZP.  
3.3.3.4 Thermal analysis of solid lipid nanoparticles 
 
The thermal behavior of drug and SLNs was analysed by differential scanning calorimetry 
(DSC) using a Mettler Toledo DSC1 (STAR
e
 system, UK), calibrated using an indium 
standard. Samples (8-10 mg) of pure TSN, GB and GP lipids, equivalent ratio of physical 
mixtures of drug and lipids (PM) and lyophilised TSN-loaded SLNs were analysed in sealed 
40 µl aluminum pans. The thermograms were recorded over a temperature range of 25-
160C at a heating rate of 10C/min under a continuous nitrogen gas purge, maintained at a 
flow rate of 50 ml/min (Kotikalapudi et al., 2012).  
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3.3.3.5 Powder X-ray diffraction analysis  
 
The effect of the encapsulation process on the crystallinity of the TSN was investigated 
using powder X-ray diffractometry (XRD, Bruker D2 Phase, UK). XRD patterns were 
obtained by analysing samples of pure TSN, GB and GP lipids, lyophilised TSN-loaded 
SLNs. Samples were placed in the stainless steel holder and the surface powder was leveled 
manually. The sample was scanned between 5 and 40 of 2θ with step size of 0.019 and a 
step time of 32.5 Sec.  
3.3.3.6 Transmission electron microscopy 
 
The morphology of SLNs was confirmed by transmission electron microscopy (TEM) using 
a JEOL 3010, which was operated at 300 kV. The SLNs dispersion was diluted with water 
and placed on a carbon film supported by a copper grid (200 mesh carbon coated copper 
grid, Agar Scientific, UK). Excess sample was removed with filter paper and to achieve a 
better imaging contrast, the samples were negatively stained with 1 % (w/w) 
phosphotungstic acid for 1 min. Stained samples were air dried at room temperature before 
analysis (Kupetz and Bunjes, 2014). 
3.3.3.7 Fourier transform infrared spectrometry  
 
The freeze dried SLN formulations and samples of pure TSN, GB and GP lipids were 
evaluated using Fourier transform infrared spectrometry (FTIR, Frontier TM, PerkinElmer; 
Santa Clara, CA, USA) equipped with a diamond crystal. All samples were run in triplicate; 
a background run (to remove the background noise of the instrument) was carried out as a 
negative control. Spectra were recorded between 4,000 and 600 cm
-1
 with a spectral 
resolution of 4 cm
-1
. 
3.3.3.8 Stability study 
 
TSN-loaded SLNs were stored for 3 months at room temperature (~20°C) and at elevated 
temperature and relative humidity (40C/75 % RH). The samples were characterised for 
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particle size, PDI and ZP following storage. The samples were studied in triplicate and 
results were expressed as mean ± SD. Statistical analysis of the data was performed using a 
student t-test. A probability of less than 0.05 (p < 0.05) was considered significant in this 
study. 
3.3.3.9 Skin permeation study 
3.3.3.9.1 In vitro skin diffusion studies  
 
Porcine skin is reported to share similar permeation characteristics to human skin (see 
section 2.2.2.2) (Flaten et al., 2015). Fresh porcine ears were obtained from a local abattoir 
(Leonard Wood and Sons, Huddersfield, UK) and cleaned under cold running water. The 
outer region of the skin was separated from the cartilage and subcutaneous fat and placed 
into a sealed bag and stored in a freezer at -20C for maximum storage period of one week.  
Frozen excised full thickness porcine ear skin was thoroughly thawed before use and 
visually inspected for defects and punctures. In vitro permeation studies were carried out 
over a period of 24 h using vertical Franz diffusion cells with a diffusion area of 3.8 cm
2 
and a receiver compartment volume of 30 ml. The skin was hydrated by immersing in PBS 
(pH 7.4) solution for 60 min prior to the start of each experiment. The skin was then cut into 
appropriate sections and mounted on the Franz diffusion cells, with the SC facing the donor 
compartment (where the formulation was applied) and the dermis facing the receiver 
compartment. The receiver compartment was filled with PBS solution (pH 7.4) containing 
1 % w/w SLS (150 mM) water circulated at 37C to maintain a skin surface temperature at 
32C, with stirring speed of 200 rpm for 24 h. The skin was equilibrated for 30 min before 
loading with SLNs formulation (equivalent to 10 mg/g TSN concentration) or aqueous 
saturated solution of TSN as control to each donor compartment and covered with Parafilm
 
to prevent evaporation. Samples (500 l) were withdrawn at regular intervals from receiver 
compartment (normally 2, 4, 6, 8, 10, 12 and 24 h) and replaced by an equal volume of 
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fresh PBS solution to maintain sink conditions. The amount of TSN permeated through skin 
over 24 h was analysed by HPLC (Section 2.2.1.1).  
3.3.3.9.2 Quantification of triclosan from skin using differential stripping technique 
 
The differential stripping technique allows the quantification of drug retained in the SC and 
in the hair follicles, differentiating between transepidermal and transfollicular penetration. 
The differential stripping technique consists of adhesive tape stripping followed by 
cyanoacrylate biopsy (Teichmann et al., 2005; Wosika and Cal, 2010). The adhesive tape 
stripping method is a commonly used method, which allows removal of the SC layer by 
layer, and can be used to determine the amount of substance retained in the skin surface 
both in vitro and in vivo. Cyanoacrylate skin surface biopsy is a non-invasive method, 
which consists of applying superglue on the skin surface and removing it after 
polymerisation, thus entrapping corneocytes and follicular casts. Hence with the differential 
stripping technique, it is possible to quantify drug SC retention by tape stripping and 
follicular retention by cyanoacrylate biopsy, making it a complete quantification method. 
After in vitro skin permeation studies, the skin surface was washed thoroughly with distilled 
water to remove any excess formulation followed by differential stripping technique. 
Adhesive tape stripping technique and cyanoacrylate skin surface biopsy 
The skin was stripped using an adhesive surgical tape (3M Transpore, UK) and was cut into 
3x3 cm
2
 pieces and applied to the SC side of the treated skin surface. The tape strips were 
pressed onto the skin by applying uniform pressure in order to obtain an intimate contact 
between tape and skin. The procedure was repeated with 15 tapes for each skin tissue.  
Following the removal of 15 tape strips, a drop of superglue was placed on the stripped area 
and the glue was covered with adhesive tape under slight pressure. After 10 min, the 
cyanoacrylate polymerised and the strip was removed with a quick motion, entrapping the 
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casts of hair follicles. Two such cyanoacrylate tapes were used for each skin sample and 
analysed individually. 
After differential stripping, the porcine skin was weighed accurately and cut into fine pieces. 
Minced skin tissue along with adhesive tape and cyanoacrylate tape samples were placed 
into vials. The first adhesive strip was analysed separately as this would represent 
unabsorbed materials on the skin surface whereas tapes 2-5, 6-10 and 11-15 were pooled 
together for analysis (Nagelreitera et al., 2015). 10 ml of methanol was added to all the vials 
and samples were sonicated for 30 min. After sonication (Transonic UK), the samples were 
centrifuged for 20 min at 400 rpm (Eppendorf centrifuge 5702, UK). The supernatant 
obtained after centrifugation was collected and analysed for amount of TSN recovered 
using HPLC (Section 2.2.1.1).   
3.3.3.9.3 In vitro comparison study of follicular penetration using differential stripping 
technique 
 
The aim of the present study was to investigate the hypothesis that in excised skin separated 
from cartilage and subcutaneous fats, the hair follicle reservoir is significantly reduced 
compared to intact skin. Therefore, drug retention data in both excised and intact full 
thickness porcine ear skin was compared using the differential adhesive tape stripping 
technique. GP-SLN formulation (GP5-2) was selected to compare the drug retention 
between intact and excised porcine ear skin.  
To study skin retention of TSN in intact, unsliced porcine ear skin, an area of 4x4 cm
2
 was 
marked in the inner side of the ear using permanent marker, and a plastic cap having an 
open compartment on both sides was used to form donor cell sample reservoir during the 
experiment (Figure 3.1). Subsequently, 1 mlof the SLN dispersion (equivalent to 10 mg/g of 
TSN concentration) was applied. After 24 h of contact time, excess formulation was 
removed from skin and the treated area was subjected to differential adhesive stripping 
(Section 3.3.3.9.2).  
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Figure 3.1 Experimental set up showing TSN skin retention study using unsliced full thickness porcine ear 
skin by GP-SLNs (GP-5-2). 
 
Similarly, excised full thickness porcine skin was prepared by cutting a 4x4 cm
2
 area of 
porcine ear skin by removing cartilage and other subcutaneous fat. Skin samples were 
mounted on Franz cells to perform the diffusion experiment. After 24 h, samples were 
subjected to the differential stripping technique. Samples from both intact and excised 
porcine ear skin were analysed using HPLC to quantify the amount of TSN recovered from 
skin and compared for follicular penetration. Experiments were repeated in triplicate and 
data obtained was represented as mean ± SD. 
3.3.3.10 Statistical analysis  
 
All the data obtained from physicochemical characterisations were performed in triplicate. 
Mean values were tested using one way analysis of variance (ANOVA) using GraphPad 
Prism 6 software and differences were considered to be statistically significant when p< 
0.05.  
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3.4 Results and Discussion 
3.4.1 Solubility studies of triclosan in buffer 
 
SLS, an anionic surfactant, possesses skin penetration enhancing properties and increases 
drug penetration into the skin by increasing the fluidity of epidermal lipids (Leveque et al., 
1993). Many studies also include SLS in the receiver medium in order to increased 
solubility of lipophilic drug and to maintain sink conditions throughout the diffusion 
experiment (Shumaia et al., 2014). This is due to the formation of micelles with 
hydrophobic molecules. A micelle is a group of surfactant aggregates, which in aqueous 
solution forms a hydrophilic head with surrounding solvent and hydrophobic tails in the 
micelle centre. Micelle formation occurs due to presence of SLS above its CMC i.e. the 
concentration above which micelles start to form, which is reported as 8.1 mM at 25C 
(Aguiar et al., 2003; Elisabet et al., 2005). Solubility data obtained after 24 h shows that 
TSN solubility increases with increasing SLS concentrations from 50 mM, 100 mM, 150 
mM, 200 mM and 250 mM (Table 3.2).  
 
Table 3.2 Solubility profile of triclosan in buffer (Mean ± SD, n = 3). 
 
SLS concentration (mM) Solubility (mg/ml) 
50 2.61 ± 0.74 
100 3.73 ± 0.52 
150 5.25 ± 0.81 
                   200 6.27 ± 0.35 
250 6.39 ± 0.23 
 
 
Priyanka and Sathali (2012) reported the ability of SLS (0.5 % w/w) to increase the release 
of montelukast sodium into dissolution media from SLNs. Another study reported by 
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Rahman et al., (2009) showed increase in rate of curcumin release with increase in 
concentration of SLS into dissolution media with results indicated maximum increase was 
found in water containing 2 % w/v of SLS. For most poorly water soluble drugs addition of 
surfactants in diffusion media improves the solubility of drugs significantly, which is 
necessary to maintain sink conditions during diffusion experiment. Hence, based on the 
results obtained and to prevent formation of excess air bubbles, 150 mM concentration of 
1 % w/v SLS was selected for the diffusion studies. 
3.4.2 Preparation and optimisation of solid lipid nanoparticles 
 
A very simple, economical and reproducible method was used for the preparation of SLNs 
(Chen et al., 2010; Fang et al., 2008). TSN-loaded SLN formulations were prepared using 
GB and GP as core matrices at different concentrations of 3, 5, 7.5 and 10 % (w/w). These 
lipid carrier systems were stabilised by T80 and TP in different ratios, i.e. 1:1, 2:1, 3:1 and 
4:1 respectively (Table 3.1). 
 
3.4.2.1 Effect of homogenisation speed and time 
 
To optimise homogenisation speed and time, GB-SLNs (GB5-2) and GP-SLNs (GP5-2) 
were prepared and the effect of different homogenisation speed and time on the mean 
particle size was determined. It was observed that when homogenisation speed was 
increased from 4000 to 10,000 rpm, the mean particle size decreased from 520 ± 10.34 nm 
to 193 ± 17.3 nm for GB5-2, while in case of GP5-2, mean particle size decreased from 584 
± 19.4 to 173 ± 12.5 nm (Figure 3.2). Therefore, 10,000 rpm was selected for obtaining 
SLNs for both GB and GP lipids. 
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Figure 3.2 Effect of homogenisation speed on mean particle size of GB-SLNs (GB5-2) and GP-SLNs (GP5-2) 
(Mean ± SD, n = 3). 
 
 
 
Figure 3.3 Effect of homogenisation time on mean particle size of GB-SLNs (GB5-2) and GP-SLNs (GP5-2) 
(Mean ± SD, n = 3). 
 
The influence of homogenisation time on the mean particle size of SLNs was studied by 
homogenising SLNs for 5, 10 and 15 min. Figure 3.3 shows the decrease in particle size for 
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both GB-SLNs and GP-SLNs when homogenisation time increased from 5 min to 10 min, 
but when homogenisation time increased to 15 min there was no further decrease in particle 
size for both GB-SLNs and GP-SLNs. The reason may be that each system has its own 
optimum homogenisation speed and time during which SLNs can undergo particle size 
reduction and beyond which, exposure of SLNs to excess cavitation forces lead to collision 
and therefore aggregation (Mehnert et al., 2001a). Thus optimised parameters selected for 
preparation of SLNs was homogenisation at 10,000 rpm for 10 min. 
 
3.4.2.2 Effect of lipid and drug ratio 
Increase in lipid concentrations with respect to drug for both lipids (GB and GP) causes an 
increase in % DEE (Table 3.3). As the lipid concentration was increased from 3 to 5 % 
(w/w), there was an increase in % DEE for both GB-SLNs and GP-SLNs, which 
subsequently decreased with further increases in lipid concentrations up to 10 % (w/w).  
 
Table 3.3 Effect of concentration of lipid on percent drug entrapment efficiency of SLNs (Mean ± SD, n = 3). 
 
Lipid: drug 
% DEE 
GB-SLNs GP-SLNs 
3: 1 76.23 ± 1.63 79.34 ± 1.86 
5: 1 83.61 ± 2.47 87.27 ± 1.48 
7.5: 1 77.56 ± 1.06 75.12 ± 1.94 
10: 1 68.23 ± 2.18 65.86 ± 2.4 
 
This might be because during crystallisation of the lipids, a partial expulsion of drug occurs 
on particle surface. Furthermore, the higher viscosity at the interface produced by high lipid 
concentrations may cause a decrease in diffusion and hence few lipid molecules will be 
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carried into the aqueous phase and therefore reduce the entrapment of drug (Abdelbary and 
Fahmy, 2009). 
3.4.2.3 Effect of surfactant and cosurfactant ratio 
 
The type of surfactant and its concentration has a great impact on the particle size 
distribution and stability of SLNs (Han et al., 2008). Low levels of surfactant can result in 
particle aggregation leading to an increase in particle size, however the use of excess 
amounts of surfactant should be avoided to prevent a decrease in % DEE, burst release, 
toxicity and any irritant effects. Literature study showed T80 as commonly used nonionic 
stabiliser for SLN formulations for various drug delivery systems (Salminen et al., 2014; 
Shah et al., 2015; Soares et al., 2013). The choice of surfactant used in preparation of SLNs 
has great influence on the physical stability of the nanoparticles, extent of drug dissolution 
and drug permeability into skin. It can also contribute to the safety of SLNs when 
administered to the body (Karn-orachaia et al., 2016). For SLNs prepared for targeted drug 
delivery system, surface modification of nanoparticles is required (Müller et al., 1995). 
Polymeric nanoparticles coated with T80 are able to deliver dalargin, the leu-enkephalin 
analogue through blood brain barrier (Alyautdin et al., 1998). Another study reported ability 
of T80 to prevent the loss of drug after filtration of SLNs by enhancing the emulsification 
of lipophilic drug compounds (Rassua et al., 2015). Addition of a cosurfactant to the 
surfactant in formulations was reported to improve dispersibility and solubility in 
formulation (Chen, 2008). TP has included as a cosurfactant to improve stability of 
formulations (Prajapati et al., 2013; Salunkhe et al., 2013).  
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Table 3.4 Effect of different ratios of surfactant and cosurfactant on mean particle size and percent drug 
entrapment efficiency of SLNs (Mean ± SD, n = 3). 
 
T80: TP 
Mean particle size (nm) % DEE 
GB-SLNs GP-SLNs GB-SLNs GP-SLNs 
1: 1 315 ± 1.33 286 ± 1.27 81.3 ± 0.79 84.5 ± 1.53 
2: 1 217 ± 2.12 184 ± 1.78 79.6 ± 1.38 81.7 ± 1.04 
3: 1 196 ± 0.93 171 ± 2.04 68.4 ± 1.73 73.5 ± 2.18 
4: 1 163 ± 1.64 154 ± 2.36 60.1 ± 1.28 66.2 ± 1.57 
 
On increasing the ratio of surfactant and cosurfactant from 1:1 to 4:1, the mean particle size 
of GB-SLNs decreased from 315 ± 1.33 nm to 163 ± 1.64 nm and the mean particle size of 
GP-SLNs decreased from 286 ± 1.27 nm to 154 ± 2.36 nm (Table 3.4). This decrease in 
particle size is due to an effective reduction in interfacial tension between aqueous and lipid 
phases leading to formation of smaller particles ( Liu et al., 2007). Hence addition of 
cosurfactant helps reduce the amount of surfactant required (Kreilgaard et al., 2000) and it 
further reduces the interfacial tension and increase the fluidity of interface (Tenjarla, 1999). 
Higher surfactant concentrations stabilise particles by forming a steric barrier on the particle 
surface thereby preventing their coalescence. 
A similar effect was observed for % DEE of TSN into SLNs, which decreased with an 
increase in ratio of surfactant and cosurfactant (Table 3.4). This can be explained by the 
partition phenomenon. High surfactant levels in the aqueous phase might increase partition 
of drug from internal lipid phase to the external aqueous phase, decreasing drug 
encapsulation (Rahman et al., 2010). 
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3.4.3 Physicochemical characterisation 
 
3.4.3.1 Determination of particle size, zeta potential and percent drug entrapment efficiency 
 
Prepared formulations were characterised based on their particle size, PDI, ZP, % DEE and 
results are shown in Table 3.5 and Table 3.6 respectively. Figure 3.4 shows a typical NTA 
image showing the particle size distribution of both GB-SLNs and GP-SLNs. The mean 
particle size of both lipid formulations ranged from 178.38 ± 12.45 nm to 942.17 ± 6.35 nm. 
The results clearly show an increase in particle size with increase in lipid concentration, 
which may be related to the viscosity of the samples, and a decrease in particle size with 
increasing surfactant concentration which might be due to reduction in interfacial tension 
between lipid and aqueous phases forming smaller, stable nanoparticles (Rahman et al., 
2010). 
 
 
                        Figure 3.4 Particle size distributions of GB-SLNs and GP-SLNs using NTA system. 
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                         Table 3.5 Physicochemical characterisation of GB-SLNs (Mean ± SD, n = 3). 
 
Formulation 
Batch 
Particle size (nm) PDI % DEE ZP (mV) 
GB3-1 350.23 ± 2.36 0.46 78.21 ± 0.82 -19.2 ± 1.2 
GB3-2 224.15 ± 5.28 0.57 77.17 ± 0.26 -20.3 ± 0.9 
GB3-3 198.03 ± 1.62 0.82 73.84 ± 2.17 -27.7 ± 1.5 
GB3-4 191.37 ± 5.58 0.71 69.10 ± 1.31 -29.3 ± 2.1 
GB5-1 419.29 ± 3.47 0.63 80.62 ± 0.88 -24.8 ± 2.5 
GB5-2 231.72 ± 6.52 0.72 78.28 ± 0.24 -25.9 ± 0.6 
GB5-3 201.42 ± 2.61 0.76 75.32 ± 0.56 -28.8 ± 0.9 
GB5-4 195.04 ± 7.72 0.77 74.14 ± 0.16 -30.1 ± 1.4 
GB7.5-1 729.43 ± 2.63 0.84 73.45 ± 0.68 -27.9 ± 1.6 
GB7.5-2 683.91 ± 8.69 0.81 71.23 ± 0.91 -28.4 ± 1.1 
GB7.5-3 604.38 ± 9.81 0.62 70.47 ± 0.39 -31.3 ± 2.8 
GB7.5-4 592.12 ± 11.03 0.72 69.52 ± 0.90 -34.7 ± 1.9 
GB10-1 942.17 ± 6.35 0.64 67.28 ± 0.52 -32.1 ± 1.4 
GB10-2 904.63 ± 8.72 0.85 67.26 ± 0.39 -33.5 ± 2.5 
GB10-3 839.59 ± 3.43 0.77 66.37 ± 1.29 -36.5 ± 1.7 
GB10-4 821.82 ± 9.86 0.82 65.21 ± 1.68 -35.2 ± 1.3 
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Table 3.6 Physicochemical characterisation of GP-SLNs (Mean ± SD, n = 3). 
 
Formulation 
Batch 
Particle size (nm) PDI % DEE ZP (mV) 
GP3-1 420.11 ± 5.34 0.43 84.12 ± 1.28 -21.8 ± 0.8 
GP3-2 201.56 ± 9.23 0.51 82.19 ± 1.42 -24.4 ± 1.2 
GP3-3 185.38 ± 13.45 0.79 79.08 ± 1.03 -26.3 ± 1.6 
GP3-4 178.38 ± 12.45 0.81 76.19 ± 0.98 -25.8 ± 1.1 
GP5-1 389.07 ± 15.23 0.61 81.29 ± 1.29 -27.2 ± 0.9 
GP5-2 192.23 ± 6.39 0.59 77.26 ± 2.17 -29.9 ± 2.1 
GP5-3 184.78 ± 18.43 0.72 75.03 ± 2.53 -24.2 ± 2.6 
GP5-4 179.13 ± 8.39 0.65 73.28 ± 2.81 -24.9 ± 1.5 
GP7.5-1 621.92 ± 12.57 0.73 76.21 ± 1.38 -31.6 ± 1.3 
GP7.5-2 597.39 ± 23.53 0.81 73.81 ± 1.44 -29.4 ± 1.7 
GP7.5-3 562.82 ± 1.54 0.56 70.42 ± 1.72 -30.1 ± 2.2 
GP7.5-4 538.03 ± 3.62      0.61 68.32 ± 1.03 -32.1 ± 1.8 
GP10-1 843.28 ± 17.52 0.69 70.17 ± 1.28 -34.5 ± 2.9 
GP10-2 829.31 ± 13.56 0.72 69.11 ± 2.16 -30.6 ± 2.3 
GP10-3 792.85 ± 26.39 0.78 68.25 ± 2.62 -28.4 ± 1.2 
GP10-4 753.17 ± 21.04 0.84 65.57 ± 2.84 -29.3 ± 1.9 
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SLNs formed using GB were larger in size than corresponding GP formulations (Table 3.5 
and Table 3.6). This may be due to differences in chain lengths and viscosities of the lipids. 
GB contains glycerol esters of behenic acid (C22), where the main fatty acid is behenic acid 
(> 85 %) along with other fatty acids (C16-C20). GP is composed of palmitic acid (C16) and 
stearic acid (C18) >90 %. A higher viscosity (Section 2.1.1) and longer hydrocarbon chain 
length may affect packing of GB resulting in a larger particle size compared to GP lipid. 
 
ZP indicates the degree of charge present on suspended particles in dispersion. A suitably 
high value of ZP (positive or negative) confers stability because the particles resist 
aggregation. As depicted in Tables 3.5 and Table 3.6, the ZP of all formulations were 
negative, ranging from -19.2 mV to -36.5 mV indicating relatively good stability and 
dispersion quality (Essa et al., 2011). The ZP values obtained for both GB-SLNs and GP-
SLNs are similar to those mentioned in literature (Negi et al., 2014; Padhye and 
Nagarsenker, 2013). The % DEE for all SLN formulations was high, ranging from 65.31 ± 
1.24 % to 85.16 ± 2.19 % (Table 3.5 and Table 3.6). % DEE is dependent upon the nature 
of the lipids. For example, crystalline lipids (e.g. monoacid triglycerides) form a perfect 
lattice and this can lead to drug expulsion (Westesen et al., 1997). However more complex 
lipids as GB and GP, being the mixture of mono, di and triglycerides form less perfect 
crystals with many imperfections offering more space to accommodate drugs (Müller et al., 
2000).  
 
Hence, based on the results obtained for mean particle size, PDI, % DEE and also 
considering minimum use of surfactant mixture to avoid skin irritation for topical 
application, SLN formulations prepared with 3 % and 5 % w/w GB and GP lipids with T80 
and TP (2:1) as Smix were selected for further characterisation and in vitro skin permeation 
studies. 
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3.4.3.2 Thermal analysis of solid lipid nanoparticles 
 
DSC was used to investigate the melting behavior of SLNs. Figure 3.5 and Figure 3.6 
represent DSC curves of pure TSN, GB and GP lipids, PM of drug with both lipids and 
TSN-loaded SLNs respectively. TSN has a relatively sharp melting endotherm at 61°C 
indicating its crystallinity. An endothermic peak for the drug was detected for physical 
mixtures at 56.5°C and 56.2°C for mixtures with GB and GP lipids respectively, which may 
reflect an interaction with lipids or may be a change in the crystal form. The lipids have 
peaks at 76.8°C and 57°C for GB and GP respectively, representing their melting points, 
but in the PM the endothermic peaks were detected at 72°C and 52°C for GB and GP lipids 
respectively.  
 
 
Figure 3.5 DSC thermogram of TSN, GB, physical mixture of GB and TSN, TSN-loaded GB-SLNs (GB3-2, 
GB5-2). 
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Figure 3.6 DSC thermogram of TSN, GP, physical mixture of GP and TSN, TSN-loaded GP-SLNs (GP3-2, 
GP5-2). 
 
 
The melting point depression could be due to polymorphism in the glycerides as they 
crystallise in different subcell arrangements such as hexagonal, orthorhombic and triclinic. 
Glycerides display polymorphism with three or more individual forms, including α, β' and 
βi modifications (Fouad et al., 2011). For TSN-loaded SLNs of both lipids, GB and GP have 
a broad endothermic peak at 64°C and 45°C for GB and GP respectively. The reduction in 
melting point for both the lipid formulations is generally due to the nanometric size of the 
particles, having a specific surface area (Nerella et al., 2014) indicating a reduction in lipid 
crystallinity. The melting endotherm of TSN was absent in both GB-SLNs and GP-SLNs, 
which show good homogenous dispersion of TSN in lipid matrix after SLN formation (Negi 
et al., 2014; Shah et al., 2015). 
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3.4.3.3 Powder X-ray diffraction analysis 
 
XRD is ideally suited for characterisation and identification of polycrystalline forms (Omar, 
2013). To study the effect of different glycerides on the crystallinity of TSN in formulations, 
XRD analysis was carried out on TSN, GB and GP lipids, TSN-loaded GB-SLNs and GP-
SLNs.  
 
                       Figure 3.7 XRD pattern showing TSN, GB, TSN-loaded GB-SLNs (GB3-2, GB5-2). 
 
 
                          Figure 3.8 XRD pattern showing TSN, GP, TSN-loaded GP-SLNs (G53-2, GP5-2). 
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TSN is a crystalline material having major diffraction peaks at 2θ scattered angles 8.2, 24.4 
and 25.4 respectively (Celebioglu et al., 2013). The XRD of GB confirms its 
semicrystalline nature (Figure 3.7) with a sharp peak at 2θ angles of 21.18, 23.38 while GP 
shows  peaks at 2θ angles of 19.5, 21.5 and 23.5(Figure 3.8). The values are similar to those 
reported for the lipids in the literature (Bhagwat et al., 2009; Josea et al., 2014). However, a 
reduction in intensity of TSN peak for both GB-SLNs and GP-SLNs indicates a reduction in 
crystallinity of TSN, which might be due to encapsulation of the drug in the lipid matrix. 
Similar results were observed for lipid based nanocarriers prepared using GB and GP lipids, 
which showed low levels of crystalline decitabine in the final formulation thus confirming a 
decrease in crystallinity of drug due to molecular dispersion into lipid matrix (Yub et al., 
2014). Another study reported the loss of crystallinity of clotrimazole after incorporation 
into SLNs prepared by GB indicating solubility of drug into lipid matrix and conversion of 
drug into amorphous forms (Das et al., 2012). XRD results of SLN formulations were in 
agreement with the DSC analysis (Section 3.4.3.2). 
 
3.4.3.4 Transmission electron microscopy 
 
TEM images of TSN loaded SLNs are shown in Figure 3.9, indicating that the SLNs in 
aqueous dispersion have a spherical shape and were in the size range 100 nm to 250 nm. 
This supported the particle size distribution data from NTA (Section 3.4.3.1) and similar 
results reported for TSN-loaded polymeric nanoparticles (Domínguez-Delgado et al., 2011). 
GB-SLNs of quercetin was evaluated for brain delivery were also spherical particles in 
nanometer range (Dhawan et al., 2011). TEM images (Figure 3.9 B) of SLNs showed 
distribution of drug in lipid rich matrix, which was observed by DSC and XRD analysis of 
formulations. 
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                                       Figure 3.9 TEM images (10,000 x) of TSN loaded SLNs. 
         
3.4.3.5 Fourier Transform infrared spectrometry 
 
FTIR spectrometry was used to investigate interactions between drug and lipids during 
formulation of SLNs. The FTIR spectra of TSN, GB and GP, TSN loaded GB-SLNs and 
GP-SLNs are shown in Figure 3.10 and Figure 3.11.  
 
 
                        Figure 3.10 FTIR spectrums of TSN, GB and TSN-loaded GB-SLNs (GB3-2, GB5-2). 
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                       Figure 3.11 FTIR spectrums of TSN, GP and TSN-loaded GP-SLNs (GP3-2, GP5-2). 
 
The FTIR spectra of pure TSN shows strong absorption of halogenated hydrocarbons 
arising from stretching vibrations of the carbon-halogen bond for the CH2-Cl group in the 
1300–1150 cm-1 region. The strong absorption bands result from the out-of-plane bending 
of the ring C-H bonds and in-plane bending bands appeared in the 1300-1000 cm
-1 
region. 
Skeletal vibrations, involving C-C stretching within the ring, are evident in the 1610-1585 
cm
-1 
and 1500-1400 cm
-1 
regions. The FTIR spectra of both the solid lipids, GB and GP, 
revealed the presence of an absorption band at 2849 and 2917 cm
-1
 due to symmetric and 
asymmetric C-H stretching; wavenumber 1702 cm
-1
 depicts C-O stretching and 2400–3400 
cm
-1
 depicts O-H stretching (Kelidari et al., 2015). However, in the FTIR spectra of TSN 
loaded GB-SLNs and GP-SLNs the characteristic peaks of TSN are absent. This is due to 
the overlapping of the characteristics peaks of TSN with other constituents, thus the FTIR 
results did not suggest any chemical interaction of ingredients (Kumar and Randhawa, 
2015; Orhan, 2012). 
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3.4.3.6 Stability study 
 
 Selected batches of GB-SLNs and GP-SLNs were stored in glass vials and placed in a 
stability cabinet at room temperature (20 ± 2°C) and under stressed conditions in humidity 
chamber (40°C/75 %  RH). The effect of time and storage conditions on the mean particle 
size, PDI and ZP of SLNs are presented in Table 3.7 and Table 3.8. Results showed no 
significant difference (p>0.05) in PDI and ZP for GB-SLN and GP-SLN formulations under 
both storage conditions. The particle size of SLNs remained almost stable, with only slight 
changes in particle size, indicating good stability over room temperature. Study reported by 
Neupanea et al., (2014) for decitabine lipid nanocarriers prepared with GB and GP as solid 
lipids, have also shown no significant difference between particle sizes of prepared SLNs 
after 45 days storage at room temperature.  
In case of SLN formulations stored at 40°C had shown increase in particle size for both GB 
and GP lipid formulations. Particle size of GP-SLNs and GB-SLNs has significant increase 
(p<0.05) after 60 days of storage, which has been shown by highlighting the data 
represented in Table 3.6 and Table 3.7 respectively. The reason of increase in particle size 
might be due to heating of lipids at high temperature for constant long period of time, which 
disturbs the crystalline structure of lipid carrier (Ghaffari et al., 2011). Study reported by 
Ruktanonchai et al., (2009) for gamma-oryzanol SLNs have shown significant increase in 
particle size at storage temperature of 45°C.  
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Table 3.7 Particle size, PDI and zeta potential of GP-SLN formulations stored at room temperature and 
accelerated humidity conditions (Mean ± SD, n=3). 
Duration 
Storage 
conditions 
 
Formulations 
Particle size 
(nm) 
PDI ZP (mV) 
Day 1 Room GP3-2 193.8 ± 8.3 0.62 ± 0.05 -24.4 ± 0.8 
  GP5-2 169.3 ± 6.2 0.87 ± 0.04 -29.9 ± 1.2 
 Humidity GP3-2 193.8 ± 8.3 0.62 ± 0.05 -24.4 ± 0.8 
  GP5-2 169.3 ± 6.2 0.87 ± 0.04 -29.9 ± 1.2 
      
Day 30 Room GP3-2 194.3 ± 9.5 0.73 ± 0.03 -29.0 ± 0.4 
  GP5-2 170.6 ± 7.3 0.89 ± 0.08 -30.3 ± 0.9 
 Humidity GP3-2 200.3 ± 8.4 0.74 ± 0.05 -29.9 ± 1.3 
  GP5-2 168.9 ± 6.9 0.85 ± 0.03 -33.8 ± 1.8 
      
Day 60 Room GP3-2 198.2 ± 9.8 0.83 ± 0.08 -32.7 ± 0.7 
  GP5-2 179.6 ± 8.1 0.96 ± 0.09 -29.4 ± 0.9 
 Humidity GP3-2 203.2 ± 8.6 1.24 ± 0.03 -31.7 ± 1.9 
  GP5-2 174.8 ± 7.2 1.06 ± 0.06 -34.9 ± 2.1 
      
Day 90 Room GP3-2 216.2 ± 10.3 0.86 ± 0.04 -22.6 ± 0.6 
  GP5-2 184.7 ± 8.6 0.98 ± 0.06 -28.7 ± 0.8 
 Humidity GP3-2 220.5 ± 9.1 1.30 ± 0.07 -32.4 ± 2.5 
  GP5-2 209.7 ± 7.8 1.25 ± 0.05 -34.9 ± 2.7 
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Table 3.8 Particle size, PDI and zeta potential of GB-SLN formulations stored at room temperature and 
accelerated humidity conditions (Mean ± SD, n=3). 
Duration 
Storage 
conditions 
 
Formulations 
Particle size 
(nm) 
PDI ZP (mV) 
Day 1 
Room 
GB3-2 175.2 ± 9.2 0.86 ± 0.03 -20.3 ± 0.9 
  GB5-2 180.1 ± 7.3 0.89 ± 0.01 -25.9 ± 0.6 
 
Humidity 
GB3-2 175.2 ± 9.2 0.86 ± 0.03 -20.3 ± 0.9 
 
 
GB5-2 180.1 ± 7.3 0.89 ± 0.01 -25.9 ± 0.6 
      
Day 30 
Room 
GB3-2 175.3 ± 10.6 0.86 ± 0.02 -25.3 ± 0.6 
  GB5-2 188.2 ± 8.4 0.61 ± 0.07 -29.1 ± 0.5 
 
Humidity 
GB3-2 180.3 ± 10.2 0.93 ± 0.02 -26.8 ± 1.2 
  GB5-2 195.6 ± 7.9 0.95 ± 0.04 -30.2 ± 1.5 
 
 
    
Day 60 
Room 
GB3-2 180.2 ± 10.9 0.92 ± 0.01 -24.6 ± 0.5 
  GB5-2 203.8 ± 9.3 0.68 ± 0.04 -26.5 ± 0.4 
 
Humidity 
GB3-2 189.5 ± 11.4 1.02 ± 0.08 -29.4 ± 1.6 
  GB5-2 198.6 ± 8.3 1.31 ± 0.04 -32.4 ± 1.8 
 
 
    
Day 90 
Room 
GB3-2 188.9 ± 11.2 0.93 ± 0.03 -28.8 ± 0.8 
  GB5-2 209.6 ± 9.7 0.72 ± 0.07 -25.5 ± 0.3 
 
Humidity 
GB3-2 217.4 ± 11.6 1.34 ± 0.01 -32.8 ± 1.9 
 
 
GB5-2 228.1 ± 9.2 1.45 ± 0.04 -33.5 ± 2.3 
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3.4.3.7 Skin permeation study 
 
3.4.3.7.1 In vitro skin permeation studies 
 
The influence of type and concentration of lipids and surfactant used, along with other 
physicochemical parameters on TSN permeation and retention within the skin were 
evaluated using in vitro skin permeation studies. Skin permeation studies were carried out 
using excised full thickness porcine ear skin with selected (GB3-2, GB5-2, GP3-2, GP5-2) 
formulations. A saturated aqueous solution of TSN was used as the control and the 
permeability coefficients and flux from formulations are summarised in Table 3.9. Skin 
permeation studies are relevant while studying topical drug delivery to ensure that 
formulations display minimum permeation through skin into the receiver medium and 
maximum skin deposition. In the present studies, the receiver medium was sampled at pre-
determined time intervals up to 24 h to determine TSN permeation through skin.  
 
  
Figure 3.12 In vitro cumulative amount of triclosan permeated following 24 h topical application of SLN 
formulations and control solution through porcine ear skin (Mean ± SD, n = 6). 
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SLNs formulations had a 4.47 fold higher rate of permeation of TSN in comparison with the 
TSN control solution (Figure 3.12). Similar results were reported for fluconazole GB-SLNs, 
which had a 1.73-fold higher fluconazole permeation compared to control solution (Gupta 
and Vyas, 2012). The increased skin delivery of drug can be attributed to the structure and 
physicochemical properties of SLNs. It has been shown that due to higher occlusive nature 
and increased skin hydration of SC, SLNs influences the percutaneous permeation of drugs 
present in the formulations (Gupta and Vyas, 2012; Schäfer-Korting et al., 2007). 
GP5-2 exhibited the highest percent cumulative TSN permeation (8.23 ± 0.42) followed by 
GB5-2 (7.64 ± 0.35), GP3-2 (4.37 ± 0.24) and GB3-2 (2.81 ± 0.09). GB5-2 and GP5-2 
resulted in a 2-fold increase in TSN permeation compared to GB3-2 and GP3-2 
formulations respectively, which might be due to small particle size, higher % DEE and 
more occlusive effect due to high content of lipids. Lee et al., (2003) used TP as a 
cosurfactant to increase permeation of TSN into skin from hydrogel patches, thus allowing 
TSN accumulation into upper skin layers for localised action. Another studies have also 
reported increased drug localisation in skin by SLNs formulated using diethyltoluamide 
(Iscan et al., 2005), glucocorticoids (Jensen et al., 2011) and betamethasone 17-valerate 
(Zhang and Smith, 2011). Statistical analysis revealed a significant difference (P < 0.01) 
between the steady-state flux values obtained for GB-SLNs and GP-SLNs (Table 3.9). The 
flux of SLNs formulations and control solutions was in the order of GP5-2 > GP3-2 > GB5-
2 > GB3-2 > control. 
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Table 3.9 In vitro permeability parameters of TSN-loaded SLN formulations and control solution in porcine 
ear skin (Mean ± SD, n = 6). 
Formulation Flux (Jss) 
µg/cm
2
/h 
Permeability coefficient 
(Kp) x 10
-5
 cm/h 
Control 0.086 0.86 
GB3-2 0.202 2.02 
GB5-2 0.245 2.45 
GP3-2 0.279 2.79 
GP5-2 0.536 5.36 
 
3.4.3.7.2 Quantification of triclosan in skin using differential stripping techniques 
 
The amount of TSN retained within skin was determined by adhesive tape stripping method 
and cyanoacrylate biopsies. Differential stripping technique was used to quantify TSN level 
in different areas of the skin, including hair follicles, epidermis and dermis and the results 
are presented in Figure 3.13.  
 
 
Figure 3.13 Triclosan uptake into skin treated with GB-SLNs (GB3-2, GB5-2), GP-SLNs (GP3-2, GP5-2) and 
control solution (Mean ± SD, n = 6). 
0
2
4
6
8
10
GB3-2 GB5-2 GP3-2 GP5-2 Control
A
m
o
u
n
t 
o
f 
tr
ic
lo
sa
n
 r
e
ta
in
e
d
 in
 s
ki
n
 (
μ
g/
m
g 
) 
TAPE 1
TAPE(2-15)
Cyanoacrylate Tape
Homogenised skin
tissue
  
113 
 
The SLN formulations had higher TSN retention within skin compared to the control 
solution, with the difference being statistically significant (p<0.001). It can be explained by 
higher occlusive effect and increased hydration of SC commonly associated with lipid 
nanoparticles (Müller et al., 2007). This is similar to the findings reported for 
podophyllotoxin-loaded SLNs prepared with tripalmitin lipid  and the epidermal targeting 
was proposed to be due to occlusion and interaction of SLNs with skin lipids (Chen et al., 
2006). The amount of TSN recovered from cyanoacrylate tape strip were 0.28 ± 0.07 µg/mg, 
0.57 ± 0.08 µg/mg, 0.97 ± 0.19 µg/mg and 1.99 ± 0.12 µg/mg of tissue for GB3-2, GB5-2, 
GP3-2 and GP5-2 respectively. The amount of TSN recovered from skin appendages 
through cyanoacrylate biopsy was observed to be dependent on the concentration of lipid 
used in the formulations. As lipid concentration increased from 3 % to 5 % (w/w) in GB-
SLNs and GP-SLNs, there was a 2-fold increase in TSN retention. 
 
TSN accumulation within the skin was higher for GP-based formulations. This may be due 
to their smaller particle size, as it has been demonstrated that the penetration depth of the 
particles can be influenced by their size resulting in the possibility of a differentiated 
targeting of specific follicular structures (Patzelt et al., 2011). In a similar study, there was a 
parabolic correlation between skin permeation of econazole nitrate and chain length of the 
fatty esters present in the lipids used in SLNs. The maximum flux of drug was observed for 
SLNs containing C17 – C19 esters, suggesting that these formulations may constitute a 
potential carrier for topical delivery of econazole nitrate (Sanna et al., 2009).  GB-SLNs 
prepared with retinol and retinyl palmitate for epidermal drug targeting, resulted in high 
retinol concentrations in the upper skin layers following application of SLNs, whereas the 
deeper regions had only very low retinol levels (Jenning et al., 2000). Similarly, vitamin A-
loaded GB-SLNs localised the drug in the upper skin layers and it was slowly released into 
  
114 
the viable epidermis in a sustained manner (Pople and Singh, 2006). Isotretinoin-loaded 
GP-SLNs provided epidermal targeting and reduced systemic uptake of tretinoin. Also, the 
SLNs formulation minimised direct skin contact thereby preventing skin irritation by the 
drug ( Liu et al., 2007). 
 
3.4.3.7.3 In vitro comparison studies of follicular penetration using differential stripping 
technique 
 
The present investigation and the observations by Starcher et al., (2005) explored  the 
theory that the elastic fibres surrounding the hair follicles contract if the skin is excised 
from cartilage and fatty tissue, possibly leading to a significant reduction of the follicular 
penetration pathway. However, other factors concerning the reduced follicular penetration 
must also be taken into consideration, such as loss of humidity and the absence of blood 
flow in excised skin. These aspects presumably additionally contribute to the differences in 
the penetration pathways to a certain extent.  
 
 
 
Figure 3.14 Amount of triclosan recovered from full thickness unsliced and excised porcine ear skin (Mean ± 
SD, n = 6). 
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The present study therefore compared follicular penetration of TSN into full thickness 
porcine skin from both unsliced and excised porcine ear skin. A similar differential 
stripping technique was used to quantify the amount of TSN retained into skin and results 
are presented in Figure 3.14. The total amount of TSN recovered from both adhesive tape 
strips and cyanoacrylate biopsies for unsliced and excised skin were 15.93 ± 1.21 µg/mg 
and 16.78 ± 1.42 µg/mg respectively. To study the difference in follicular penetration of 
TSN between unsliced and excised full thickness skin only cyanoacrylate biopsy data was 
considered. The similar amount of TSN (2 µg/mg) was recovered from unsliced and excised 
skin. 
  
  
116 
3.5 Conclusion 
 
As SLNs have gained popularity as drug delivery systems, there has been increasing interest 
in understanding the parameters that control drug loading. While studies have provided 
information on how the choice of lipids and surfactants as well as their concentrations may 
play a role in determining the extent and localisation of drug loading, information on how 
the properties of the drug itself may affect its entrapment and permeation remain limited. In 
this study, encapsulation of TSN was compared with two different solid lipids such as GB 
and GP. In order to understand how the drug was loaded, the physicochemical properties of 
SLNs including its particle size, shape along with its interaction with the other component 
of the formulations were studied. In vitro drug permeation studies were also performed to 
quantify amount of TSN permeated and retained in full thickness porcine ear skin. 
 
TSN was loaded at 10 mg/g of formulation, with encapsulation efficiency ranges between 
65- 80 % for both GB and GP lipids, with higher encapsulation in GP-SLNs compared to 
GB-SLNs. TSN-loaded SLNs exhibited a lipid concentration dependent increase in the 
particle size and decrease in % DEE. Morphological studies confirmed their spherical shape 
with a lipid rich matrix. Thermal and structural characterisation was performed to analyse 
drug and excipient interaction in SLN formulations. From the DSC results, it appears that 
TSN was molecularly dispersed into the lipid matrix to give a homogenous dispersion 
within in the formulation. Similarly XRD and FTIR studies also supported homogenous 
dispersion of TSN into lipid matrix without any specific interaction between drug, lipids 
and other excipients of formulations. 
 
Formulations containing 3 % and 5 % w/w GB and GP lipids (GB3-2, GB5-2, GP3-2 and 
GP5-2) were selected for permeation studies using excised full thickness porcine ear skin. 
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There was less than 8 % of total applied dose of drug permeation over 24 h, thus its 
permeation into receiver medium was low, which is important for localised action of topical 
formulations. A differential stripping technique was used to quantify the amount of TSN 
retained within the skin. Higher amounts of TSN were localised within the skin for GP5-2 
indicating a superior ability of GP as a lipid carrier of TSN compared to GB lipid. 
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4. CHAPTER: DESIGNS AND DEVELOPMENT OF 
ANTIBACTERIAL NANOEMULSIONS FOR TOPICAL DELIVERY 
 
4.1 Introduction 
A wound is a breach in the skin that allows access of microbes to the warm, moist and 
nutritious environment that is favourable to infections caused by bacteria, fungi, etc. MRSA 
is a common opportunistic microbe found in skin abrasions and open wounds caused by 
Staphylococcus aureus, often acquired due to infections that can occur in hospitals. Such 
infection prolongs illness and increases the length of stay and cost of hospital treatment. 
The goal of wound management is to provide the most favourable environment for 
regeneration of the epidermis. During the period of epidermal renewal, it is imperative to 
avoid further injury to the skin to minimise wound infection. Popular topical antimicrobial 
dressings used for wound treatments are iodine (Iodoflex
®
, Iodozyme
®
), silver sulfadiazine 
(Silvercel
®
, Acticoat
®
) (Neely et al., 2009; Shupp et al., 2010). These antimicrobial 
dressings have numerous limitations, such as poor skin adherence,  short duration of activity 
against Gram-negative and Gram-positive bacteria and potential toxicity to host immune 
cells (Hemmila et al., 2010). Hence, there is a need to develop a new generation delivery 
system, which can deliver topical antimicrobial agent deeper into the skin for controlled 
drug release for prolonged time.  
 
The term "nanoemulsion" refers to a thermodynamically or kinetically stable liquid 
dispersion of an oil phase and a water phase, in combination with a surfactant. O/W NEs 
refer to a system in which oil droplets are dispersed in an aqueous phase This is a 
favourable delivery system for hydrophobic active substances, whereas W/O NEs are 
suitable for hydrophilic substances (Henry et al., 2009; Mason et al., 2006). NEs can be 
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formulated using various methods, including high energy and low energy approaches. The 
details of various production methods were described in Chapter 1 (Section 1.4.2).  
Essential oils derived from plants are well known for their insecticidal, antifungal, and 
antibacterial properties (Burt, 2004). EO contains 1,8-cineole (eucalyptol), which has been 
found to possess strong antimicrobial activity against human and food borne pathogens 
(Bakkali et al., 2008). The intradermal administration of EO increases capillary 
permeability and favours wound healing (Sarkar, 1994). Olives are the fruit of the olive tree 
(Olea europea), belonging to the family Oleaceae. Due to its high content of 
monounsaturated and polyunsaturated fatty acids, olive oil (OO) has been used extensively 
in the cosmetics and pharmaceutical products (Eid et al., 2013).  
 
Regarding the selection of surfactants, the efficiency by which the surfactant facilitates NEs 
fabrication, either alone or in combination with a cosurfactant, is an important consideration 
(Azeem et al., 2009; Donsi et al., 2012). The surfactant system should effectively stabilise 
the oil-water interface. During the high energy homogenisation process, it is important to 
ensure that a sufficient amount of surfactant is rapidly adsorbed to the newly formed droplet 
surface and covers it well enough to prevent coalescence. With respect to the active 
ingredient in a formulation, the primary goal using NEs as a carrier system is to protect and 
deliver the active ingredient. Hence, the compatibility of formulation ingredients with the 
active ingredient and the capacity of formulation ingredients to solubilise and stabilise the 
active ingredient must be considered. Prerequisite information, such as the physicochemical 
properties of the active ingredient, is needed in order to select an appropriate surfactant 
system and oil phase. 
In the present work, EO and OO were used to solubilise TSN for topical applications. NEs 
were produced containing EO and OO in different concentrations, along with the use of T80 
and S80 as a surfactant and cosurfactant mixture (Smix). The effects of the different 
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formulation excipients were investigated in terms of formulation stability, physicochemical 
characterisation, and in vitro skin permeation.  
 
4.2 Aims of the study 
 
The aims of present study were, 
 
 To formulate NEs of TSN using EO and OO as the oil phase and to study the effects 
of composition of the liquid lipid phase on physicochemical properties of NE 
formulations. 
 To determine optimised concentration and ratio of oils and surfactants to prepare 
stable NE formulations using pseudoternary phase diagrams. 
 To characterise prepared NE formulations by performing series of experiments to 
select optimised batches for in vitro diffusion study using excised full thickness 
porcine ear skin. 
 To evaluate the ability of SLNs and NEs as nanocarriers drug delivery system for 
enhanced skin retention of TSN by comparing the amount of TSN recovered from 
skin using an adhesive tape stripping method. 
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4.3 Materials and Methods 
Materials:  
Triclosan was a gift from Vivimed Labs (India). Eucalyptus oil, olive oil, Tween
®
 80, 
Span
®
 80, sodium lauryl sulphate and phosphate buffer saline tablets were purchased from 
Sigma Aldrich (UK). All other reagents were of analytical grade. 
4.3.1 Solubility study of triclosan 
 
Aliquots of EO, OO, T80, S80 and deionised water (5 ml) were placed in vials and an 
excess amount of TSN was added. Samples were kept at a constant temperature 
(25 ± 0.5°C) under shaking for 48 h to reach equilibrium (Parveen et al., 2011). The 
samples were centrifuged at 4000 rpm (Eppendorf AG 5702, Germany) for 15 min and the 
solubilised TSN in the supernatant was then recovered and quantified by HPLC (Section 
2.2.1.1). 
4.3.2 Construction of pseudoternary phase diagrams 
 
The objective of this study was to identify and select the optimum concentration of 
surfactant system using HLB values and to investigate the pseudoternary phase diagram 
behaviour of surfactants with oil and water. HLB is an empirical expression of the 
relationship between the hydrophilic and lipophilic groups in the surfactant. All surfactant 
systems comprise entities that combine both hydrophilic and lipophilic groups. HLB values 
are used to identify suitable surfactant systems for oil and water emulsification. Surfactants 
having HLB values  of <10 are considered to be oil soluble and those with HLB values >10 
are water soluble (Aulton and Taylor, 2013). Surfactants with suitable HLB values are 
selected based on the type of emulsion system to be prepared (O/W emulsion or W/O 
emulsion). 
In present study, OO and EO were used as the oil phases, as they have been successfully 
used in preparations of NEs for dermal delivery (Eid et al., 2013; Sugumar et al., 2014). 
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T80 (HLB – 15), S80 (HLB - 4.3) and water were used as surfactant, cosurfactant and 
aqueous phase respectively. Different mass ratios (1:1, 2:1, 3:1, 4:1) of Smix were prepared 
for phase studies, with increasing concentrations of T80 with respect to S80. Each phase 
diagram was prepared using EO and OO with Smix combinations, at the specific ratios of 1:9, 
2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1, in separate vials. This was done to identify clear NE 
regions, in order to select appropriate concentrations of oils and Smix to prepare stable 
formulations. Aliquots of EO and OO were mixed with each Smix at room temperature under 
gentle magnetic stirring and phase diagrams were constructed using an aqueous titration 
method in which water was added dropwise to the oil and Smix. After equilibration, the 
systems were visually inspected for transparent fluid system, which were refereed as NE. 
Highly viscous systems that did not show a change in meniscus after being tilted to an angle 
of 90° were considered gels. The phase diagrams were constructed using JMP 11 software 
(SAS Institute Inc., USA). 
4.3.3 Formulation of triclosan nanoemulsions 
 
Different batches of NEs were produced using a HSH followed by probe ultrasonication 
method (Rao and McClements, 2011; Tripathy, 2014). The HSH provides intense disruptive 
forces that cause the larger droplets of the coarse emulsion to be broken down into smaller 
ones. The homogenisation speed, time and surfactant concentration all contribute to 
controlling the droplet size. In practice, to reduce the droplet size to the level required in 
NEs, it is usually necessary to operate at extremely high speeds to ensure adequate intensity 
of the disruptive forces. 
 
Droplet size and size distribution served as criteria for the selection of process parameters 
and NE composition. They not only characterise the NE system, but also serve as indicators 
of the quality and stability of the formulation. Each NE formulation was prepared by 
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heating the oil phase containing TSN (loading dose 10 mg/g of formulation) to 40ºC to 
ensure complete dissolution of the drug in oil. The aqueous phase, containing the Smix, was 
heated to the same temperature. The hot oil phase was slowly added to the hot aqueous 
phase under HSH (Silverson, UK). This hot primary emulsion was then subjected to 
ultrasonication (Sonics and Materials Inc., USA) for 15 min at 70 % frequency amplitude. 
The compositions of the preliminary NE formulations prepared are shown in Table 4.1.  
                               Table 4.1 Compositions of preliminary TSN-loaded NE formulations 
Formulation Code 
Oil T80: S80 (2:1) 
% w/w Type 
Concentration 
(% w/w) 
EO-5;2.5 
Eucalyptus oil 
5 2.5 
EO-5;5  5 
EO-5;7.5  7.5 
EO-5;10  10 
EO-10;2.5 10 2.5 
EO-10;5  5 
EO-10;7.5  7.5 
EO-10;10  10 
EO-15;2.5 15 2.5 
EO-15;5  5 
EO-15;7.5  7.5 
EO-15;10  10 
OO-5;2.5 
Olive oil 
5 2.5 
OO-5;5  5 
OO-5;7.5  7.5 
OO-5;10  10 
OO-10;2.5 10 2.5 
OO-10;5  5 
OO-10;7.5  7.5 
OO-10;10  10 
OO-15;2.5 15 2.5 
OO-15;5  5 
OO-15;7.5  7.5 
OO-15;10  10 
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4.3.4 Physicochemical characterisation of the nanoemulsion formulations 
 
Physicochemical characterisation, i.e. determination of droplet size and PDI, ZP, % DEE, 
thermal analysis, FTIR and morphological studies, were performed using similar methods 
as described in detail in chapter 3 (Section 3.3.3). 
4.3.4.1 Accelerated stability studies 
 
The NE formulations were subjected to temperature stress studies. The composition of the 
formulation and the ratio of oil and aqueous phase affect the physical stability of NEs. The 
stress test was carried out in three stages: centrifugation, heating-cooling and freeze-
thawing for 3 cycles over 6 days (Loo et al., 2011; Srilatha et al., 2013). 
Centrifugation stage: All the samples were centrifuged at 4400 rpm for 20 min (Eppendorf 
AG5702, Germany). The formulations were examined for phase separation, creaming and 
cracking. 
Heating-cooling stage: The effect of change in temperature on the stability of NEs was 
analysed by storing the samples between 4°C and 40°C for a period of 48 h. The stable 
formulations were then subjected to a freeze thaw cycle. 
Freeze-thaw stage: The formulations were subjected to -20°C and 25°C for a period of 48 
h each. Freeze-thaw cycles were performed in the triplicate and samples were studied for 
phase separation.  
The formulations that were stable under accelerated stability studies were subjected to 
further characterisation studies. 
4.3.4.2 pH determination 
 
The pH of the NEs formulations was measured at ambient temperature using a digital pH 
meter. Each pH value was measured in triplicate and average value (mean ± SD) was 
recorded. 
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4.3.4.3 Determination of viscosity 
 
The viscosities of the NEs formulation were evaluated using Bohlin Gemini cone and plate 
rheometer (Aimil Ltd., India). The viscosities were measured in triplicate at a temperature 
of 25°C using a shear ramp between 0.1 and 100 s
-1
 (Alam et al., 2015). 
 
4.3.4.4 In vitro drug release and skin permeation studies 
 
Release and permeation studies for the NE formulations were carried out in Franz diffusion 
cells. The setup and experimental conditions were similar to those described in the chapter 3 
(Section 3.3.3.9). For the release studies, a cellulose acetate membrane (Sigma Aldrich, 
UK), 23 mm in diameter with a molecular weight cut off of 12-14 kDa was selected. For the 
skin permeation and retention studies excised full thickness porcine ear skin was used. 
A saturated aqueous solution of TSN was used as a control solution. The donor 
compartment was filled with either the appropriate NE formulation or control solution 
(equivalent to 10 mg/g of TSN). Subsequently, 500 l samples were collected from the 
receiver compartment at 4, 6, 8, 10, 12 and 24 h and replaced by an equal volume of fresh 
receiver medium. All samples were analysed by the previously validated HPLC method 
(Section 2.2.1.1). The cumulative amount of TSN released though dialysis membrane and 
the amount of TSN permeated through the skin were plotted as a function of time. 
4.3.4.5 Quantification of triclosan in skin using an adhesive tape stripping method 
 
At the end of the permeation study, the amount of TSN retained within the skin was 
quantified using the adhesive tape stripping method (Yu et al., 2014). After 24 h of contact, 
the skin was carefully removed from the cell and washed with distilled water to remove any 
residual formulation. The tape stripping process was performed and samples were analysed 
as described in chapter 3 (Section 3.3.3.9.2). 
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4.3.4.6 Statistical analysis 
 
All the data obtained were reported as the mean ± SD and statistically analysed by one way 
ANOVA and Tukey's test, using GraphPad Prism 5 software. Differences were considered 
to be statistically significant at p < 0.05. 
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4.4 Results and Discussion 
4.4.1 Determination of triclosan solubility 
 
The solubility of the drug in the internal oil phase is an important factor to consider when 
designing NEs as carriers for lipophilic drugs (Benita and Levy, 1993). TSN is a poorly 
water soluble drug and thus it is essential to incorporate it into the oil core of the NEs to 
formulate it for topical drug delivery. Solubility of TSN in selected oils and surfactants i.e.  
EO, OO, T80 and S80 was investigated and reported in Table 4.2.  
 
 
Table 4.2 Solubility of triclosan obtained in different oils and surfactants after 48 h equilibration at 25°C 
(Mean ± SD, n = 3). 
 
Solvent Solubility (mg/g) 
EO 5.23 ± 0.02 
OO 3.51 ± 0.05 
T80 41.23 ± 0.14 
S80 29.13 ± 0.03 
 
Based on solubility data and type of NEs to be prepared (O/W), T80 and S80 were selected 
as surfactant and cosurfactant respectively. S80 forms a close packed, complex film with 
T80 at the oil-water interface. Calligaris et al. (2015) used T80 as a surfactant in preparation 
of silybin NEs using OO, sunflower oil and castor oil. Another study reported the use of 
T80 and S80 (1:1, HLB – 9.65) as Smix for preparation of NEs using various oils such as 
isopropyl myristate, EO, OO and mineral oil (Syed and Peh, 2014). 
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4.4.2 Construction of pseudoternary phase diagrams 
 
The NE formation zone in phase diagrams is controlled by the physicochemical nature of 
oil and aqueous phase, low interfacial surface tension and association of oil with surfactants 
at the interfacial surface (El Maghraby, 2008).  
Phase diagrams were constructed using EO, OO as the oil phase and T80, S80 as the 
surfactant and cosurfactant respectively. Nonionic surfactants are generally considered safe 
due to their relatively compatible behaviour with other excipients in the formulations for 
skin and in biological tissues (Baroli et al., 2000; Syed and Peh, 2014). A combination of 
lipophilic and hydrophilic nonionic surfactants can be used to build highly structured 
emulsions. The effect of the Smix on NE formation was evaluated for further optimisation of 
the system. The pseudoternary phase diagrams for EO and OO, with T80 alone or in 
combination with S80 (1:1, 2:1, 3:1, 4:1) at ambient temperature are represented in Figures 
4.1, 4.2 and 4.3 respectively. 
In the presence of T80 alone (Figure 4.1), the NE zone occupied about 20 % of the total 
area of the phase diagram. When S80 is absent, it is possible that the T80 is not able to 
sufficiently reduce the oil-water interfacial tension due to its hydrophilic nature. At very 
low oil concentrations, a maximum of 30 % water was solubilised in the surfactant-oil blend. 
The amount of incorporated water was reduced progressively with increasing oil 
concentrations. Addition of cosurfactant increased the maximum amount of water 
incorporated into the oil–surfactant system, with the extent of the NE zone increasing in all 
cases compared to the cosurfactant-free system. 
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Figure 4.1 Pseudoternary phase diagrams of a) eucalyptus oil and b) olive oil with surfactant (T80) and water. 
 
 
When T80 with S80 were incorporated in equal amounts (Smix 1:1; HLB 9.65), a larger NE 
region was observed, perhaps due to the further reduction in interfacial tension and 
increased fluidity of the interface (Figures 4.2a and 4.3a). As the surfactant concentration 
was increased to Smix 2:1 (HLB 11.57) and Smix 3:1 (HLB 12.32) (Figure 4.2b, c and Figure 
4.3b, c), the NE region increased in size compared to that seen with Smix 1:1. When the 
surfactant concentration was further increased to Smix 4:1 (HLB 12.82) (Figures 4.2d and 
4.3d), a decrease in the NE region compared to Smix 3:1 was observed (Mahdi et al., 2011). 
  
130 
 
Figure 4.2 Pseudoternary phase diagrams of eucalyptus oil, water and different ratios of surfactant mixture 
(T80:S80) a) Smix 1:1, b) Smix 2:1, c) Smix 3:1, d) Smix 4:1. 
When the surfactant concentration was increased in comparison to cosurfactant, the NE 
region increased in size up to the 3:1 Smix ratio, but at the 4:1 ratio, the size of the NE region 
decreased, hence further ratios of Smix was not evaluated. Reported HLB required for EO 
and OO is 9.8 and 7 respectively (Orafidiya and Oladimeji, 2002). To obtain the smaller NE 
droplet size and stable formulations which is related to required HLB, it is proposed that the 
most stable NE is the one which was formulated with the HLB of Smix nearest to required 
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HLB of oil phase (Prinderre et al., 1998; Salager, 2000). Based on this the 2:1 Smix with 
HLB value 11.57 was selected to prepare NEs using EO and OO as oil phase. 
 
 
Figure 4.3 Pseudoternary phase diagrams of olive oil, water and different ratios of surfactant mixture 
(T80:S80) a) Smix 1:1, b) Smix 2:1, c) Smix 3:1, d) Smix 4:1. 
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4.4.3 Preparation of nanoemulsions 
 
The NEs formulations were prepared using HSH followed by probe ultrasonication. The 
initial batches of NEs were prepared using different concentrations of oil (5, 10 and 15 % w/w), 
while concentrations of Smix (2:1) used were 2.5, 5, 7.5 and 10 % w/w.  
4.4.3.1 Impact of homogenisation time 
 
Mean droplet size is a critical parameter of the NEs formulation due to its direct influence on 
formulation stability, appearance and efficacy of delivery. The effect of different 
homogenisation times (10, 15, 20, and 25 min) on the mean droplet size was determined for 5 % 
w/w EO-NEs (EO-5;5) and OO-NEs (OO-5;5) stabilised by 5 % w/w T80 and S80 Smix (2:1). 
 
Figure 4.4 Impact of homogenisation time on mean droplet size of EO-NEs and OO-NEs (Mean ± SD, n = 3). 
 
Average droplet size decreased with increased homogenisation duration (Figure 4.4) for both 
NEs. When the duration was increased from 10 min to 20 min, EO-NEs droplet size decreased 
from 293.4 ± 2.9 nm to 87.6 ± 1.2 nm, while OO-NEs droplet size decreased from 321.2 ± 
3.2 nm to 96.2 ± 1.7 nm. When the time was further extended from 20 min to 25 min, no 
significant change in droplet size was seen for either EO or OO. As the duration of 
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homogenisation determines the amount of energy input into generating NEs, longer durations 
mean more energy input, thus enhancing the intense disruptive forces necessary for successful 
size reduction. Similar results were reported by Shahavi et al., (2015) for clove oil NEs 
prepared using a Smix containing T80 and S80. Their results showed a decrease in droplet size 
from 160 nm to 40 nm when sonication time was increased from 1 min to 10 min with no 
further reduction in droplet size when time was increased to 15 min. Hence, based on the data 
obtained from present study, the homogenisation time for the preparation of TSN-loaded NEs 
was set at 20 min. 
4.4.3.2. Impact of formulation variables 
The types and concentrations of oil and surfactants used in the preparation of TSN-loaded NEs 
are very important because they affect the solubility of lipophilic drug and the physicochemical 
properties of the formulation, namely its density, viscosity, interfacial tension and phase 
behaviour (Wooster, 2008). In the present study, the effects of oil and surfactant concentrations 
on NE droplet size and distribution were studied. EO and OO, at concentrations of 5, 10, and 
15 % w/w, were used to prepare NEs containing 2.5, 5, 7.5 and 10 % w/w Smix (3:1). The results 
summarised in Table 4.3 reveal that the concentration of oil greatly influenced the NEs droplet 
size and its distribution with increasing size when the oil concentration was increased from 5 % 
to 15% w/w. The efficiency of NE formation decreased with increasing amounts of oil and the 
formulation became unstable at oil concentrations of 15 % w/w.  
Increasing oil concentration reduces the surfactant ability to lower the interfacial tension, which 
results in instability of the system. Moreover, increasing concentrations of oil increased the 
collision rate between droplets, promoting increase in rate of flocculation resulting in a droplet 
size increase (Soleimanpour et al., 2013). With an increase in droplet size, PDI increases, which 
favours the coalescence of droplets, such that droplets join together to make larger volume 
with less interfacial area to dissipate the free energy. This eventually leads to phase 
separation, in which all of the droplets coalesce to form two separated phases (Taylor, 
1998). 
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                           Table 4.3 Effect of oil and surfactant concentrations on droplet size and distribution in EO-NE and OO-NE formulations (Mean ± SD, n = 3). 
 
Formulation Code Particle size (nm) PDI Formulation Code Particle size (nm) PDI 
EO-5;2.5 
139.2 ± 4.2        0.84 ± 0.15 
OO-5;2.5 
145.2 ± 2.4 0.75 ± 0.03 
EO-5;5 
87.5 ± 2.3 0.74 ± 0.13 
OO-5;5 
96.3 ± 3.5 0.58 ± 0.06 
EO-5;7.5 
71.3 ± 1.3 0.88 ± 0.03 
OO-5;7.5 
87.4 ± 2.1 0.68 ± 0.04 
EO-5;10 
69.4 ± 3.8 0.81 ± 0.02 
OO-5;10 
79.1 ± 1.2 0.63 ± 0.07 
EO-10;2.5 
152.4 ± 2.2 0.92 ± 0.07 
OO-10;2.5 
184.1 ± 4.7 0.89 ± 0.05 
EO-10;5 
106.8 ± 2.8 0.61 ± 0.15 
OO-10;5 
121.7 ± 2.3 0.64 ± 0.04 
EO-10;7.5 
95.3 ± 1.8 0.94 ± 0.05 
OO-10;7.5 
106.5 ± 3.8 0.79 ± 0.13  
EO-10;10 
87.5 ± 1.7 0.66 ± 0.08 
OO-10;10 
94.1 ± 1.4 0.68 ± 0.15 
EO-15;2.5 
251.5 ± 4.6 1.45 ± 0.17 
OO-15;2.5 
291.4 ± 3.2 1.24 ± 0.21 
EO-15;5 
208.9 ± 1.9 1.27 ± 0.26 
OO-15;5 
258.1 ± 2.7 1.84 ± 0.15 
EO-15;7.5 
185.1 ± 2.4 1.37 ± 0.72 
OO-15;7.5 
215.4 ± 4.2 1.47 ± 0.24 
EO-15;10 
189.4 ± 1.5 1.52 ± 0.83 
OO-15;10 
210.4 ± 2.7 1.89 ± 0.34 
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The surfactant is the other important component in NE formation, as it controls the rate of 
adsorption and coalescence by modifying the interface. The concentration, rate of collision 
and activity at the interface determine the efficiency of NE formation under fixed process 
parameters (McClement, 2011). During the HSH process, the surfactant molecules adsorb onto 
the newly formed oil-water interface, reducing the surface tension, facilitating droplet 
disruption, and restricting the coalescence and aggregation of emulsion droplets (Guzey and 
McClements, 2006). The adsorption kinetics of the emulsifier have a significant effect on the 
size and its distribution of droplets.  
The results presented in Table 4.3 show a decrease in droplet size when surfactant concentration 
was increased from 2.5 % w/w to 10 % w/w for both EO and OO. However, there was no 
significant difference (p>0.05) in the droplet size of the NEs when the concentration of 
surfactant was increased from 5 % w/w to 10 % w/w. Hence, the critical diameter may have 
been reached, with the distribution then becoming narrower rather than the droplets further 
fragmenting (Håkansson et al., 2009; Soon et al., 2001). The observed decrease in droplet 
diameter with increasing surfactant concentration can be attributed to various factors: faster 
surfactant adsorption to the oil droplets surfaces during homogenisation leads to lower 
interfacial tension, thereby facilitating droplets breakup; and more surfactant is available to 
cover the droplets surfaces formed during homogenisation (Jafari et al., 2008; Ziani et al., 
2011). Moreover, in practice, it is usually advantageous to use the lowest amount of surfactant 
required to form stable emulsions, since this reduces both cost and potential toxicity. In addition, 
high concentrations of non-adsorbed surfactant may decrease emulsion stability by promoting 
Ostwald ripening or droplet flocculation (Klang and Valenta, 2011; Weiss et al., 2000). 
In this study, 5 % w/w of the surfactant mixture was sufficient to enable the newly created 
surface area resulting from droplets breakup to be coated rapidly during the emulsification 
process. Based on these data, formulation batches containing 5 % w/w and 10 % w/w EO-NEs 
(EO-5;2.5 to EO-10;10) and OO-NEs (OO-5;2.5 to OO-10;10) were further subjected to 
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accelerated stability studies, while the formulations containing 15 % w/w oil were discarded 
due to instability and phase separation.  
4.4.4 Accelerated stability study 
 
Assessment of long term stability of TSN-loaded NEs under environmental storage 
conditions can be both tedious and time consuming, and is considered uneconomical. Thus, 
the NE formulations were subjected to a variety of extreme storage conditions, such as 
centrifugation, heating-cooling cycle and freeze-thaw cycles, to predict the stability of 
formulations samples over a period of time.  
Centrifugation can accelerate the rate of creaming or sedimentation, which demonstrates 
that the breakdown of an emulsion may be related to the action of gravitational force. O/W 
NE systems often exhibit creaming rather than sedimentation due to the lower density of oil 
droplets compared to the aqueous medium. The results from the accelerated stability study 
of the TSN-loaded EO-NEs and OO-NEs are shown in Table 4.4. Changes in physical 
appearance were also recorded upon completion of the centrifugation process. EO-5;10, 
EO-10;7.5, EO-10;10, OO-5;7.5, and OO-10;10 separated into two distinct layers after 
centrifugation, resulting from instability in the NE system. It is possible that the amount of 
surfactant used was either too high or was not sufficient to achieve a structured interfacial 
film in emulsions with a high amount of oily phase.  
Only formulations that were stable against centrifugation were subjected to storage at 
elevated temperatures. The heating-cooling study showed formulations EO-5;2.5, EO-5;7.5, 
EO-10;2.5, OO-5;7.5, OO-5;10, OO-10;2.5 and OO-10;7.5 underwent phase separation. 
Sample storage at elevated temperatures contributes to higher kinetic energy in the 
Brownian motion of oil droplets, speeding up the movement and increasing collisions 
between the oil droplets. Upon freezing, the oil droplet in the formulations segregated due 
to the formation of crystallised ice particles, resulting in the disruption of the lipid film 
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surrounding the droplets. When the samples were thawed, the droplets melted and 
immediately coalesced with surrounding droplets, resulting in phase separation. After the 
freeze-thaw cycle, only NEs containing 5 % w/w surfactant mixtures for both EO-NEs (EO-
5;5, EO-10;5) and OO-NEs (OO-5;5, OO-10;5) formulations maintained homogeneity.  
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                       Table 4.4 Accelerated stability assessment of EO-NE and OO-NE formulations. 
 
Formulation 
Code 
Centrifugation 
Heating-cooling cycle 
Freeze-thaw 
cycle 4°C 25°C 
EO-5;2.5 
√ X X X 
EO-5;5 
√ √ √ √ 
EO-5;7.5 
√ √ X X 
EO-5;10 
X N/A N/A  N/A  
EO-10;2.5 
√ √ X X 
EO-10;5 
√ √ √ √ 
EO-10;7.5 
X N/A  N/A  N/A  
EO-10;10 
√ √ √ √ 
OO-5;2.5 
√ √ √ X 
OO-5;5 
√ √ √ √ 
OO-5;7.5 
√ √ X X 
OO-5;10 
√ X X X 
OO-10;2.5 
√ √ X X 
OO-10;5 
√ √ √ √ 
OO-10;7.5 
√ √ X X 
OO-10;10 
X N/A  N/A   N/A 
 
Note: √ - stable (no phase separation), X – unstable (phase separation), N/A – (not applicable) 
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4.4.5 Physicochemical characterisation of nanoemulsions 
 
The NE formulations that passed the accelerated stress testing were then subjected to 
further characterisation. The measured ZP, % DEE, pH and viscosities of the NEs are 
shown in Table 4.5. ZP has been identified as an important factor to determine the surface 
charge, which is important for the stability of the colloidal system (Laouini et al., 2012). In 
present study, negative ZP values were obtained for all the NEs formulation, which ranged 
between -28.91 ± 1.23 mV and -37.13 ± 1.72 mV. The charge derives from the presence of 
negatively charged chlorinated poly aromatic phenol groups in TSN. High ZP is required 
for good colloidal stability, as charged droplets more strongly repel one another, thus 
overcoming the natural tendency to aggregate (Grosse et al., 2002; Tagne et al., 2008). 
Thus the obtained ZP values were sufficient to prevent droplet coalescence and indicate 
stability of the prepared NE formulations. 
Measurement of % DEE was carried out to determine the maximum amount of TSN 
encapsulated in the oil droplets. % DEE of TSN increased with increased oil concentration, 
for both EO and OO formulations. The % DEE for EO-5;5, EO-10;5, OO-5;5, and OO-10;5 
was found to be 78.61 ± 1.28, 86.14 ± 0.93, 75.49 ± 1.16, and 81.19 ± 2.15, respectively. 
However, no significant differences (p>0.05) in % DEE were observed between the EO-
NEs and OO-NEs. The pH range for healthy human skin is between 5.4 to 5.9 (Braun-Falco 
and Korting, 1986) and the pH of dermal formulations is an important factor in avoiding 
skin irritation or susceptibility to bacterial infection. The pH of all optimised formulations 
ranged from 5.23 to 5.91 values compatible with human skin pH and suitable for topical 
application.  
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Table 4.5 Physicochemical characterisation of optimised NE formulations (Mean ± SD, n = 3). 
 
Formulation 
Code 
ZP  (mV) % DEE pH Viscosity (cP) 
EO-5;5 -37.13 ± 1.72 78.83 ± 1.28 5.23 20.08 ± 1.14 
EO-10;5 -31.84 ± 0.91 86.14 ± 0.93 5.71 24.15 ± 0.94 
OO-5;5 -34.56 ± 1.21 75.49 ± 1.16 5.54 22.31 ± 1.29 
OO-10;5 -28.91 ± 1.23 81.19 ± 2.15 5.91 28.46 ± 1.73 
 
The shear viscosities of the NEs were measured at a controlled shear rate. Overall, the 
viscosities of the optimised formulations were low, as expected for O/W NEs (Alvarado et 
al., 2015). It was observed that increasing the oil concentrations slightly increased the 
viscosity of the NEs, an effect that could be associated with increased micelle diameter. 
This phenomenon is usually followed by an increase in the viscosity of systems (Chanamai 
and McClements, 2000; Chiesa et al., 2008; Mayer et al., 2013). EO-5;5 and OO-5;5 had 
low viscosities of 20.08 ± 1.14 cP and 22.31 ± 1.29 cP, respectively, perhaps due to higher 
aqueous content. These results were significantly different from (p < 0.05) the EO-10;5 and 
OO-10;5 formulations. 
4.4.6 Morphological study  
 
The NE formulations were examined by TEM to observe the particle shape and verify the 
droplet size determined by NTA. A TEM micrograph of a TSN-loaded NE formulation is 
shown in Figure 4.5. The observed droplets are spherical in shape, with an average droplet 
size of 100 nm. The TEM images for all of the optimised formulations were similar in size 
and shape. The droplet size results showed good agreement with the results obtained from 
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droplet size analysis by NTA (Section 4.4.3.2). Similar morphology was reported by Vatsraj 
et al. (2014) for clarithromycin OO-NE formulations. 
 
 
 Figure 4.5 TEM image of TSN-loaded NEs (EO-5;5). 
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4.4.7 Thermal analysis 
 
The effect of drug loading on the thermal behaviour and structural properties of the 
developed NEs, as well as the potential interactions among ingredients, were examined 
using DSC. Figures 4.6 and Figure 4.7 shows DSC thermograms for TSN, TSN free NE 
formulations (Blank EO-NEs and OO-NEs) and the TSN-loaded EO-NE and OO-NE 
formulations respectively. 
 
          Figure 4.6 DSC thermograms for TSN, blank EO-NEs, and TSN-loaded EO-NEs (EO-5;5, EO-10;5). 
  
         Figure 4.7 DSC thermograms for TSN, blank OO-NEs, and TSN-loaded OO-NEs (OO-5;5, OO-10;5). 
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The DSC thermogram for TSN has an endothermic peak at 61°C, corresponding to the 
melting of the drug. In the DSC curves for both blank and the TSN-loaded NEs 
formulations, a broad endothermic peak was observed around 110°C, most likely due to 
water evaporation. However, for the TSN-loaded NEs, no melting peak of the drug was 
detected, suggesting that TSN was molecularly dispersed, i.e. dissolved in the oil phase of 
the NEs. 
4.4.8 Fourier transform infrared analysis 
 
The FTIR spectrum provides valuable information about functional groups and possible 
intermolecular interactions between the drug and other components in the developed NEs 
formulations. The FTIR spectra for TSN, EO and OO, TSN free NEs (blank EO-NEs and 
OO-NEs) and TSN-loaded NEs are shown in Figures 4.8 and 4.9 respectively. 
The FTIR spectrum for TSN has strong absorption bands for halogenated hydrocarbons 
arising from stretching vibrations of the carbon-halogen bond for the CH2-Cl group in the 
1300–1150 cm-1 region. Other bands ascribed to out-of-plane bending of the ring C-H bonds, 
and in-plane bending bands appear in the 1300-1000 cm
-1 
region. Skeletal vibrations 
involving C-C stretching within the ring, are evident in the 1610-1585 cm
-1 
and 1500-1400 
cm
-1 
regions. 
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          Figure 4.8 FTIR spectra for TSN, EO, Blank EO-NEs and the TSN-loaded EO-NEs (EO-5;5, EO-10;5). 
 
    Figure 4.9 FTIR spectra for TSN, OO, Blank OO-NEs and the TSN-loaded OO-NEs (OO-5;5, OO-10;5). 
 
EO has a multiple band at 2969 cm
-1
, owing to methylene groups (-CH2-) (Figure 4.8); at 
1721 cm
-1
 related to carbonyl C=O stretching; at 1672 cm
-1
 due to C=C stretching of 
aromatic groups; and at 1445 cm
-1 
due to C-H deformation (Esteves et al., 2013; Sheet et al., 
2007). The FTIR spectra for blank EO-NEs and the TSN-loaded EO-NEs (EO-5;5, EO-
10;5) had a broad band in the range of 2500 cm
-1 
to 4000 cm
-1 
due to O-H stretching, 
confirming the presence of water in the formulation. The appearance of a new band at 1635 
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cm
-1 
and the broadening of bands in the TSN spectrum (in the region of 1610 – 1585 cm-1 
and C-H stretching at 1649 cm
-1
) indicated that the TSN was molecularly dispersed in oil 
(Herculano et al., 2015). 
Figure 4.9 shows a characteristic FTIR spectra for bulk OO, Blank OO-NEs and the TSN-
loaded OO-NEs (OO-5;5, OO-10;5). A weak band is visible near 3005 cm
−1
 at the higher 
wavenumber side of this region, generated by the cis double-bond C-H stretching vibration. 
In addition, this infrared region is dominated by two strong bands at 2925 and 2854 cm
−1
, 
resulting from the respective asymmetric and symmetric stretching vibrations of the acyl 
CH2 groups (Guillen and Cabo, 1997; Voort et al., 2001). Peaks observed at 1465 cm
−1
 and 
1377 cm
−1
 are due to bending vibrations of methyl and methylene groups. The large peak 
around 1740 cm
−1
 is due to C=O double bond stretching vibration and stretching vibration 
of C–O result in peaks in the 1500–650 cm−1 region (Rohman and Che Man, 2012). FTIR 
spectra for the TSN-loaded NEs showed significant broadening of the 2925 cm
−1
 band 
compared to bulk OO, which may be due to stretching of C=C bond in the aromatic ring of 
TSN. The NEs also showed a characteristic peak between 1700 cm
−1 
and 1500 cm
−1 
resulting in the appearance of superimposed peaks for TSN and OO in these regions. This 
confirmed the successful encapsulation of TSN with retained stability, as well as the 
absence of any significant interaction between drug and oils (Devi and Kakati, 2013; 
Herrero et al., 2011). 
4.4.9 In vitro release study 
The in vitro release of TSN from the optimised NE formulations and a control solution was 
investigated and the percentage cumulative TSN release was plotted against time (Figure 
4.10). All NE formulations showed higher drug release compared to control solution, 
indicating that the formulation plays an important role in the process of drug release into the 
receiver medium (Costa and Lobo, 2001). After 24 h, drug release from the NEs was less 
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than 2 % of total applied dose, which is advantageous for localised effect of topical 
formulations. 
 
Figure 4.10 In vitro release profiles of TSN from EO-NEs (EO-5;5, EO-10;5), OO-NEs (OO-5;5, 00-10,5) and 
control solution (Mean ± SD, n = 6). 
 
Drug release from EO-NEs was higher compared to the OO-NEs and control, which might 
be due to smaller droplet size and lower viscosity compared to the OO-NEs. Similar results 
were reported by Rajan and Vasudevan (2012) for atorvastatin NEs prepared with oleic acid 
and having a droplet size and viscosity range similar to EO-NEs obtained in the present 
study. Another study reported increased ketoconazole drug release from a topical hydrogel 
prepared with EO, which enhanced drug release (Jain et al., 2013). 
4.4.10 In vitro skin permeation study 
 
Skin permeation studies were performed to compare the permeation of drug from optimised 
NE formulations (EO-5;5, EO-10;5, OO-5;5, OO-10;5) and control solution. The 
cumulative amount of TSN permeated, flux and permeability coefficients for the NEs and 
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control solution are presented in Table 4.5. The cumulative amounts of TSN that permeated 
through excised full thickness porcine ear skin from the NEs and control solution are shown 
in Figure 4.11. More drug permeated from the NE formulations compared to control, 
indicating the suitability of NEs as a carrier for use in dermal delivery of lipophilic dugs. 
Several mechanisms have been proposed to explain NEs ability to improve dermal 
permeation and retention. Solubility of TSN is increased by NE formulations due to 
presence of a lipophilic oil phase, which favours drug partition into the skin because only 
the fraction of the drug dissolved in the vehicle can enter the skin (Heuschkel et al., 2008). 
NE formulations may interact with lipid layers of SC, enhancing drug permeation and 
retention into the skin (Malcolmson et al., 1998). Also, it is proposed that NEs can carry 
drug through the skin due to their small droplet size (McClements and Xiao, 2012). 
 
 
Figure 4.11 In vitro skin permeation profile of NE formulations (EO-5;5, EO-10;5, OO-5;5, OO-10;5) and 
control solution (Mean ± SD, n = 6). 
 
The EO-NEs showed higher drug permeation through the skin compared to the OO-NEs. 
This might be due to the physicochemical properties of NEs, including higher solubility of 
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TSN in EO, smaller droplet size, lower viscosity and the permeation enhancing effect of EO. 
The in vitro permeation studies showed percent cumulative TSN permeated through skin is 
higher for EO-10;5 (1.38
 
± 0.02) provides greater drug permeation than EO-5;5 (1.13
 
± 
0.05), OO-5;5 (0.48
 
± 0.006), and OO-10;5 (0.83
 
± 0.002).  
Similar permeation results were reported by Shafaat et al. (2013) for transdermal delivery 
of clozapine NEs. Results showed formulation with small droplet size and low viscosity had 
increased the permeation uptake of clozapine through skin. Another study reported increase 
in the in vitro percutaneous delivery of sumatriptan succinate formulation using EO by a 
mechanism in which the terpenes modify the barrier properties of the SC, improving drug 
partitioning into the tissue (Femenía-Fonta et al., 2005;  Williams and Barry, 1991). In the 
present study, statistical analysis showed significant differences (p<0.05) between the 
steady-state flux values obtained for EO-NEs and those of the OO-NEs (Table 4.6) 
            Table 4.6 In vitro skin permeation parameters for NEs and control solution (Mean ± SD, n = 6). 
 
Formulation Code 
Flux (Jss) 
µg/cm
2
/h 
Permeability coefficient 
(Kp) x 10
-5
 cm/h 
Control 0.086 0.86 
EO-5;5 0.497 4.97 
EO-10;5 0.315 3.15 
OO-5;5 0.195 1.95 
OO-10;5 0.236 2.36 
4.4.10.1 Quantification of triclosan in skin using adhesive tape stripping method 
 
Tape stripping method is used to quantify the amount of drug retained within the skin. 
Adhesive tapes were used to remove the superficial layers of SC, which were then analysed 
for drug content (Lademann et al., 2009; Weigmann et al., 2009). TSN levels in different 
layers of skin were studied using the adhesive tape stripping method and the results are 
presented in Figure 4.12. 
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Figure 4.12 In vitro profile of TSN accumulation in skin layers 24 h following topical application of control, 
EO-NEs (EO-5;5, EO-10;5) and OO-NEs (OO-5;5, OO-10;5) (Mean ± SD, n = 6). HOMO refers to 
homogenised tissue after removal of the SC layers. 
 
The NE formulations resulted in higher amounts of TSN retained in the skin compared to 
the control, with the difference being statistically significant (p<0.05). Encapsulation of 
TSN into nanosized oil droplets increases skin hydration, improving the delivery of drug 
through the skin. The large surface area of the NE systems enhances the penetration of drug 
through the skin surface (Tharwat et al., 2004). The data obtained from adhesive tape 
stripping method (Tape 1 – Tape 15) shows difference in TSN retention between the EO-
NEs and OO-NEs. The TSN level for the control solution was 2.15 ± 0.03 µg/mg, compared 
to the NE formulations, which were 4.89 ± 0.15 µg/mg, 10.35 ± 0.05 µg/mg, 2.41 ± 0.07 
µg/mg and 3.51 ± 0.08 µg/mg for EO-5;5, EO-10;5, OO-5;5 and OO-10;5, respectively. 
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TSN retention in skin was higher for EO-NEs compared to the OO-NEs, which aligns with 
the in vitro drug release and skin permeation data discussed in previous study (Sections 
4.4.9 and 4.4.10). EO contains about 80 % cineole, which has been reported to be a skin 
penetration enhancer (Amin et al., 2008; Saify et al., 2000; Shen et al., 2013). A study by 
Williams and Barry (1989) reported the penetration enhancement activities of EO through 
excised human skin using 5-fluorouracil as a model drug.  
4.4.11 Comparison of skin penetration of lipid nanocarriers for topical delivery of triclosan 
using in vitro diffusion studies 
 
Nanocarriers such as SLNs and NEs were prepared and characterised individually to 
evaluate their ability to deliver TSN into skin. GP-SLNs and EO-NEs were found to have 
better skin retention ability compared to other prepared formulations hence, similar 
formulations containing 5 % w/w solid lipid (GP5-2) and 5 % w/w liquid lipid EO-NEs 
(EO-5;5) were selected. Figure 4.13 depicts the amount of TSN in the skin obtained using 
adhesive tape stripping method for SLNs and NEs. 
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Figure 4.13 Amount of triclosan in the skin following application of GP-SLNs (GP5-2) and EO-NEs (EO-5;5) 
(Mean ± SD, n = 6). 
 
The total amount of TSN recovered from the skin was higher for NEs (17.49 ± 0.16 µg/mg) 
compared to SLNs (14.42 ± 0.27 µg/mg) with the difference being statistically significant 
(p<0.05). This might be due to the difference in composition and physical state of lipids 
used in preparation of SLNs and NEs. SLNs were composed of lipids containing mono and 
diglycerides whereas NEs were produced using oils composed of mixtures of mono-, di- 
and triglycerides. In addition, SLNs contains a solid lipid core compared to the soft flexible 
core in NEs.  
A similar study reported by Aditya et al., (2014) evaluated the effect of composition and 
physical state on the quercetin bioaccessibility in simulated intestinal conditions using 
different lipid nanocarriers. They found lower bioaccessibility from SLNs compared to NEs. 
This may be attributed by the formation of a less ordered lattice defect in NEs with more 
space for guest molecules (Nayak et al., 2010; Severino et al., 2012).  This is in line with 
other studies reported by Clares et al., (2014), in which retinyl palmitate was encapsulated 
in SLNs and NEs, and drug permeation was higher from NEs. It was reported that the 
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penetration enhancement of vehicles through the skin depends on the flexibility of the 
carrier (Garduno-Ramirez et al., 2012).  
 
 
  
153 
4.5 Conclusion 
The NE formulations containing TSN were formulated using EO and OO by HSH followed 
by ultrasonication. Pseudoternary phase diagrams studies allowed the identification of 
different regions, as well as the selection of maximum and minimum concentrations of each 
component required for obtaining stable formulations. The effect of different concentrations 
of oil phase and surfactant on droplet size distribution and other physicochemical 
parameters were studied. Amount of TSN released and permeated through artificial 
membrane and full thickness porcine skin was evaluated by diffusion studies. 
TSN-loaded NEs were prepared successfully using EO and OO, with EO-NEs having 
smaller droplet size and higher % DEE compared to OO-NEs. Concentrations of oil and 
surfactant had opposing actions on droplet size, with an increase in the oil phase increasing 
droplet size while an increase in surfactant concentration caused a decrease in droplet size. 
Morphological studies confirmed the formation of spherical NEs droplet while thermal and 
structural characterisation demonstrated the molecular dispersion of drug within the oil 
phase of the formulation. Optimised formulations containing 5 % w/w and 10 % w/w EO-
NEs and OO-NEs (EO-5;5, EO-10;5, OO-5;5, OO-10;5) were selected for further in vitro 
drug release and permeation studies. EO-NEs demonstrated higher drug permeation though 
skin compared to OO-NEs due to the influence of physicochemical properties such as 
higher solubility of TSN in EO, smaller droplet size, low viscosity and permeation 
enhancement effects of EO. Higher amounts of TSN were recovered from skin following 
application of NE formulation EO-10;5 (10.35 ± 0.05 µg/mg) compared to other NE 
formulations. The results reported in this work clearly demonstrate the potential of these 
NEs for enhanced topical dermal delivery. 
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5. CHAPTER – NANOEMULSIONS AS CARRIERS OF 
HYDROPHILIC COMPOUNDS FOR TOPICAL DELIVERY 
 
5.1 Introduction 
HAIs are caused either by a medical intervention such as a surgical procedure or from 
contact within a healthcare setting. Although they cover a wide range of infections, SSIs are 
the most commonly reported nosocomial infections, accounting for 14–16 % of all 
nosocomial infections among hospital patients (Smyth and Emmerson, 2000). SSIs are the 
result of contamination of skin during pre or post-surgical procedure by microorganisms 
originated either from patient’s own flora or any contaminated item in the sterile surgical 
field, including a device or the hubs of an intravascular device. 
 CHG has been an important components as a topical antiseptic agent for more than 50 
years to reduce the risk of HAIs (Edmiston et al., 2007; Hibbard, 2005; Holder and 
Zellinger, 2009). It is used as either in the form of aqueous or alcoholic solution in surgical 
environment to disinfect the skin prior to surgery. CHG is a bisbiguanide with broad 
spectrum antiseptic activity against a wide range of both Gram-positive and Gram-negative 
bacteria and lipophilic viruses (Pratt et al., 2007). The effectiveness and widespread use of 
CHG has led to some concern over the emergence of bacterial resistance. Many studies 
have been performed to understand the CHG resistance over various microorganisms (Barry 
et al., 1999; Zhang et al., 2011).  
 Karpanen et al. (2008)  reported poor permeation of CHG from 2 % w/v aqueous solution 
into the deeper layers of the skin. Therefore, there is a need to develop an effective carrier 
system or formulations in order to achieve effective skin antisepsis to permeate CHG 
deeper into skin. This includes potentially using CHG with a combination of other 
antimicrobial agents or permeation enhancers. 
 
  
155 
EO has been used medicinally and is recognised as possessing broad spectrum antimicrobial 
and permeation enhancement activities (Edris, 2007). Due to its antibacterial properties, EO 
is a common ingredient in topical antiseptics, soaps and mouthwashes. Furthermore, it is 
generally considered safe when applied topically (Higgins et al., 2015). The addition of EO 
to CHG was shown to significantly enhance skin penetration of CHG into the epidermis and 
dermis (Karpanen et al., 2010). Another oil, OO has been used for health and personal care 
for thousands of years: Egyptian pharaohs used it to moisturise their skin and hair, whereas 
the Romans used it to treat wounds. Badiu et al. (2010) reported beneficial effects of OO on 
capillary blood flow and endothelial function, the exact mechanism of which is currently 
unknown. 
Altrazeal
®
, a flexible methacrylate dressing (Uluru Inc., Addison, TX, USA), supplied as 
powder, contains a hydrophilic polymer consisting of a methacrylate backbone and terminal 
hydroxyl group. Altrazeal
 
can be directly applied into a wound, or can be hydrated with 
saline or another sterile solution, resulting in rapid hydration of methacrylate particles to 
form a strong uniform gel material that can conform to surfaces in the wound bed.  
Altrazeal
 
has also been studied as a drug delivery vehicle for various cationic and anionic 
wound antiseptics, such as povidone-iodine, polyhexamethylene biguanide and octenidine 
dihydrochloride (Forstner et al., 2013). 
Human skin has been widely used as a model for studying in vitro diffusion of transdermal 
and topical formulations. However, human skin suffers from high biological variability 
such as thickness of the skin, lipid content and lipid composition (Schmook et al., 2001; 
Trauera et al., 2014). Recently, Strat-M
®
 membrane (Merck Millipore, UK) has become 
available commercially as an artificial skin mimic membrane. As a synthetic membrane, it 
has low batch-to-batch variability, thus providing more consistent data. Takashi et al., 
(2015) evaluated the permeation of parabens, lidocaine hydrochloride, antipyrine, 
aminopyrine and isosorbide dinitrate using Strat-M
 
membrane. Results showed similar 
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permeability coefficients and partition coefficient values as human and animal skin models. 
Hence, in the present research work Strat-M membrane was used to analyse CHG 
permeation and was compared with permeability coefficient data obtained using porcine ear 
skin as an in vitro skin model. 
The present work includes the formulation and evaluation of various CHG-NE formulations 
using oils such as EO and OO, and S80 and T80 as a surfactant and cosurfactant mixture 
(Smix). In vitro drug release and skin permeation of CHG were studied using different 
synthetic membranes and excised full thickness porcine ear skin, respectively. 
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5.2 Aims of the study 
The aims of this study were, 
 
 To evaluate NEs as hydrophilic drug carriers for CHG by preparing various 
compositions of NEs using EO and OO as oil phase for topical dermal delivery. 
 To characterise the prepared NE formulations based on their physicochemical 
properties and to compare the drug release, skin permeation and retention of CHG 
using dialysis membrane, Strat-M membrane and excised full thickness porcine ear 
skin. 
 To study the impact of damage SC on drug permeation using adhesive tape stripping 
method to mimic wound condition by in vitro skin diffusion study. 
 To evaluate a methacrylate powder dressing as a drug delivery vehicle to control the 
release of CHG by in vitro skin diffusion study. 
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5.3 Materials and Method 
Materials:  
 
Chlorhexidine digluconate solution (20 % w/v), eucalyptus oil, olive oil, Tween
®
 80, Span
®
 
80 and dialysis membrane were purchased from Sigma Aldrich (UK). Altrazeal
® 
powder 
was a gift from Uluru Inc, UK. Strat-M
® 
membrane was purchased from Merck Millipore, 
UK. All other reagents used were of analytical grade. 
5.3.1 Construction of pseudoternary phase diagrams 
 
Pseudoternary phase diagrams for the development of NEs were prepared using water, S80, 
T80, and EO or OO as the aqueous, surfactant, cosurfactant and oil phases, respectively. 
W/O type NEs were prepared using an oil phase titration method (Shakeel and Ramadan, 
2010; Shakeel et al., 2013). S80 and T80 were mixed in mass ratios of 1:0, 1:1, 2:1, 3:1 and 
4:1. Aqueous phase and specific ratios of Smix were combined using a vortex mixer in mass 
ratios ranging from 1:9 to 9:1. The mixtures of aqueous phase and Smix were titrated using 
the slow addition of the oil phase (EO, OO), and pseudoternary phase diagrams were 
constructed using JMP 11 software (SAS Institute Inc., USA) and NE regions were 
identified based on visual observations.  
5.3.2 Formulation of chlorhexidine digluconate nanoemulsions 
 
CHG-NEs were prepared using the previously described HSH followed by probe 
ultrasonication (Urban and Wagner, 2006). The hot oil phase was prepared using either EO 
or OO with S80 by heating at 40°C to ensure effective mixing, while the hot aqueous phase 
was prepared by mixing CHG (equivalent to 20 mg/g of formulations) with T80 and water 
at same temperature. The hot aqueous phase was slowly added into the hot oil phase under 
HSH (Silverson, UK). This primary hot emulsion was subjected to ultrasonication (Sonics 
and Materials Inc., USA) for 10 min using 70 % frequency amplitude for further size 
reduction of the droplets. The preliminary composition of the NE mixtures, as defined in the 
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isotropic regions of the pseudoternary phase diagrams, were prepared using different ratios 
of Smix and are presented in Table 5.1. 
                                Table 5.1 Composition of preliminary CHG-loaded NE formulations. 
Formulation 
Code 
Oil 
S80: T80 (2:1) 
% w/w Type 
Concentration 
(% w/w) 
C-EO-70(5) 
Eucalyptus oil 
70 5 
C-EO-70(10)  10 
C-EO-70(15)  15 
C-EO-75(5) 75 5 
C-EO-75(10)  10 
C-EO-75(15)  15 
C-OO-70(5) 
Olive oil 
70 5 
C-OO-70(10)  10 
C-OO-70(15)  15 
C-OO-75(5) 75 5 
C-OO-75(10)  10 
C-OO-75(15)  15 
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5.3.3 Physicochemical characterisation of nanoemulsion formulations 
 
All physicochemical characterisation, i.e., determination of droplet size, PDI, ZP, % DEE, 
pH, viscosity, morphological examination using TEM, FTIR, and accelerated thermal stress 
testing were carried out as described in detail in the chapter 4 (Section 4.3.4). 
5.3.3.1 In vitro drug release and skin permeation studies 
 
In vitro drug release and skin permeation studies for the CHG-NE formulations were 
carried out using Franz diffusion cells. The setup and experimental conditions were similar 
to those described in the chapter 3 (Section 3.3.3.9), except for the receiver medium, which 
contained PBS (pH 7.4) without the use of SLS. For the release studies, a cellulose acetate 
membrane (Sigma Aldrich, UK), 23 mm in diameter, with a molecular weight cut off of 12-
14 kDa was selected and for the skin permeation studies excised full thickness porcine ear 
skin was used. 
An aqueous solution of CHG (2 % w/v) was used as a control solution. The dialysis 
membrane or skin was equilibrated for 30 min before loading NE formulations (equivalent 
to 20 mg/g CHG concentration) or similar concentration of control solution to donor 
compartment and covered with Parafilm to prevent evaporation. Subsequently, 500 l 
samples were collected from the receiver compartment at 4, 6, 8, 10, 12 and 24 h and 
replaced by an equal volume of fresh receiver medium to maintain sink conditions. All 
samples were analysed for amount of CHG released or permeated using HPLC (Section 
2.2.1.1). The cumulative amount of CHG released, or the amount that permeated through 
the artificial membrane or porcine ear skin was plotted as a function of time. 
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5.3.3.2 Quantification of chlorhexidine digluconate in skin using adhesive tape stripping 
method 
 
The amount of CHG retained within the skin following application of the NE formulations 
and the control solution was quantified using the adhesive tape stripping method. The tape 
stripping method was performed and the samples were analysed as similar as described in 
chapter 3 (Section 3.3.3.9.2). 
5.3.3.3 In vitro skin diffusion studies of chlorhexidine digluconate nanoemulsions using 
methacrylate dressing powder 
 
Altrazeal dressing powder was studied as a drug delivery vehicle for CHG using the in vitro 
Franz diffusion cells. Accurately weighed Altrazeal powder (500 mg) was placed in the 
donor compartment and loaded with NE formulations or control solution (equivalent to 20 
mg/g CHG concentration) using a micropipette. Addition of cationic CHG caused hydration 
of methacrylate polymer particles, transforming the powder into a porous gel matrix (Figure 
5.1), for detailed gelation mechanism refer Section 5.1. The amount of CHG that permeated 
into receiver compartment after 24 h and the amount retained within skin was analysed 
using HPLC. 
 
Figure 5.1 Hydrogel conversion of methacrylate powder dressing following the addition of CHG-NEs [C-EO-
70(10)]. 
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5.3.3.5 In vitro diffusion studies of chlorhexidine digluconate permeation using porcine ear 
skin and Strat- M
® 
membrane 
 
In the present study, in vitro permeation was performed with Strat-M membrane and 
excised full thickness porcine ear skin, in order to compare the permeability coefficient and 
flux of the applied CHG-NE formulations and control solution (equivalent to 20 mg/g CHG 
concentration). The experimental set up and conditions was as similar as described in 
previous study (Section 5.3.3.1) and the amount of CHG released or permeated into receiver 
medium was analysed by HPLC (Section 2.2.1.2). 
5.3.3.6 Studies of chlorhexidine digluconate penetration into barrier-intact and barrier-
impaired porcine ear skin 
 
The treatment of skin infections and wounds implies the application of a drug to skin 
having a damaged or completely removed epidermal barrier, which is likely to affect the 
penetration profile of the carrier and drug substance into the skin. To mimic this effect, the 
skin barrier was disrupted using 15 successive adhesive tape strips using surgical tape (3M 
Transpore, UK) as described by Simonsen and Fullerton (2007). In vitro diffusion studies 
were carried out as described in Section 5.3.3.1 using barrier-intact and barrier-impaired 
excised full thickness porcine ear skin. The influence of skin barrier properties on the 
penetration profile of CHG from NE formulations and control solution was studied. 
5.3.3.7 Statistical analysis 
 
All measurements were repeated at least three times and the data are reported as the mean ± 
SD. Data obtained was statically analysed by one way ANOVA using GraphPad Prism 5 
software. Differences were considered to be statistically significant at p < 0.05. 
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5.4 Results and Discussion 
5.4.1 Pseudoternary phase diagrams 
 
Various CHG-NEs were prepared by constructing pseudoternary phase diagrams with water, 
S80, T80, and EO or OO as the aqueous, surfactant, cosurfactant and oil phases, 
respectively. The pseudoternary phase diagrams were developed using the oil titration 
method for each Smix to identify the NE zones. The resulting diagrams are presented in 
Figures 5.2, 5.3 and 5.4. 
 
Figure 5.2 Pseudoternary phase diagrams of a) eucalyptus oil and b) olive oil with surfactant (S80) and water. 
 
 
It was observed that when S80 was used alone without T80 (Smix ratio 1:0), only a small 
amount of aqueous phase was incorporated at higher concentrations of S80 for both EO and 
OO (Figure 5.2). The maximum amount of water that could be added was found to be 10 % 
w/w at a high (81 % w/w) Smix concentration. However, when S80 and T80 concentrations 
were kept equal (Smix ratio 1:1), the NEs zones increased slightly as compared to the 1:0 
ratio. The aqueous phase found to be solubilised to only 17 % w/w when the Smix 
concentration was 63 % w/w (Figures 5.3a and 5.4a).  
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Figure 5.3 Pseudoternary phase diagrams of eucalyptus oil, water and different ratios of surfactant mixture 
(S80:T80) a) Smix 1:1, b) Smix 2:1, c) Smix 3:1, d) Smix 4:1. 
 
When the Smix ratio was increased to 2:1, it was observed that the NE zone increased 
markedly as compared to Smix ratio 1:1 (Figures 5.3b and 5.4b), allowing 31 % w/w 
incorporation of the aqueous phase with a lower concentration (20 % w/w) of Smix. 
However, when the Smix ratio was increased to 3:1, the NE zone decreased compared to the 
2:1 ratio (Figure 5.3c and 5.4c). The maximum amount of aqueous phase solubilised was 
26 % w/w when incorporating 45 % w/w Smix. Upon further increasing the Smix ratio to 4:1, 
the NE zone decreased further compared to the 2:1 and 3:1 ratios (Figure 5.3d and 5.4d). As 
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indicated by the phase diagrams, the maximum NE zone was achieved at a Smix ratio of 2:1. 
Therefore, this ratio was used in the preliminary NE formulations.  
 
Figure 5.4 Pseudoternary phase diagrams of olive oil, water and different ratios of surfactant mixture 
(S80:T80) a) Smix 1:1, b) Smix 2:1, c) Smix 3:1, d) Smix 4:1. 
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5.4.2 Preparation and characterisation of nanoemulsions 
 
W/O NEs of CHG were prepared using a HSH followed by ultrasonication method. The 
initial batches of CHG-EO and CHG-OO NEs were prepared using different concentrations 
of Smix 2:1 (5, 10 and 15 % w/w), while the concentrations of oil used were 70 and 75 % 
w/w to maintain CHG concentrations (loading dose of 20 mg/g CHG) in final formulation. 
The low weight percentage of water was selected to minimise droplet collision, and excess 
surfactant was used (up to 15 % w/w) to minimise coalescence. 
5.4.2.1 Influence of homogenisation stirring speed and processing time 
 
It has been reported that droplet size depends on the energy input, e.g. stirring speed and 
time of homogenisation (Jasińskaa et al., 2014). The effect of different homogenisation 
speeds (4000 to 10,000 rpm) and time (10, 15 and 20 min) on the mean droplet size was 
determined for CHG-EO [C-EO-70(10)] and CHG-OO [C-OO-70(10)] NE formulations are 
shown in Figure 5.5. 
As homogenisation speed increased from 4000 rpm to 10,000 rpm, there was a decrease in 
droplet size, due to higher deformation stress. The decrease in mean droplet size measured 
immediately after preparation of NEs was from 764 ± 12.24 nm to 273 ± 17.51 nm for the 
CHG-EO NEs, while in case of the CHG-OO NEs, mean droplet size decreased from 851 ± 
13.47 nm to 308 ± 9.36 nm. Differences in droplet size may be due to the different 
physicochemical properties of EO and OO such as their chemical composition, viscosity 
and HLB values (Orafidiya and Oladimeji, 2002). It may be possible to decrease the droplet 
size further using HSH but due to the specification of homogeniser used, the highest 
available speed was 10,000 rpm hence, the homogenisation speed used for preparation of 
NEs was 10,000 rpm. 
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Figure 5.5 Influence of homogenisation speed on droplet size of CHG-loaded EO-NEs [C-EO-70(10)] and 
CHG-OO NEs [C-OO-70(10)] (Mean ± SD, n = 3). 
 
Droplet size reduced as homogenisation time was extended for both CHG-EO and CHG-
OO NEs (Figure 5.6). When the homogenisation time increased from 10 min to 15 min, the 
droplet size of the CHG-EO NEs decreased from 492 ± 10.34 nm to 271 ± 14.31 nm, while 
the CHG-OO NEs droplet size decreased from 574 ± 18.24 nm to 315 ± 16.71 nm. However, 
when the duration was further increased to 20 min, there was a slight increase in droplet 
size for both the CHG-EO NEs and CHG-OO NEs. Similar results were reported by Tang et 
al., (2013) for the formulation of an aspirin NEs using an ultrasonication method, which 
showed increase in processing duration led to an decrease in NEs droplet size. Qian and 
McClements, (2011) reported that, with certain types of emulsifiers extended durations of 
homogenisation may lead to “over-processing” which caused an increase in droplet size. 
The preliminary CHG-NEs were formulated using 10,000 rpm homogenisation speed for 15 
min followed by ultrasonication for 10 min at 70 % frequency amplitude. 
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Figure 5.6  Influence of duration of homogenisation on droplet size of CHG-loaded OO-NEs [C-EO-70(10)] 
and CHG-OO NEs [C-OO-70(10)] (Mean ± SD, n = 3). 
 
 
5.4.2.2. Influence of surfactant concentration  
 
The type and concentration of surfactants used to prepare W/O CHG-NEs are very 
important because they affect the droplet size and its distribution, along with formulation 
stability. A series of NEs containing 5, 10 and 15 % w/w Smix (2:1) in the oil phase were 
prepared and the effects of surfactant concentration on droplet size and PDI was determined 
by using NTA, which are shown in Table 5.2. 
Droplet size decreased when surfactant concentration was increased from 5 to 10 % w/w for 
both CHG-EO and CHG-OO NE formulations. This effect demonstrates the dynamic 
equilibrium between droplet break up and coalescence present in the emulsion (Niknafs et 
al., 2011). At low concentrations, the levels of surfactant in the water-oil interfacial layer 
are not sufficient to completely cover the surface of the drops causing coalescence and 
flocculation of droplets, thus leading to increased size. 
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Table 5.2 Influence of surfactant concentration on droplet size and distribution of CHG-loaded EO-NEs and 
OO-NEs (Mean ± SD, n = 3). 
 
Formulation 
Droplet size 
(nm) 
PDI Formulation 
Droplet size 
(nm) 
PDI 
C-EO-70(5) 
389.2 ± 9.2 0.74 ± 0.15 
C-OO-70(5) 
415.2 ± 10.5 0.85 ± 0.03 
C-EO-70(10) 
257.5 ± 12.4 0.56 ± 0.13 
C-OO-70(10) 
285.3 ± 13.4 0.61 ± 0.06 
C-EO-70(15) 
291.3 ± 15.8 0.62 ± 0.24 
C-OO-70(15) 
338.2 ± 12.4 0.69 ± 0.04 
C-EO-75(5) 
438.4 ± 13.9 0.81 ± 0.02 
C-OO-75(5) 
485.1 ± 14.8 0.73 ± 0.07 
C-EO-75(10) 
305.4 ± 12.2 0.59 ± 0.07 
C-OO-75(10) 
348.1 ± 4.7 0.64 ± 0.05 
C-EO-75(15) 
341.8 ± 17.5 0.63 ± 0.15 
C-OO-75(15) 
382.7 ± 18.4 0.74 ± 0.04 
 
Increasing the surfactant concentration results in a greater number of surfactant molecules 
migrating from the aqueous phase to the oil phase, producing nanodroplets (Saberi et al., 
2013). However, increasing the surfactant concentration up to 15 % w/w both increased 
droplet size and resulted in a broader PDI. By increasing the surfactant concentration, the 
surfactant can form micelles in the continuous phase rather than orienting at the particle 
surface, resulting in increased local osmotic pressure, thus causing depletion of the 
continuous phase between droplets. Consequently, aggregation takes place and particle size 
increases (Wulff-Perez and Torcello-Gomez, 2009). 
 
5.4.3 Thermal stability study 
 
Thermodynamic stability tests were performed to identify any unstable or metastable NEs 
compositions (Shakeel et al., 2014a, 2014b). All of the prepared formulations were 
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subjected to stability studies that included centrifugation, heating-cooling and freeze-thaw 
cycles, as described in detail in chapter 4 (Section 4.4.4).  
 
The C-EO-75(5) NE formulation underwent phase separation following centrifugation, 
while the other formulations were stable (Table 5.3). These were then subjected to thermal 
stress under two different conditions, 4°C and 25°C. Only the formulations that remained 
stable were then subjected to the freeze-thaw cycle. The formulations containing 10 % w/w 
Smix for both EO [C-EO-70(10), C-EO-75(10)] and OO [C-OO-70(10), C-OO-75(10)] were 
found to be stable under all three testing conditions. 
 
Based on the results obtained from studies of effect of different homogenisation speed, time 
and stability studies, the CHG-EO NEs [C-EO-70(10), C-EO-75(10)]and CHG-OO NEs [C-
OO-70(10), C-OO-75(10)] each containing a surfactant concentration of 10 % w/w, were 
found to have the smallest droplet size, PDI and stable under all thermal stress studies, thus 
these formulations were selected for further physicochemical characterisation and in vitro 
diffusion studies. 
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Table 5.3 Thermal stability assessments of CHG-loaded EO-NE and OO-NE formulations. 
 
Formulation Code Centrifugation 
Heating-cooling cycle 
Freeze-thaw 
cycle 4°C 25°C 
C-EO-70(5) 
√ X X N/A 
C-EO-70(10) 
√ √ √ √ 
C-EO-70(15) 
√ √ X X 
C-EO-75(5) 
X N/A N/A  N/A  
C-EO-75(10) 
√ √ √ √ 
C-EO-75(15) 
√ √ X N/A 
C-OO-70(5) 
√ X N/A  N/A  
C-OO-70(10) 
√ √ √ √ 
C-OO-70(15) 
√ √ X N/A 
C-OO-75(5) 
√ √ √ X 
C-OO-75(10) 
√ √ √ √ 
C-OO-75(15) 
√ √ X N/A 
 
 
Note: √ - stable (no phase separation), X – unstable (phase separation), N/A – (not applicable) 
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5.4.4 Physicochemical characterisation of nanoemulsions 
 
The formulations that passed the thermal stability testing were further characterised for 
ZP, % DEE, pH and viscosity and results are presented in Table 5.4. High zeta values have 
been suggested as an indicator of the physical stability of NEs, as they can ensure the 
creation of a high energy barrier against coalescence of the inner phase droplets (Zhao et al., 
2010). All formulations had high positive ZPs, ranging from 39.53 ± 1.21 mV to 47.16 ± 
1.72 mV. This indicates a reasonable electrostatic repulsion between the droplets (Baspinar 
et al., 2010). The positive charge of NE formulations was likely due to the presence of 
water soluble, positively charged CHG. The % DEE of all the NEs formulations were C-
EO-70(10), C-EO-75(10), C-OO-70(10) and C-OO-75(10) were 79.83 ± 2.28, 82.14 ± 1.93, 
73.49 ± 2.06 and 78.19 ± 1.35 respectively. The % DEE for both EO and OO formulations 
were found to be almost similar with C-EO-75(10) having the highest entrapment efficiency. 
                         Table 5.4 Physicochemical characterisation of NE formulation (Mean ± SD, n = 3). 
 
Formulation  ZP  (mV) % DEE pH Viscosity (cP) 
C-EO-70(10) 47.16 ± 1.72 79.83 ± 2.28 5.78 23.08 ± 1.14 
C-EO-75(10) 44.82 ± 0.91 82.14 ± 1.93 5.65 25.15 ± 0.94 
C-OO-70(10) 39.53 ± 1.21 73.49 ± 2.06 5.41 29.31 ± 1.29 
C-OO-75(10) 41.91 ± 1.23 78.19 ± 1.35 5.36 33.46 ± 1.73 
 
The pH of skin ranges between 5 and 6, with 5.5 considered to be average pH of the skin 
(Ohman and Vahlquist, 1998). Therefore, formulations intended for application to skin 
should have a pH close to this range. The pH values for all the NEs formulations prepared 
were found to be in the range of 5.36 to 5.78, suitable for topical application.  
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Viscosity of EO and OO reported in literature is 30 cP and 40 cP at 40°C respectively 
(Diamante and Lan, 2014; Tarabet et al., 2012). Viscosities of the both CHG-EO NEs and 
CHG-OO NEs were less than the respective oils due to the presence of water in 
formulations. Similar results were reported by Shakeel et al., (2015), using W/O EO-NEs, 
which showed a direct relationship between oil concentration and viscosities of NEs 
formulations. 
5.4.5 Morphological study 
 
The CHG-NEs were examined using TEM to observe the droplet shape and verify the 
droplets size determined by NTA. The droplets of the CHG-NEs appeared dark, and the 
surrounding liquid appeared bright, as shown in Figure 5.7. As seen in the displayed image, 
the observed droplets were spherical in shape, and ranged in size from 200 nm – 300 nm. 
The TEM images for all the formulated NEs were similar in shape, and the droplet size 
range was in agreement with the NTA results (Section 5.4.2.2).  
 
 
                                          Figure 5.7 TEM image of CHG-loaded NEs [C-EO-70(10)]. 
Li et al. (2015) reported a similar droplet shape for a chlorhexidine acetate NE designed to 
improve chlorhexidine solubility and to enhance its antimicrobial activity against 
Spreptococcus mutans in vitro and in vivo. They reported minimum inhibitory concentration 
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(MIC) of a chlorhexidine acetate control solution was 0.8 µg/ml, which was two times 
higher than chlorhexidine acetate NEs (0.4 µg/ml). Also the NE formulations exhibited a 
fast-acting bactericidal activity against Spreptococcus mutans, causing over 95 % death 
within 5 min, compared to chlorhexidine acetate solution (73 %). These data showed the 
potential role of NE formulation to prevent bacterial infection during the wound healing 
process. 
5.4.6 Fourier transform infrared spectrometry 
 
The FTIR absorption spectra were obtained to study the drug and excipient interaction in 
the NE formulations. The FTIR spectra of CHG, EO and OO, CHG free formulations 
(blank EO-NEs and OO-NEs) and CHG-loaded NEs are shown in Figures 5.8 and Figure 
5.9 respectively. 
The FTIR spectrum of CHG had a broad symmetrical absorption peak between 3700–2700 
cm
-1
, representing OH stretching due to the presence of water. Sharper amide bands were 
seen at 1650 cm
-1
 (C = O stretch), 1538 cm
-1
 (secondary N-H bend and C-N stretch) 
corresponding presence of CHG characteristic peaks. As seen in Figures 5.8 and 5.9, EO 
and OO had multiple absorption bands, which are described in detail in the previous chapter 
(Section 4.4.8). 
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Figure 5.8 FTIR spectra for CHG, EO, Blank EO-NEs and CHG-loaded EO-NEs [C-EO-70(10), C-EO-
75(10)]. 
 
 
Figure 5.9 FTIR spectra for CHG, OO, Blank OO-NEs and CHG-loaded OO-NEs [C-OO-70(10), C-OO-
75(10)]. 
The FTIR spectra for both blank and CHG-loaded NEs of EO and OO (Figure 5.8 and 
Figure 5.9) had a broad symmetrical absorption peak between 3700–2700 cm-1, 
representing the OH stretching mode of water superimposed over the CHG bands. The 
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broad peak seen between 1500 cm
-1 
and 1700 cm
-1 
in the blank and the CHG-loaded NEs 
formulations is due to the C=O double bond stretching vibration, resulting in superimposed 
peaks for CHG and EO and OO in this region (Kim et al., 2008). Results obtained from 
FTIR spectra does not show any new peaks or modification of existing peaks between 
prepared NEs and individual components of NE system, which represents no chemical 
interaction between drug and excipients during formulation. 
5.4.7 In vitro drug release study 
 
The in vitro release of CHG from the NE formulations and control solution (loading dose 
for both equivalent to 20 mg/g CHG concentration) was investigated using dialysis 
membrane, and the amount of CHG released was plotted against time (Figure 5.10). The 
data shows an initial burst release of CHG from the NEs and control solution for up to 4 h, 
the first time point, followed by a slow release up to 24 h.  
 
Figure 5.10 In vitro release profiles of CHG from NE formulations [C-EO-70(10), C-EO-75(10), C-OO-
70(10), C-OO-75(10)] and control solution (Mean ± SD, n = 6). 
 Release data shows lower CHG release from NE formulations compared to control solution, 
which might be due to the effect of formulation excipients. The amount of oil in the 
formulation restricts partitioning of the drug between the oil and water interface and 
0
20
40
60
80
100
120
0 4 8 12 16 20 24
C
o
n
ce
n
tr
a
ti
o
n
 o
f 
C
H
G
 r
e
le
a
se
 (
μ
g
/m
l 
) 
 
Time (h) 
Control
C-EO-75(10)
C-EO-70(10)
C-OO-75(10)
C-OO-70(10)
  
177 
dialysis membrane controls the rate of drug release (Sandhu et al., 2012). Literature study 
reported by Syed (2013) for in vitro evaluation of docetaxel OO-NEs (10 % w/w oil) 
formulated using similar production method.  Results showed lower release of docetaxel 
from NE formulations compared to it control solution. Another study reported evaluation of 
in vitro release and epidermal permeation of dapsone NEs for topical delivery (Borges et al., 
2013). Release of dapsone was found to be less from NEs compared to a control solution, 
confirming the role of formulation excipients and composition in controlled release of drug 
into receiver.  
5.4.8 In vitro skin diffusion studies 
 
 
In vitro skin permeation of all CHG-NE formulations and control solution was performed 
using Franz diffusion cells to study the localisation of drug within the skin layers and to 
determine if the formulation had any influence on this. Cumulative permeation was plotted 
against time (Figure 5.11), and permeability coefficient and steady state flux were 
calculated (Table 5.5). After 24 h less than 1 % w/w of the total applied dose of CHG 
reached the receiver compartment from NE formulations compared to 1.6 % w/w from the 
control solution. The reduced permeation through the skin may be as a result of altering the 
pathway into the skin. It has been reported that NEs may more effectively target hair 
follicles, thus differences will be seen between lipid formulations and the solution. The 
positive charge on the NEs in this study may also influence interactions with protein 
residues compared to non-charged equivalents  (Yilmaz and Borchert, 2005).  
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Figure 5.11 In vitro skin permeation of CHG from NE formulations [C-EO-70(10), C-EO-75(10), C-OO-
70(10), C-OO-75(10)] and control solution (Mean ± SD, n = 6). 
 
In our study, permeation graphs show slow release of CHG from NEs, which unexpectedly 
plateaued after 12 h of diffusion experiment for CHG-OO NEs and control solution. Based 
on the literature study, CHG has been found to be stable at experimental conditions such as 
pH and temperature and also sink condition was maintained throughout experiment to 
establish concentration gradient across skin. The possible explanation could be binding of 
CHG with lipids and ceramides present in the SC of the epidermis, which enhances CHG 
penetration and retention after its application to the skin reducing its permeation into 
receiver compartment (Lorian, 2005). Similar permeation results were reported by 
Karpanen et al. (2008) in evaluation of CHG penetration into human skin, which had 
showed less CHG permeation into receiver compartment. Another study reported by Tsai et 
al., (2014) showed effect of NEs as carrier for hydrophilic ropinirole hydrochloride. Skin 
permeation study showed no detectable level of drug in receiver compartment after 12 h of 
diffusion experiment. Less permeation of CHG from NE formulations compared to control 
solution might be due to the presence of formulation excipients such as oil, surfactant and 
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cosurfactant which enhances the penetration of CHG into skin by interacting and disrupting 
barrier properties of SC (Makraduli et al., 2013; Tsai et al., 2013).  
Statistical analysis revealed a significant difference (p<0.05) in steady state flux values 
obtained for CHG-EO NEs and CHG-OO NEs. The flux of NEs and control solution was in 
order of control > C-EO-75(10) > C-EO-70(10) > C-OO-75(10) > C-OO-70(10). 
Table 5.5 In vitro permeability parameters of CHG from NE formulations and control solution 
 (Mean ± SD, n = 6). 
 
Formulation Code 
Flux (Jss) 
µg/cm
2
/h 
Permeability coefficient 
(Kp) x 10
-4
 cm/h 
Control 1.23 2.81 
C-EO-75(10) 0.91 1.29 
C-EO-70(10) 0.87 1.52 
C-OO-75(10) 0.84 0.26 
C-OO-70(10) 0.76 0.22 
 
5.4.8.1 Quantification of chlorhexidine digluconate in skin using adhesive tape stripping 
method 
 
The adhesive tape stripping method is used for quantification of topically applied 
substances in the skin. It removes the superficial layers of SC and allows the determination 
of the amount of drug that has penetrated into the skin. The CHG levels found in the skin 
are presented in Figure 5.12. 
CHG penetration into the skin was higher for NE formulations compared to the control, 
with the differences being statistically significant (p<0.05). In addition, CHG skin 
penetration was significantly higher (p<0.05) for CHG-EO NEs compared to CHG-OO NEs 
and the control solution.  The amount of CHG recovered from the skin for the control 
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solution was 3.01 ± 0.02 µg/mg, compared to 6.15 ± 0.12 µg/mg, 5.31 ± 0.08 µg/mg, 4.39 ± 
0.04 µg/mg and 3.98 ± 0.06 µg/mg for C-EO-75(10), C-EO-70(10), C-OO-75(10) and C-
OO-70(10) respectively. The C-EO-75(10) formulation had the CHG retention in skin, 
which is above the MIC range (2 g/ml) required to inhibit the growth of many Gram-
positive and Gram-negative microorganisms reported in literature (Kärpänen, 2008; 
Popovich et al., 2012).  
 
Figure 5.12 Penetration profiles showing the concentrations of CHG (µg/mg tissue) in porcine ear skin after 
24 h exposure to the NE formulations [C-EO-70(10), C-EO-75(10), C-OO-70(10), C-OO-75(10)] and control 
solution (Mean ± SD, n = 6). HOMO refers to homogenised tissue after removal of the SC layers. 
EO enhances the permeation of CHG into the skin, suggesting that a combination of CHG 
and EO may be a potential method to improve skin antisepsis in clinical practice. EO 
contains 1,8-cineole, which has been shown to bind in large quantities to the SC (Cornwell 
et al., 1996). It is thought to enhance lipophilic drug penetration by increasing the partition 
coefficient (partitioning of drug between vehicle and SC), as well as hydrophilic drug 
penetration by increasing the diffusion coefficient (Cal et al., 2001). Williams et al., (2006) 
also showed that 1,8-cineole partitioning in the skin lipids is heterogeneous, leading to both 
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ordered and disordered areas in SC lipids. Furthermore, it has been shown in in vitro assays 
that cineole does not permeate through the skin but is retained in the skin (Cal et al., 2006). 
Biruss et al., (2007) reported increased skin penetration of steroid hormones using an EO 
(45 % v/v) microemulsion for topical delivery with EO shown to enhance percutaneous 
absorption by SC lipid extraction and loosening the hydrogen bond between the ceramides 
leading to fluidisation of lipid bilayers (Chena et al., 2014). Topical application of EO and 
other essential oil mixtures on necrotic ulcers on the neck areas of cancer patients, resulted 
in not only antibacterial but also an anti-inflammatory activity (Warnke et al., 2006). EO 
exhibited low toxicity and greater efficacy in reduction of morbidity associated with 
neoplastic ulcers. These studies indicate the potential of EO as a topical skin penetration 
enhancer and also suggest useful future work to determine the antibacterial effect of CHG-
NE formulations in the prevention of bacterial skin infections. Another study reported 
amount of CHG recovered from top layers of human skin (100 µm thickness) with 
combination of EO with CHG was 0.157 µg/mg, which was higher than the concentration 
required to kill many common skin microorganisms (Kärpänen, T., 2008). 
5.4.9 In vitro skin diffusion studies of chlorhexidine digluconate nanoemulsions using 
methacrylate dressing powder  
 
The amount of CHG permeated into and retained within the skin using a methacrylate 
powder dressing as a drug delivery vehicle are presented in Figure 5.13 and Figure 5.14. 
The amount of CHG permeated through skin using methacrylate powder dressing is <1 % 
w/w of total applied dose from NEs and control solution, which is lower than corresponding 
results obtained without use of the methacrylate powder dressing as discussed in previous 
study (Section 5.4.8).  
 
  
182 
 
Figure 5.13 In vitro skin permeation of CHG in presence of methacrylate powder dressing from NE 
formulations [C-EO-70(10), C-EO-75(10), C-OO-70(10), C-OO-75(10)] and control solution (Mean ± SD, n = 
6). 
The amount of CHG penetrated into the skin was higher from CHG-EO NEs [C-EO-75(10)] 
compared to other NEs and the control solution. The amount of CHG recovered from skin 
for the control solution was 1.64 ± 0.07 µg/mg, compared to 3.43 ± 0.09 µg/mg, 2.87 ± 0.05 
µg/mg, 2.93 ± 0.08 µg/mg and 2.84 ± 0.03 µg/mg for C-EO-75(10), C-EO-70(10), C-OO-
75(10) and C-OO-70(10) respectively (Figure 5.14). A previous study by Forstner et al., 
(2013) evaluated the antibacterial efficacy of various antiseptic agents, polyhexamethylene 
biguanide, povidone-iodine and octenidine dihydrochloride alone and in combination, using 
a methacrylate dressing as the drug delivery vehicle. Without the antiseptic agent, the 
dressing did not prevent bacterial growth but it reduced bacterial multiplication, whereas 
the inclusion of the antiseptic led to a greater reduction in bacterial growth.  
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Figure 5.14 Penetration profiles showing the concentrations of CHG (µg/mg tissue) in presence of 
methacrylate powder dressing from NE formulations [C-EO-70(10), C-EO-75(10), C-OO-70(10), C-OO-
75(10)] and control solution (Mean ± SD, n = 6) HOMO refers to homogenised tissue after removal of the SC 
layers. 
St. John (2010) used a methacrylate dressing powder containing silver sulfadiazine to 
evaluate antimicrobial efficacy and wound management properties. The methacrylate 
dressing was applied to surgical wounds in a porcine model over 14 days using multiple 
bacterial strains. The silver rapidly converted to silver chloride on addition of saline 
solution to hydrate the methacrylate powder. The dressing was able to release the silver 
over prolonged period of time for complete recovery of wound. 
Biocompatibility testing performed by Forstner et al., (2013) found the methacrylate 
powder to be non-toxic, non-irritant and non-sensitising with a preclinical study found a 
faster time to reepithelialisation when compared to cellulose dressings in a surgical porcine 
wound healing model. They also reported methacrylate dressing contain approximately 
68 % water, which is similar to the water content of the skin (72 % – 74 %), further 
increasing its biological compatibility 
In present study, when CHG was added to methacrylate powder dressing, the cationic 
nature of CHG caused gelation of methacrylate polymer to form a porous flexible gel 
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structure, which allowed controlled release of CHG. The amount of CHG recovered from 
skin following application of the NEs with methacrylate dressing (Figure 5.14) was lower 
than the without use of methacrylate dressing (Figure 5.12). Hence, the methacrylate 
dressing might holds the drug within its porous gel structure for extended periods and this 
may be advantageous for prevention of bacterial growth during the surgical wound healing 
process.  
5.4.10 In vitro diffusion studies of chlorhexidine digluconate permeation using porcine ear 
skin and Strat- M
® 
membrane  
 
The percent cumulative amounts of CHG permeated from control solution and NE 
formulations [C-EO-75(10), C-OO-75(10)] were plotted against time (Figure 5.15) and 
were similar to the amount of CHG permeated through porcine ear skin i.e., for the control 
solution, C-EO-75(10) and C-OO-75(10) was 1.64 ± 0.12, 1.08 ± 0.09 and 0.85 ± 0.17 
respectively, while in case of porcine skin, the cumulative amount permeated was 1.59 ± 
0.17, 0.93 ± 0.13 and 0.62 ± 0.07
 
for control, C-EO-75(10) and C-OO-75(10) respectively 
(Figure 5.11). Thus NEs reduced CHG permeation in both skin and the Strat-M membrane 
model. 
 
  
185 
 
Figure 5.15 In vitro skin diffusion studies of CHG through Strat-M membrane from NE formulations [C-EO-
75(10), C-OO-75(10)] and control solution (Mean ± SD, n = 6). 
 
The flux and permeability coefficients of CHG through porcine skin and Strat-M
 
are not 
significantly different (p>0.05) (Table 5.6). Similar results were reported for a NE based gel 
formulation of diclofenac diethylamine using Strat-M
 
membrane (Hamed et al., 2015), with 
results from in vitro diffusion studies showing a good correlation between the permeability 
coefficient in human skin and Strat-M
 
membrane. Study reported using Strat-M membrane, 
human skin and hairless rat skin to compare permeability coefficients and partition 
coefficients of various chemical compounds applied as an aqueous solution (Uchida et al., 
2015) also found very similar results for Strat-M to those in human and rat skin.  
These reports indicate the suitability of Strat-M
 
membrane as a substitute for in vitro 
diffusion studies for human and animal skin for laboratory use in certain circumstances.  
Strat-M contains two layers of polyethersulfone that are resistant to diffusion and a top 
layer of polyolefin which more open and diffusive, thus mimicking the SC barrier structure 
and composition of human and animal skin. Further experiments need to be conducted with 
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various formulations in order to verify that Strat-M
 
can be used to screen the impact of 
formulation design on the topical and/or transdermal delivery of compounds. 
 
Table 5. 6 Permeability parameters for CHG from control solution and NEs in porcine ear skin and Strat-M 
membrane (Mean ± SD, n = 6). 
 
Formulations 
% CHG permeation 
Permeability coefficient (Kp) 
(cm/h) 
Porcine 
skin 
Strat-M 
membrane 
Porcine 
skin 
Strat-M 
membrane 
Control 1.26 0.96 2.85 x 10
-3
 2.82 x 10
-3
 
C-EO-75(10) 0.66 0.54 1.52 x 10
-3
 1.15 x 10
-3
 
C-OO-75(10) 0.11 0.13 0.22 x 10
-3
 0.31 x 10
-3
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5.4.11 Studies of chlorhexidine digluconate penetration into barrier-intact and barrier-
impaired porcine ear skin 
 
The amount of CHG permeated and recovered from control solution and NE formulations 
using barrier-impaired, full thickness porcine ear skin was analysed and plotted against time 
(Figure 5.16).  
 
 
Figure 5.16 In vitro skin diffusion of CHG through barrier impaired skin from NE formulations [C-EO-
70(10), C-EO-75(10), C-OO-70(10), C-OO-75(10)] and control solution (Mean ± SD, n = 6). 
 
The permeation data obtained from both barrier-intact and barrier-impaired skin showed no 
significant difference (p>0.05) between amount of CHG permeated through skin, while the 
amount of CHG recovered from barrier-impaired skin was significantly higher (p<0.05) 
than the amount recovered from intact skin (Table 5.6). Both CHG-EO NEs and CHG-OO 
NEs caused a 2-fold increase in CHG retention in barrier-impaired skin compared to 
barrier-intact skin, while retention of the CHG was only slightly increased for the control 
solution.  
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Table 5. 7 Amount of CHG recovered from the SC (15 tapes) and homogenised tissue following barrier-intact 
and barrier-impaired skin permeation studies (Mean ± SD, n = 6). 
 
Formulations 
Amount of CHG recovered (µg/mg) 
Barrier-intact skin Barrier-impaired skin 
Control 3.01 ± 0.02 4.45 ± 0.19 
C-EO-75(10) 6.15 ± 0.12 12.07 ± 0.23 
C-EO-70(10) 5.31 ± 0.08 9.85 ± 0.35 
C-OO-75(10) 4.39 ± 0.04 8.37 ± 0.15 
C-OO-70(10) 3.98 ± 0.06 7.16 ± 0.28 
 
Spagnul et al., (2011) investigated uranium penetration through barrier-impaired and barrier 
intact porcine ear skin following application of a calixarene NE formulations. Skin barrier 
properties was disrupted by using application of 60 adhesive tape strips to confirm the 
removal of SC. After skin permeation study they found increase in steady state flux of 
uranium about 55 times higher across barrier-impaired skin compared to barrier-intact skin 
indicating removal of SC had a greater influence on uranium skin penetration. Another 
study evaluated release and antimicrobial efficacy of chlorhexidine phosphanilate (CHP) 
cream formulation by analysing chlorhexidine penetration through barrier-intact and 
barrier-impaired human skin (Wang et al., 1990). To remove the SC from epidermis skin 
was incubated in 0.2 % trypsin solution at 37 °C for 30 min. Data obtained after diffusion 
experiment showed that a negligible amount of CHP permeated to receiver compartment 
through barrier-intact skin, while barrier impaired skin showed 107 µg/ml of CHP 
permeation (2 %w/w CHP cream formulation). It showed the rate-limiting step in barrier-
impaired skin is the release and dissolution rate of CHP from cream formulation. CHG 
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binds to the proteins present in the skin and mucous membranes with limited systemic or 
body absorption (Edmiston et al., 2013). Though in present study, we did not observe 
massive increase in concentration of CHG between barrier-intact and barrier-impaired skin 
compared to the data reported in literature. The reason might be the tape stripping method 
was used in present study to disrupt SC using 15 strips might not be sufficient and robust 
enough to remove and damage SC completely but data obtained from barrier-impaired skin 
shows some degree of damage to SC due to increase in CHG retention into skin.  
 
Removal and damage of SC might also enhance the systemic absorption of active drugs 
causing risk of toxic effects in body. In case of CHG, being topical antiseptic agent several 
studies have reported anaphylactic reactions following  parenteral and mucosal application 
(Bae et al., 2008; Okano et al., 1989), but very limited data is available on topical dermal 
application (Autegarden et al., 1999).  
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5.5 Conclusion 
NEs were produced by HSH and ultrasonication for topical drug delivery of the hydrophilic 
CHG, an antimicrobial agent. W/O NEs were formulated using S80 and T80 as surfactant 
and cosurfactant at various ratios with EO and OO as oil phase, in an attempt to enhance its 
skin penetration and provide controlled drug release. NEs droplet size were affected by use 
of S80 and T80 mixtures at various concentration levels with different HLB values. 
Pseudoternary phase diagram was constructed to select a suitable surfactant and 
cosurfactant ratio to prepare stable NE formulations. A ratio of 2:1 (S80 and T80) was 
found to produce NEs with mean droplet size below 350 nm for both EO and OO, with 
positively charged NEs, most likely as a consequence of presence of cationic CHG.  
 
CHG-EO NEs [C-EO-70(10), C-EO-75(10)] and CHG-OO NEs [C-OO-70(10), C-OO-
75(10)] formulations were used for in vitro drug release and skin permeation studies using 
Franz diffusion cells. Results from in vitro permeation studies showed a good correlation 
between permeability coefficients for Strat-M membrane (a synthetic model) and porcine 
ear skin. An in vitro skin permeation study carried out using full thickness porcine ear skin 
showed less than 2 % w/w of total applied CHG permeated into the receiver compartment 
making it a potential drug delivery system for localised topical antiseptic action. The 
concentration of CHG recovered from skin following application of CHG-EO NEs [C-EO-
75(10)] was 6.15 ± 0.12 µg/mg, which is above the MIC level for many microorganisms.  
Nanostructured methacrylate dressing was applied to the skin and formed a flexible, porous 
gel structure on contact with cationic CHG. In vitro diffusion studies showed the potential 
of the methacrylate dressing to hold the CHG within polymer matrix and facilitate 
controlled release of CHG over a prolonged period of time. This opens new possibilities for 
topical antimicrobial treatment and prophylactic strategies in wound care management, 
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which needs to be elucidated in future studies, as to whether these effects correlate with the 
clinical situation in infected or contaminated wounds.  
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6. CHAPTER: FINAL DISCUSSION AND FUTURE WORK 
 
 
Effective skin antisepsis is imperative prior to incision of the skin, for example during 
surgery, insertion of intravascular devices and other invasive procedures. HAIs are a major 
concern within the health services as they inflict a significant financial burden and time 
constraints on the healthcare system due to increased morbidity and mortality rates, 
prolonged hospital occupancy and intensified treatment regimes, including repeated surgical 
procedures (Vilela et al., 2007). SSIs are responsible for an estimated 15 % of HAIs, 
represent a considerable proportion of all nosocomial infections, and are the most common 
infection occurring in surgical patients (Stevens, 2009). Whilst post-operative care can 
reduce infection rates, an effective pre-operative procedure is crucial to avoid development 
of many preventable infections. 
 
In the majority of SSIs cases, microorganisms such as Staphylococcus aureus and 
Staphylococcus epidermidis are the most common pathogens derived from surgical sites. 
When skin is incised, underlying tissue is exposed to the overlying endogenous flora, 
resulting in an increasing proportion of such infections (Piette and Verschraegen, 2009). 
The ability of these microorganisms to grow within skin despite using a prior skin antiseptic 
procedure creates additional complications due to their reduced susceptibility to 
antimicrobial agents. Current evidence based guidelines recommend that 2 % w/v CHG, 
preferably in 70 % (v/v) IPA, is used for skin antisepsis prior to incision of the skin 
(Loveday et al., 2014). Microorganisms have been shown to persist within the skin 
following skin antisepsis, and the poor skin permeation of many antiseptic agents may 
contribute to SSIs (Hendley and Ashe, 2003; Karpanen et al., 2008). It is therefore proposed 
to have a carrier system, which can enhance skin penetration of an antimicrobial agent for a 
  
193 
prolonged period of time prior to surgical procedure to inhibit bacterial growth and prevent 
skin infections. 
 
In this study, the efficiency of lipid-based carriers was to accessed enhance skin retention of 
antimicrobial agents such as TSN and CHG for topical drug delivery. Among the lipid-
based delivery systems, were SLNs and NEs are extensively studied due to  relative easy 
production methods, non-toxicity and biocompatibility of lipids, easy availability of 
excipients and scale-up possibilities made these systems academically and industrially 
attractive. In addition, by manipulating surfactants to have a suitable HLB, it is possible to 
fabricate stable nanosized carriers (Chen et al., 2010; Severino et al., 2012b). Among these 
nanocarriers, SLNs are produced using lipids, which are solid at room and body 
temperature. If these solid lipids are exchanged for liquid lipid, NEs can be produced. Thus, 
even though SLNs and NEs are composed of lipids, but they differ in their physical state 
and composition of lipids. Therefore, the key purposes of this study were to produce SLNs 
and NEs using HSH followed by probe ultrasonication and to study the effect of differences 
in composition of each delivery system on various physicochemical properties of 
nanocarrier formulations and their skin retention properties using in vitro diffusion studies.  
 
In chapter 3, SLNs of TSN (equivalent to TSN concentration to 10 mg/g of formulation) 
was formulated using GB and GP as solid lipids. GP-SLNs had smaller particle size with 
higher % DEE compared GB-SLNs made under the same conditions. SLNs of both lipids 
showed lipid concentration dependent increase in the particle size and decrease in % DEE. 
Morphological and thermal studies confirmed the presence of spherical particles with no 
chemical interaction between drug and other excipients. SLN formulations with 3 % w/w 
and 5 % w/w of both GB and GP lipids were used to assess skin targeting behavior and 
TSN skin permeation was higher with SLNs compared to TSN solution. This increased skin 
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delivery by SLNs is a result of the large surface area due to small particle size, an occlusive 
effect of lipids and a penetration enhancement effect of surfactants into the skin. The 
amount of TSN retained within the skin was evaluated by differential stripping technique by 
combining adhesive tape stripping and cyanoacrylate biopsies. The amount of TSN retained 
within skin was higher from SLNs compared to the control solution, with the difference 
being statistically significant (p<0.001). It can be explained by higher occlusive effect and 
increased hydration of SC commonly associated with lipid nanoparticles (Müller et al., 
2007). Lipid concentration dependent increases in TSN retention were observed, as lipid 
concentration increased from 3 % to 5 % (w/w) in GB-SLNs and GP-SLNs, there was a 2-
fold increase in TSN retention. Skin retention of TSN was higher for GP-SLNs (5 % w/w 
GP lipid) formulations compared to the others, indicating a superior ability of GP as a lipid 
carrier of TSN compared to GB solid lipid. 
 
In addition to SLNs, skin penetration of TSN was also evaluated by preparation of TSN-
loaded NEs using EO and OO as the internal oil phase and T80 and S80 as surfactant and 
cosurfactant mixture (chapter 4). The aim of these work was to find better nanocarrier 
system for TSN delivery to skin with enhance skin penetration properties. NEs are one of 
the most promising formulations for enhancing the percutaneous absorption of an active 
substance, as they are a thermodynamically and kinetically stable liquid dispersion of an oil 
phase and a water phase, in combination with a surfactant. EO has been shown to enhance 
skin permeation of both lipophilic and hydrophilic compounds, which is thought to be due 
to its terpene constituents.  EO contains 1,8-cineole which has also demonstrated skin 
penetration enhancing properties (Aqil et al., 2007; Narishetty and Panchagnula, 2005). OO 
due to its high content of monounsaturated and polyunsaturated fatty acids has been used 
extensively in cosmetics and pharmaceutical products (Eid et al., 2013). Pseudoternary 
phase diagrams behavior studies allowed the identification of different regions, as well as 
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the selection of maximum and minimum concentrations of each component required for 
obtaining stable formulations. EO-NEs had a smaller droplet size and higher % DEE 
compared to OO-NEs. Concentrations of oil and surfactant had opposing actions on droplet 
size, with an increase in the oil phase increasing droplet size while an increase in surfactant 
concentration caused a decrease in droplet size.  
 
Formulations prepared with 5 % w/w and 10 % w/w oil phase and 5 % w/w surfactant 
mixture were selected for further in vitro skin permeation studies. EO-NEs demonstrated 
higher drug permeation through skin compared to OO-NEs due to the influence of 
physicochemical properties such as higher solubility of TSN in EO, smaller droplet size and 
low viscosity of formulation with permeation enhancement effects of EO. Higher amounts 
of TSN (10.35 ± 0.05 µg/mg) were recovered from skin following administration of EO-
NEs [EO-10(5)] compared to other EO-NE and OO-NE formulations. NEs and previous 
findings of SLNs for topical delivery of TSN in chapter 3 were compared for better 
retention of solid and liquid lipid nanocarriers was compared using in vitro skin permeation 
studies and quantifying amount of TSN recovered from skin using adhesive tape stripping 
method. The SLN and NE formulations containing equal amount of lipids i.e. GP-SLNs 
(GP5-2) and EO-NEs [EO-5(5)] were selected for in vitro skin diffusion study using 
porcine ear skin. The amount of TSN recovered from skin was higher for NEs (17.49 ± 0.16 
µg/mg) compared to SLNs (14.42 ± 0.27 µg/mg) with the difference being statistically 
significant (p<0.05). This might be due to difference in composition and physical state of 
lipids used and difference in the physicochemical properties of nanocarriers. The results 
reported in this work have clearly demonstrated the suitability of NEs for enhanced skin 
retention of TSN upon topical administration. 
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In chapter 5 of this thesis, another commonly used antimicrobial agent CHG was selected to 
formulate into NEs to enhance its skin retention properties. W/O NEs of CHG (equivalent 
of CHG concentration to 20 mg/g of formulation) were formulated and evaluated using EO 
and OO as external oil phase due to hydrophilic nature of CHG. Pseudoternary phase 
diagrams study helped to select a surfactant and cosurfactant ratio of 2:1 (S80 and T80) to 
produce stable NEs with mean droplet size less than 350 nm for both EO and OO up to 
83 % drug encapsulation efficiency. Selected formulations of EO-NEs and OO-NEs were 
used to study in vitro drug release and skin permeation using synthetic membranes such as 
dialysis membrane, Strat-M
 
membrane and excised full thickness porcine ear skin. Release 
and permeation studies detected < 2 % w/w of the total applied dose of CHG after 24 h of 
contact, thus making it advantageous for localised topical delivery of CHG. EO-NEs 
showed significantly greater (p<0.05) CHG skin penetration than the OO-NEs and control. 
The results demonstrate that EO enhances the permeation of CHG into the skin, suggesting 
that a combination of CHG and EO may be used to improve skin penetration in clinical 
practice. EO contains 1,8-cineole, which has been shown to bind in large quantities to the 
SC (Cornwell et al., 1996). The results from this study clearly demonstrate the enhanced 
skin delivery of CHG with EO-NEs into the deeper layers of the skin, therefore enhancing 
skin retention. These results clearly lay the foundation for future work. However, the 
penetration of EO into the skin, its potential side effects and skin tolerability need to be 
investigated before in vivo studies are undertaken in the clinical setting.  
 
In the healthcare environment the increasing numbers of resistant microorganisms is a 
major concern. The extensive use of many antimicrobial agents has contributed to the 
acquired resistance among many pathogens. Thus it is important to search for new drug 
delivery systems for better and prolonged skin penetration activity of antimicrobial agents 
without increasing systemic absorption. Potential future work may be the incorporation of 
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prepared lipid nanoformulations into suitable hydrogels or polymers for easy skin 
application, evaluation of antimicrobial efficacy of prepared SLNs and NEs using various 
microbial strains and to study the skin penetration enhancement ability of SLN and NE 
formulations prepared with different types of solid lipids and oils. The main findings of this 
thesis are the enhanced skin penetration of TSN and CHG from lipid nanoformulations 
using GB, GP as solid lipids and EO and OO as oils, with special emphasis on NEs as lipid 
carriers for the enhanced skin delivery of TSN are exciting and clearly lay the foundation 
for future work.  
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